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General introduction
Partly published as: “Coinhibitory molecules in hematologic malignancies: targets
for therapeutic intervention.”
Wieger J. Norde*, Willemijn Hobo*, Robbert van der Voort and Harry Dolstra.
* These authors contributed equally
Blood 2012;120:728-736

Hematological malignancies
Despite the powerful aspects of the immune system, most often tumor cells are able
to evade immune recognition and destruction. Mechanisms exploited by tumor cells
to escape T cell-mediated immunity include disruption of antigen presentation, down-
regulation of HLA molecules, secretion of immunosuppressive cytokines, as well as
recruitment of regulatory T cells (TREG) and myeloid-derived suppressor cells.
1 In
the last decade, another powerful immunosuppressive mechanism gained much atten-
tion: the repressive action of co-inhibitory molecules.2 Hematological malignancies
also employ these factors to suppress spontaneous anti-tumor immunity, or specific
immunotherapies like allogeneic stem cell transplantation (alloSCT). We have investi-
gated the role of these mechanisms in anti-tumor effects against hematologic cancers,
and this chapter provides an introduction into the studies performed in this thesis.
Hematological malignancies
Malignancies of the hematopoietic system comprise of a group of heterogeneous neo-
plasms, which account for approximately 7% of all new cancer diagnoses in Europe.3
Based on location and origin these are generally categorized in four major groups:
acute and chronic leukemias, lymphomas and plasma cell malignancies. Etiology, in-
cidence and prognosis greatly vary among these groups. Genetic abnormalities of the
tumor as well as patient age and health status are important factors in the disease
prognosis, and consequently determine the choice of therapy. Standard treatment in-
cludes radiotherapy and chemotherapy, in order to reduce tumor burden and induce
clinical remission. Since these harsh treatments also target healthy hematopoietic
cells, radio/chemotherapy is sometimes combined with autologous stem cell trans-
plantation (SCT), to reconstitute the bone marrow. Dependent on the indication
this can result in complete tumor eradication, however too often long-term remission
is not achieved and patients frequently relapse. In the past years, new therapeutics
have been developed that more specifically target tumor cells. Currently, the first-line
drug in chronic myeloid leukemia (CML) is Imatinib or second-generation variants
like Dasatinib, which are tyrosine kinase inhibitors (TKI) that target the BCR-ABL
fusion protein.4,5 This fusion protein is the cause of malignant transformation, and
the result of the signature CML t(9;22) chromosomal translocation, known as the
Philadelphia chromosome. Also the treatment of B-cell lymphomas has greatly im-
proved by the introduction of the anti-CD20 monoclonal antibody Rituximab, since
it effectively induces death of CD20+ tumor cells through antibody-dependent cel-
lular cytotoxicity (ADCC), among other mechanisms.6 Other effective drugs espe-
cially exploited against multiple myeloma (MM) are Bortezomib, a proteasome in-
hibitor,7 and the immunomodulatory drug Lenalidomide, which both lead to tumor
cell apoptosis and enhanced anti-tumor immune effects.8 In addition, the fact that
DNA methylation is often disturbed in tumors boosted the use of the demythylating
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agent azacitidine (i.e. Vidaza) in the treatment of myelodysplastic syndrome (MDS)
and acute myeloid leukemia (AML).9 However, although much progress has been
achieved, current treatments still have their limitations. Next to the risk of therapy
resistance, patients often suffer from severe side effects and frequently relapse. Im-
portantly, most treatments are not curative and lead to life-long medication. Hence,
there is a strong need for other or adjuvant therapeutic strategies with curative poten-
tial. In this regard, cellular immunotherapy is an attractive treatment option to cure
hematological malignancies. Such cell-based immunotherapies include alloSCT, T
cell and natural killer (NK) cell adoptive transfer, and vaccination-based approaches
using various antigen formulations or dendritic cells (DC). The aim in these treat-
ments is to stimulate and enhance either the patient’s own or an introduced donor
immune system to reject and destroy tumors.
Allogeneic hematopoietic stem cell transplantation
Since the first alloSCT in 1957, this procedure has progressed to an effective type of
cellular immunotherapy that is able to cure inherited disorders of the hematopoietic
system and various hematological cancers.10 A drawback of high-dose chemo- and
radiotherapy, which was thought to be needed to eradicate the malignancy, is the
destruction of healthy hematopoietic cells resulting in a patient without a proper
blood-forming organ. Since alloSCT comprises of replacing the patient bone marrow
(BM) with that of a donor, this therapy enabled intensive chemo- and radiotherapy
regiments prior to alloSCT.
However, allogeneic differences between the patient and donor cells play a cru-
cial role in this transplantation, and especially the human leukocyte antigens (HLA)
have been proven to be important. A mismatch in HLA generally results in se-
vere graft-versus-host-disease (GVHD), a life-threatening condition in which healthy
tissues are being damaged by alloreactive donor T cells.11 Fortunately, ensuring a
haplo-identical- or fully HLA-matched patient-donor couple greatly reduced this risk.
However, even when the HLA type is matched, donor and recipient still differ in single
nucleotide polymorphisms (SNP), reflecting normal genetic variation between indi-
viduals. Non-synonymous SNPs cause small differences in the amino acid sequence
of intracellular proteins. Following proteasomal cleavage of these proteins, peptides
are subsequently loaded onto HLA molecules, and these polymorphic peptides are
presented to T cells. These antigens are known as minor histocompatibility antigens
(MiHA).12 Since the patient-specific MiHA are not expressed in the donor, they will
be regarded as foreign by the donor immune system. Therefore, MiHA are the prime
immunological targets of alloreactive T cell responses after HLA-matched alloSCT.
Since MiHA are also expressed by hematological cancer cells, these immunogenic
peptides can cause an anti-tumor response, referred to as the graft-versus-tumor ef-
12
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Figure 1.1: Kinetics of a MiHA-specific immune response. This graph shows the
presence of LRH-1-specific T cells and the leukemic load after stem cell transplantation of a patient
with CML-blast crisis (BC). After alloSCT and two DLI, a robust LRH-1-specific T cell response
was observed, which coincided with a decline of leukemia cells. After this immune response, LRH-
1-specific memory T cells were formed, which were detectable for the rest of the patient’s life.
Unfortunately, after 60 months the patient developed relapse, without a secondary expansion of
LRH-1-specific T cells. Furthermore, additional DLI did not affect the relapse, and rapid resistance
to the TKI Imatinib (Glivec) was observed, leading to the death of the patient. At several time
points the patient was treated against GVHD with Cyclosporin A (CsA). Adjusted from de Rijke
et al.22
fect (GVT).13 This GVT response is a powerful T cell mediated immune response
that can lead to eradication of all tumor cells, thereby achieving complete remission.
Unfortunately, some MiHA are not only expressed by malignant cells, but also by
healthy tissues of the patient. When these tissues are targeted by alloreactive T cells,
GVHD can be induced. Liver, skin, and the gastrointestinal tract are most prone to
GVHD, and this condition greatly impacts the quality of life, and can be fatal. A
positive balance between the beneficial GVT and detrimental GVHD effect has been
the goal of much experimental and clinical research.
In the past decade, the conditioning regimen prior to alloSCT has been optimized,
resulting in a reduced intensity condition (RIC) treatment option, which is particu-
larly applicable for high-risk patients such as the elderly.14 In contrast to standard
myeloablative conditioning, RIC does not destroy all recipient immune cells, but does
allow for engraftment of the donor hematopoietic stem cells. The advantage of RIC
is a significant reduction in complications such as infections and GVHD. Another
means to minimize side effects is the depletion of T cells from the graft, resulting in
less GVHD. However, the curative GVT effect is also dependent on donor T cells.
Therefore, in addition to allowing a low T cell presence in the initial graft, extra
13
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T cells are giving to the patient at later time points, known as donor lymphocyte
infusion (DLI).15 These DLI are either pre-emptive or therapeutic, and often result
in boosting of GVT responses. Because of the curative effect of GVT and the detri-
mental effect of GVHD, the holy grail in alloSCT is to separate the recognition of
malignant hematological cells from the attack of healthy tissues. The key to achieve
this is to therapeutically exploit MiHA that are exclusively expressed by the patient’s
hematopoietic system, including the malignant cells. Since the patient hematopoi-
etic cells are replaced by the donor cells, the destruction of these patient cells is not
detrimental. Therefore, our group and others have focused on the identification and
application of hemato-restricted MiHA.
Therapeutically applicable MiHA
Historically, the identification of MiHA is a laborious process involving both T cell
culture and bioinformatics. However, in recent years several new approaches, most
prominently the genome wide association study (GWAS) approach, have been intro-
duced which greatly accelerated MiHA-identification.16 To date, over forty autoso-
mal-chromosome encoded MiHA have been identified. The therapeutic applicability
of these MiHA depends on several factors. Firstly, their expression profile should
be preferentially limited to hematopoietic tissues in order to prevent potential in-
duction of GVHD. Secondly, the population frequency of the MiHA-encoding SNP
should be optimal for mismatching in the GVT direction. Finally, the HLA molecule
should be fairly common in order to render the MiHA applicable in sufficient num-
bers of patients. Attractive MiHA that meet these criteria are HA-1,17 HA-2,18
ACC-1/ACC-2,19 HB-1,20 PANE1,21 LRH-1,22 UTA2-1 (personal communication
T. Mutis), ARHGDIB23 and ZAPHIR,24 some of which are being exploited in clini-
cal trials using DC vaccination and adoptive transfer.
In 2005, we identified a hematopoiesis-restricted MiHA, designated LRH-1, which
elicited an HLA-B7-restricted cytotoxic T lymphocyte (CTL) response in an ad-
vanced CML patient treated with DLI, as shown in Figure 1.1.22 Using isolated
LRH-1-specific CTLs from this patient, we demonstrated that immunogenicity of
LRH-1 resulted from differential expression of the P2X5 protein in recipient and
donor cells as a consequence of a single nucleotide frameshift polymorphism. Inter-
estingly, tetramer analysis showed a direct association between in vivo expansion of
LRH-1-specific CD8+ T cells and the disappearance of Bcr-Abl-positive CML cells
following DLI. Moreover, gene expression studies revealed that P2X5 is not expressed
in non-hematopoietic tissues, including prominent GVHD target tissues such as skin,
liver, colon, and small intestine. These findings illustrate that the P2X5 -encoded
MiHA LRH-1 may play a significant role in inducing GVL-specific immunity against
myeloid leukemia. Although we had shown that P2X5 mRNA is significantly ex-
14
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pressed in leukemic CD34+CD38− and CD34+CD38+ subpopulations from most
CML and AML patients, it remained to be investigated whether myeloid leukemic
progenitor cells are susceptible to lysis by LRH-1-specific CTL. Therefore, in Chap-
ter 2 we describe that LRH-1-reactive CTL specifically and efficiently targeted
CD34+ leukemic progenitor cells from CML and AML patients. Importantly, the
CD34+ progenitor cells contain the leukemic stem cells, which are relatively resistant
to TKI. These findings illustrated that LRH-1 is an attractive target for eradication
of residual or persisting myeloid leukemic progenitor cells after allogeneic SCT.
Dynamics of MiHA-specific T cell responses
The kinetics of alloreactive T cells constituting the GVT effect is divided in sev-
eral stages.25 First, the CD62L+CCR7+CD45RA+ na¨ıve T cells (TN) encounter the
antigen presented by MiHA-expressing DC. Due to expression of the selectin CD62L
and the chemokine receptor CCR7 these cells home to the secondary lymphoid or-
gans. However, upon this stimulation by the DC, these T cells clonally expand and
loose the expression of CD62L, CCR7, CD28 and CD45RA, while upregulating ac-
tivation markers such as CD45RO, CD69 and CD25. These effector T cells (TEFF)
subsequently migrate to the target tissues, where they eradicate the MiHA+ tumor
cells. After the peak of the response, upon which most or all target cells have been
destroyed, the contraction phase commences, and most MiHA-specific T cells will
undergo apoptosis. However, a minority of the T cells will survive to become long-
lived memory cells, either effector (TEM) or central memory (TCM). While the TEM
reside in the periphery and upon recall show a strong effector response, the TCM
have a strong proliferative property, regain expression of CD62L and CCR7, and mi-
grate to the lymph nodes and BM, where they convey a lifelong memory against the
antigen of their specificity. However, we have observed that despite the presence of
MiHA-specific TEM/CM cells for many years, late relapses do occur in patients with
advanced myeloid leukemia (e.g. see Figure 1.1). Moreover, even when MiHA dis-
parities are present on a genomic level, not always an initial specific T cell response
is observed. This indicates that although GVT responses after alloSCT is a power-
ful immune mechanism, often tumor cells are able to escape or suppress immunity.
These escape mechanisms include disruption of antigen presentation, down-regulation
of HLA molecules,26 secretion of immunosuppressive cytokines as well as recruitment
of regulatory T cells (TREG) and myeloid-derived suppressor cells (MDSC).
1 These
immunosuppressive mechanisms are summarized in Figure 1.2.
Another mechanism of immune evasion is the acquisition of intrinsic resistance
to T cell-induced apoptosis including upregulation of inhibitors of apoptosis. In-
terestingly, in Chapter 2 we have investigated a panel of apoptotic mediators in
myeloid leukemias, and found that X-linked inhibitor of apoptosis (XIAP) was up-
15
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Figure 1.2: Immunosuppressive mechanisms deployed by tumor cells. Tumor
cells utilize a number of ways to suppress and evade the immune system, including cell-
intrinsic and cell-extrinsic factors. T cell-induced apoptosis can be avoided by the up- or
downregulation of anti- and pro-apoptotic factors, respectively. Secondly, the expression
of co-inhibitory ligands on tumor cells can bind to the co-inhibitory receptors on T cells,
thereby dampening the immune response. In addition, suppressive cytokines can be secreted,
either directly by the tumor cell, or from suppressive cells like tolerogenic DC, MDSC or
TREG. These cells have been recruited into the tumor microenvironment. Finally, immune
recognition can be affected by either downregulation of antigens, reduced antigen processing
and loading, and a lower expression of HLA molecules. All these mechanisms result in a
reduced immune response and tumor immune evasion.
16
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Figure 1.3: Co-signaling ultimately deter-
mines T cell activation. T cell stimulation de-
pends on two signals: first the specific signal 1, where
the TCR recognizes its cognate peptide presented by
the APC within the context of self-HLA. Whether or
not the T cell is activated depends on the balance be-
tween co-stimulatory and co-inhibitory signals, consti-
tuting signal 2.
regulated in the malignant cells. This coincided with a partial resistance against lysis
by MiHA-specific T cells. In a recent study, interfering with apoptosis pathways in
CML rendered quiescent CML stem cells which are normally resistant to TKI, sensi-
tive to Imatinib in a synergistic fashion.27 Interestingly, an antisense oligonucleotide
of XIAP is currently tested in clinical trials. In a study with patients with AML,
it was shown that this drug preferentially induced apoptosis in the CD34+CD38−
AML stem cells.28 These findings suggest that the incorporation of XIAP inhibition
into current immunetherapies would also enhance clinical effects. Intriguingly, in the
last decade another powerful immunosuppressive mechanism came into the spotlight:
the influence of co-inhibitory molecules.2
Co-inhibitory molecules
T cell activation is dependent on co-signaling events between members of the CD28/
B7 family, which encompasses both co-stimulatory and co-inhibitory members. The
balance between positive and negative co-signals determines whether T cells are
activated, and are therefore essential for immune homeostasis (Figure 1.3).
In addition to T cell activation, tolerance for self-antigens can be established and
autoimmune responses are prevented. In addition to the physiological role of co-
signaling, tumor cells utilize it to evade immune control by down-regulating stimu-
latory molecules such as CD80 and CD86, and up-regulating various co-inhibitory
ligands, thereby limiting the current therapeutic potential of immune therapy against
cancer. Studies by us and others demonstrated that cellular immunotherapies are of-
ten hampered by the action of co-inhibitory molecules that attenuate tumor-reactive
T cell responses, resulting in sub-optimal clinical results. In a recent review, we
addressed the role of co-inhibitory molecules in immune evasion by hematological
malignancies, and discussed options to circumvent T cell inhibition without severe
17
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adverse effects such as pathological autoimmunity and GVHD.29 Today a variety of
co-inhibitory molecules have been implicated in immune escape of cancer. In the
next paragraphs, currently known co-inhibitory molecules involved in suppressing
anti-tumor immunity against hematological malignancies are being discussed (sum-
marized in Table 1.1).
Table 1.1: Major co-inhibitory molecules and their corresponding binding part-
ners involved in attenuating anti-tumor immunity
Receptor Binding partners
Name Expression
pattern
Name Expression on
normal cells
Expression
on malignant
cells
CTLA-4 Activated T,
TREG
CD80/CD86 T,B,DCs, macrophages Down-
regulated on
AML,
MM(43,45)
PD-1 Activated T and
B, NKT,
monocytes,
myeloid cells
PD-L1 Activated T, B, DCs,
macrophages,
monocytes,
nonlymphoid tissues
AML, NHL,
MM (45,57)
PD-L2 DCs, monocytes AML, NHL,
MM (45,57)
BTLA T, B, DCs,
myeloid cells
HVEM T, B, DCs, NK,
myeloid cells and
nonlymphoid tissues
AML, CLL,
NHL, MM
(92,93,100)
LAG-3 Activated T,
TREG, B, pDCs,
NK
MHC-II Activated T, B, DCs,
macrophages,
monocytes,
endothelium
Down-
regulated in
tumors (1)
TIM-3 Th1 CD4+ T,
CD8+ T, DCs,
NK, monocytes,
epithelium
Galectin-9 CD4 T cells, TREG,
DCs, fibroblasts,
granulocytes,
endothelium
AML,
lymphoma
(118,119)
CD200R Activated T, B,
NK, DCs, mast
cells, myeloid cells,
neutrophils
CD200 Activated T, B, DCs,
thymocytes,
endothelium,
nonlymphoid tissues
AML, CLL,
MM
(109,110,132)
T indicates T cells; B, B cells; pDCs, plasmacytoid cells; NK(T), natural killer (T) cells;
CLL, chronic lymphoid leukemia; and (B-)NHL, (B-cell) non-Hodgkin lymphoma
18
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Expression and function of CTLA-4
Cytotoxic T lymphocyte associated antigen-4 (CTLA-4; CD152), was the first co-
inhibitory molecule identified, and is partly similar to the co-signaling molecule
CD28.30 However, while CD28 is constitutively expressed on the membrane of na¨ıve
T cells, CTLA-4 is primarily localized in intracellular compartments and rapidly
translocates to the cell membrane upon T cell activation. The inhibitory function of
CTLA-4 was revealed in knockout mice, which developed lethal lymphoproliferative
disease with multiorgan T cell infiltration.31 Like CD28, CTLA-4 has an extracel-
lular domain containing the MYPPPY binding motif, enabling both receptors to
interact with CD80 (B7-1) and CD86 (B7-2) expressed by antigen-presenting cells
(APC). However, the binding affinity of CTLA-4 for these ligands is 10-100 fold
higher, thereby outcompeting CD28 and promoting immune inhibition.32
As CTLA-4 is up-regulated upon T cell receptor (TCR) ligation, it plays an
important role in dampening effector T cell activation and regulating immune home-
ostasis. Additionally, CTLA-4 signaling in immunosuppressive TREG mediates the
control of auto-reactive T cells, as in vivo interference with CTLA-4 on these cells
elicited pathological autoimmunity.33 The effect of CTLA-4 interference could either
be due to depletion and/or inhibition of TREG. Wing et al. showed that TREG-
specific CTLA-4 deficiency resulted in impaired suppressive TREG function, since
CTLA-4 enables the downregulation of CD80/CD86 on APC,34 which can be partly
due to endocytosis of CD80 and CD86 by TREG.
35 This renders a less stimulatory
APC, resulting in a lasting cell-extrinsic inhibitory effect. Therefore, CTLA-4 sig-
naling can attenuate adaptive immune responses in chronic viral infections and can-
cer. CTLA-4 as such is not a marker of exhausted cells, but elevated levels on viral
antigen-specific T cells correlated with their dysfunction in patients with chronic viral
infections, which could be restored by CTLA-4 blockade.36 Also in cancer, high ex-
pression of CTLA-4 was correlated to antigen-specific T cell dysfunction in metastatic
melanoma.37 In various CD80 and CD86-positive solid tumor models, monotherapy
with CTLA-4 blocking antibody resulted in elimination of established tumors and
long-lasting anti-tumor immunity.38 Several clinical trials have been performed with
anti-CTLA-4 antibodies, mostly with Ipilimumab in melanoma. Interestingly, an in-
crease in overall survival of melanoma patients has been observed.39 However, not
all patients gain clinical benefit and individual responses are hard to predict. Fur-
thermore, occurrence of adverse toxic effects remains a problem. Interestingly, in one
trial patients responding to Ipilimumab were reported to have high titers of anti-
MICA-antibodies, probably because of enhanced CD4+ T cell function resulting in
increased antibody responses. These antibodies may revert the functional inhibition
19
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of NK and CD8+ T cells induced by tumor-secreted MICA. In 2011, the FDA and
EMA approved Ipilimumab treatment for advanced melanoma, paving the way for
further exploration of therapies targeting co-inhibitory molecules in cancer.40 Al-
though anti-CTLA-4 treatment works in vivo, either alone or in combination with
vaccines, in vitro CTLA-4 blockade has not been very successful in reversing T cell
dysfunction. This might be due to limitations of the in vitro models, as CTLA-
4 blockade probably exerts it’s in vivo action via multiple immune mediators (e.g.
effector T cells, TREG, antibody responses).
41
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Numerous experimental and clinical studies have demonstrated that co-inhibitory
molecules hamper T cell immunity against hematological cancers in both the auto-
logous and allogeneic setting (Table 1.2, 1.3 and 1.4).
For instance, a causal relationship between CTLA-4 and TREG was demonstrated in
lymphoma patients.42 A large proportion of the lymphoma-infiltrating lymphocytes
was identified as CTLA-4+ TREG, and TREG-mediated T cell suppression could be
abrogated by CTLA-4 blockade. Additionally, CTLA-4:CD80/86 interactions also
take place between T cells and tumor cells. In MM patients, CD86 but not CD80
was expressed by tumor cells, while CTLA-4 was up-regulated on T cells, resulting
in anergy of tumor-specific T cells.43 In concordance with these results, T cells from
chronic lymphocytic leukemia (CLL) patients responded to anti-CD3 activation by a
decrease in CD28 and an increase in CTLA-4 expression, resulting in an inhibitory
phenotype.44 Similar to MM, we and others showed that acute myeloid leukemia
(AML) cells heterogeneously express CD86, but CD80 levels are generally low or
absent.45,46 As CD80 and CD86 can mediate either T cell stimulation via CD28
or T cell inhibition via CTLA-4, their role in the induction of tumor-specific T
cell immunity was investigated in an AML model.47 Expression of CD86 on AML
resulted in tumor rejection, whereas CD80+ AML tumors grew progressively. The
latter observation was shown to be CTLA-4 dependent, as blockade with anti-CTLA-
4 resulted in clearance of CD80+ AML cells.
Because of their potent suppressive function, co-inhibitory molecules became ma-
jor targets of preclinical and clinical blocking studies. For example, in a murine
thymoma model, CTLA-4 blockade after DC vaccination improved survival and re-
sulted in a sustained increase in the number of antigen-specific T cells.48 In a phase I
study that included four non-Hodgkin lymphoma (NHL) patients, two subjects devel-
oped a clinical response upon Ipilimumab treatment.49 No enhanced T cell-mediated
anti-tumor reactivity could be observed, although TREG levels decreased, suggesting
that CTLA-4’s effectiveness may be attributed to TREG depletion via ADCC. In a
follow-up study with 18 NHL patients, Ipilimumab administration resulted in clinical
responses in 2 patients, and in a number of patients enhanced T cell responses against
20
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Table 1.2: Outcome of interference with murine co-inhibitory molecules in au-
tologous setting
Molecule Therapy Tumor Outcome Reference
CTLA-4 Anti-CTLA-4
+ ova-DC
vaccination
Thymoma Improved tumor rejection,
enhanced antigen-specific
T cell responses
23
CTLA-4 Anti-CTLA-4;
CTLA-4
deletional
knockout
AML Increased survival and
improved tumor rejection
22
CTLA-4 Anti-CTLA-4 AML Enhanced T cell response,
prolonged survival
54
PD-1 Anti-PD-1;
PD-1 knockout
MM Delayed tumor growth;
complete tumor rejection
in PD-1 knockout
49
PD-1 HSCT + whole
cell vaccination
+ antiPD-L1
MM Increased survival 52
PD-1 AntiPD-L1;
PD-1 knockout
AML Enhanced T cell response,
improved tumor rejection,
increased survival
50
PD-1/
TIM-3
Anti-PD-L1
and/or
mTim-3 hFc
AML Delayed tumor growth on
monotherapy, improved
tumor rejection on
combined blockade
93
CD200 Anti-CD200 AML Increased survival 86
CD200 Anti-CD200 B-CLL Improved tumor rejection 87
CD200 Anti-CD200 B-cell lymphoma Delayed tumor growth 88
B-CLL indicates B-cell chronic lymphoid leukemia
KLH and tetanus toxoid were observed.50 Overall toxic effects were limited in these
studies, and although durable responses were rare, the response rate resembled that
of the first clinical trials in solid cancers. Since only small numbers of patients with
hematological malignancies have been treated so far, more research is warranted to
draw conclusions.
Allogeneic T cell function after alloSCT is also strongly influenced by co-inhibitory
molecules. The importance of CTLA-4 in modulating allogeneic immune responses
has been confirmed by association of certain CTLA-4 genotypes with the incidence
of leukemia relapse and overall survival after alloSCT.51 Although not all functional
consequences of reported polymorphisms have been elucidated, the CT60 single nu-
cleotide polymorphism is postulated to influence the transcription of the sCTLA-4
variant, hampering normal CTLA-4 function.52 Interestingly, it was demonstrated
that CTLA-4 blockade shortly after alloSCT increased GVHD in a CD28-dependent
21
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Table 1.3: Outcome of interference with murine co-inhibitory molecules in al-
logeneic setting
Molecule Therapy Tumor Outcome Reference
CTLA-4 Anti-CTLA-4 AML Enhanced T cell response
and GVHD early after
BMT; enhanced
tumor-specific T cell
response later after BMT
with low GVHD
28
PD-1 Anti-PD-L1 Lymphoma Enhanced T cell response 63
PD-1 Anti-PD-L1 None Enhanced T cell response,
no GVHD
64
PD-1 Anti-PD-L1;
PD-1 knockout
CML Increased survival 65
BTLA BTLA agonist B-cell
lymphoma
Early after BMT:
prevention of GVHD; later
after BMT: no effect on
GVHD; effective GVT
response
78
BTLA BTLA agonist Mastocytoma/
T cell
lymphoma
Inhibition of alloreactive
T cell response, prevention
from GVHD
79
HVEM Specific blockade
of BTLA binding
None Prevention from acute
GVHD
80
PD-1H/
VISTA
PD-1H/VISTA
agonist
None Prevention from acute
GVHD
103
BMT indicates bone marrow transplantation
manner.53 However, when anti-CTLA-4 was administered at later time points after
alloSCT, the GVT effect was boosted without signs of GVHD. Shortly after alloSCT,
conditioning-related mucosal barrier injury, leading to a pro-inflammatory cytokine
storm, tissue damage and inflammation, may induce major T cell activation in GVHD
tissues. However, at later time points these inflammatory events have diminished,
and there is no general T cell activation. In patients, Ipilimumab administration at
late time points after alloSCT has been explored in one phase I trial.54 Following
a single infusion of Ipilimumab in 29 alloSCT patients with a recurrent or progres-
sive hematological malignancy, 3 clinical responses were observed. Importantly, no
induction or exacerbation of clinical GVHD was reported, although similar to other
CTLA-4 blockade trials 14% of the patients showed organ-specific immune adverse
events. The lack of GVHD induction is likely attributed to the median interval of
1 year between last donor cell infusion and Ipilimumab administration. This pro-
vides a window for anti-tumor immunotherapy in the post-transplantation setting
and emphasizes the importance of appropriate timing.
22
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Table 1.4: Outcome of interference with human co-inhibitory molecules
Molecule Therapy Tumor Outcome Reference
CTLA-4 Ipilimumab,
in vivo
NHL Two of 4 tumor regression, no
increase in vaccine-specific T
cell responses, reduction in
TREG number early after
treatment; toxicity: mainly
grade 1 or 2, 1 times grade 3
24
CTLA-4 Ipilimumab,
in vivo
Relapsed/
refractory
B-cell NHL
Two of 18 clinical response, 5
of 16 enhanced T cell response
to recall Ag; toxicity: mainly
grade 1 or 2, 6 of 18 grade 3
25
CTLA-4 Ipilimumab
after
alloSCT, in
vivo
AML, CML,
CLL, HL,
NHL, MM
Three of 29 clinical response;
toxicity: no induction of
GVHD, 4 of 29 organ-specific
immune adverse events
29
CTLA-4 Anti-CTLA-
4, ex
vivo
HL Abrogated TREG suppression 17
CTLA-4 Anti-CTLA-
4, ex
vivo
CLL Enhanced tumor-specific T
cell response
109
PD-1 BMS-936,
558, ex vivo
ALL, AML,
CML, NHL,
MM
Enhanced alloreactive T cell
response
20
PD-1 Anti-PD-L1,
ex vivo
NHL Enhanced T cell response 52
ALL indicates acute lymphoid leukemia; CLL, chronic lymphoid leukemia; NHL, non-
Hodgkin lymphoma; MDS, myelodysplastic syndrome; HCV, hepatitis C virus; and GI,
gastrointestinal tract
PD-1
Expression and function of PD-1
Programmed death 1 (PD-1; CD279) is another immunoreceptor belonging to the
B7/CD28 family.55 In 1992, PD-1 was identified on hybridoma T cells undergoing
apoptosis and was believed to be a programmed cell death-induced gene.56 Further
characterization demonstrated that PD-1 is inducibly expressed on stimulated CD4+
T cells, CD8+ T cells, B cells and monocytes.57 PD-1 binds two B7 family ligands,
PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC; CD273).58 Their interaction with PD-1
differs in affinity59 and type, due to a conformational transition in PD-L1, but not
PD-L2, upon binding.60 While PD-L2 expression is mainly restricted to APC, like
DCs and macrophages, PD-L1 is expressed on many non-lymphoid tissues as well.61
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Table 1.4: Outcome of interference with human co-inhibitory molecules (con-
tinued)
Molecule Therapy Tumor Outcome Reference
PD-1 Anti-PD-L1
and
anti-PD-L2,
ex vivo
HL Restored T cell response 53
PD-1 Anti-PD-L1,
ex vivo
HCV
lymphoma
Abrogated TREG suppresion,
reduction in TREG number
55
PD-1 CT-011, in
vivo
AML, CLL,
HL, NHL,
MDS, MM
Six of 17 clinical response, 1
complete remission, no
toxicity
57
PD-1 CT-011 with
or without
lenalido-
mide, ex
vivo
MM Enhanced NK cytotoxicity,
additive effect of lenalidomide
58
PD-1 CT-011 +
tumor/DC
vaccination,
ex vivo
MM Reduction in TREG number,
enhanced T cell response
59
PD-1 DC vaccina-
tion with
PD-L silen-
cing, ex vivo
AML, CML Enhanced alloreactive T cell
response
105
BTLA Anti-BTLA,
ex vivo
ALL, AML,
CML, NHL,
MM
Enhanced alloreactive T cell
response
67
CD200 Anti-CD200,
ex vivo
AML Enhanced NK cytotoxicity 84
CD200 Anti-CD200,
ex vivo
CLL Enhanced antigen-specific T
cell responses, reduction in
TREG number
85
ALL indicates acute lymphoid leukemia; CLL, chronic lymphoid leukemia; NHL, non-
Hodgkin lymphoma; MDS, myelodysplastic syndrome; HCV, hepatitis C virus; and GI,
gastrointestinal tract
Furthermore, multiple tumor types express PD-L1 and its expression is elevated fol-
lowing IFN-γ exposure.62 PD-L1 molecules on tumor cells can deliver negative sig-
nals towards PD-1-expressing tumor-reactive T cells, thereby inhibiting anti-tumor
immunity.63 Indeed, PD-L1 expression has been associated with poor prognosis in
solid tumors.62,64 Interestingly, PD-L1 is also able to bind CD80, mediating T cell
inhibition.65 In addition to downstream signaling of PD-L1,66 also engagement of
PD-L2 resulted in T cell inhibition, further illustrating the complexity of these in-
teractions.67
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It has been well demonstrated that PD-1 plays a crucial role in T cell regulation in
various immune responses such as peripheral tolerance, autoimmunity, infection and
anti-tumor immunity.61 Elevated PD-1 expression on viral antigen-specific CD8+ T
cells in chronic viral infections was recognized as a hallmark for T cell dysfunction
upon antigen re-stimulation.68 This phenomenon known as exhaustion is character-
ized by the sequential loss of the ability to proliferate, secrete cytokines and lyse
target cells. Especially in HIV infection, T cell impairment could be relieved by
PD-1 blockade both in vitro and in animal models.69,70 Exhausted T cells have in-
creased expression of multiple co-inhibitory receptors and a distinct gene signature,
different from anergic cells, resulting in changes in TCR and cytokine signaling path-
ways.71 Indeed, an exhaustion-specific gene signature, recently defined by Quigley et
al., demonstrated that PD-1 downstream signaling effects play an important role in
the exhaustion of HIV-specific T cells.72 Furthermore, they showed that the tran-
scription factor BATF (Basic leucine zipper transcription factor, ATF-like) appears
essential for downstream PD-1 signaling. In addition to these signaling effects, the
PD-1 gene itself is subject to epigenetic regulation, as increased PD-1 expression
on activated CD8+ T cells results from demethylation of the Pdcd1 locus.73 During
conversion to functional memory T cells remethylation of Pdcd1 occurs, whereas in
exhausted T cells the Pdcd1 regulatory region remains demethylated.
PD-1 in hematological malignancies
In addition to CTLA-4, PD-1/PD-L interactions were shown to be of importance
in hematological malignancies. For instance, PD-L1 overexpression enhanced MM
invasiveness and rendered tumor cells less susceptible to CTL.74 This effect was alle-
viated in PD-1 knockout mice or by anti-PD-L1 antibody treatment, demonstrating
the importance of the PD-1/PD-L pathway in this process. This role of PD-1 was
also confirmed in an AML model, and interestingly, PD-L1 expression was elevated
on tumor cells in vivo compared to in vitro.75 In another report, increased levels of
PD-L1 on MM cells together with enhanced PD-1 expression on exhausted T cells
was demonstrated.76 As expected, in mice PD-L1 blockade improved survival af-
ter autologous SCT and whole cell vaccination from 0 to 40%. In humans, PD-L1
expression was observed on NHL tumor cells, and blockade greatly enhanced cy-
tokine production of autologous tumor-reactive T cells.77 Furthermore, it was shown
that tumor cells of Hodgkin lymphoma (HL) patients can express both PD-L1 and
PD-L2, and PD-1 expression was elevated on HL-infiltrating T cells.78 Also in this
case, blockade of PD-Ls mediated increased cytokine secretion by the infiltrated T
cells. Additionally, long-term persistent murine leukemia cells were shown to sequen-
tially up-regulate PD-L1 and CD80, thereby conferring protection against immune
destruction.79 Upon PD-L1 or CTLA-4 blockade, CTL-mediated lysis of these persis-
tent AML cells was improved. Similar to the link of CTLA-4 and TREG, an elevated
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number of TREG exhibiting high PD-1 expression was described in HCV-associated
lymphoma.80 In addition to PD-1 expression on CD8+ T cells and TREG, PD-L1 ex-
pression on APCs was important for tumor persistence of murine AML. Combining
PD-L1 blockade with TREG depletion showed superior efficacy in clearance of AML,
due to alleviation of PD-1-dependent TREG-mediated suppression.
81
Although clinical PD-1 blockade has not been as extensively tested as Ipili-
mumab for CTLA-4, multiple clinical grade antagonistic anti-PD-1 antibodies have
been developed, i.e. CT-011, BMS-936,558 and MK-3475 (NCT01295827). Further-
more, two anti-PD-L1 antibodies, BMS-936,559 (NCT00729664) and MPDL2180A
(NCT01375842), one anti-PD-L2 antibody (NCT00658892) and a PD-L2 fusion pro-
tein AMP-224 (NCT01352884) are being tested in phase I clinical trials. Three
studies involving hematological cancers were performed with CT-011. One phase
I clinical trial was conducted in patients with varying hematological malignancies,
and showed a clinical response in 6 out of 17 patients, with few adverse events.82
Although the CD4+ T cell count was elevated in the treated patients, no additional
evidence of T cell activation was found. In a preclinical study, ex vivo treatment
with CT-011 enhanced the functionality of NK cells against autologous primary MM
cells.83 In addition, the drug Lenalidomide down-regulated PD-L1, and an additive
effect was shown by combining Lenalidomide with CT-011, rendering this combina-
tion a promising therapy for MM patients. Another study examined whether PD-1
blockade improves the effectiveness of myeloma/DC vaccination therapy, since it is
known that both myeloma cells and myeloma/DC hybridomas highly express PD-
L1.84 Indeed, ex vivo addition of CT-011 resulted in enhanced myeloma lysis by T
cells, as well as a reduction in the number of TREG. However, until now the most
promising effects have been obtained with the monoclonal human anti-PD-1 anti-
body BMS-936,558 (MDX-1106; ONO-4538). Administration to patients with solid
tumors was well tolerated and only one serious adverse event, inflammatory colitis,
was reported.85 Recently, reports on large clinical trials in patients with solid tu-
mors targeting either PD-1 or PD-L1 with BMS antibodies were published in the
New England Journal of Medicine.86,87 PD-1 or PD-L1 blockade resulted in an ob-
jective response in 18-28% or 6-17%, respectively. Most interestingly, PD-1 blockade
induced a durable response in 20/31 patients, and overall the grade 3-4 toxicity was
limited to 14% of the patients. The lack of strong toxic effects in this study holds
promise that PD-1 blockade might have a more subtle effect than CTLA-4 block-
ade, thereby highlighting anti-PD-1 antibodies as interesting candidates for cancer
therapy.
The role of PD-1 in alloSCT has been investigated both in mice and men. In
two similar murine studies dissecting the role of alloantigens in GVT and GVHD re-
activity, it was found that alloreactive T cells recognizing antigens on GVHD-prone
tissues are driven into dysfunction and apoptosis.88 Furthermore, the interaction of
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non-hematopoietic cells with alloreactive T cells prevented the formation of proper
alloreactive memory cells by exploiting the PD-1/PD-L pathway.89 This means that
in addition to the detrimental effect of GVHD as such, also the beneficial GVT effect
is hampered as alloreactive T cells become functionally impaired. Notably, PD-L1
blockade late after alloSCT may partly restore the GVT reactivity without inducing
GVHD. Moreover, these results support the importance of targeting hematopoietic-
restricted MiHA, since these are solely expressed by hematopoietic tumor cells and
residual healthy immune cells of the recipient, but not by GVHD-prone tissues. In
one of the few studies investigating CML, using a retrovirus-induced CML model, it
was demonstrated that tumor-specific T cells can become exhausted.90 In this model,
consisting of PD-1+ tumor-specific T cells and PD-L1+ CML cells, exhaustion was
overcome by either using PD-1-deficient cells or anti-PD-L1 administration. We and
others have investigated the role of PD-1 in GVT immunity in alloSCT patients. In
Chapter 3 of this thesis, we show that high PD-1 expression was observed on allore-
active CD8+ TEM cells that specifically recognize hematopoietic-restricted MiHA in
myeloid leukemia patients.45 In agreement, Mumprecht et al. showed that the total
T cell population from CML patients had elevated levels of PD-1.90 Also CD117+
progenitor AML cells displayed low levels of CD80 and CD86, whereas PD-L1 was
highly expressed, especially under inflammatory conditions.45 Since these observa-
tions were made in alloSCT patients who relapsed after initial powerful MiHA-specific
T cell responses, we postulated that PD-1 expression is involved in T cell exhaustion.
By stimulation with MiHA-loaded DC ex vivo, we aimed at activating these PD-1+
MiHA-specific TEM cells, however results were suboptimal, suggesting an impaired
state. Importantly, upon treatment with anti-PD-1 or anti-PD-L1 blocking antibod-
ies we were able to reinvigorate MiHA-specific TEM proliferation. Notably, the effect
of PD-1 blockade on MiHA-specific TEM cells from relapsed patients compared to
patients in long-term remission was significantly stronger, indicating the function of
PD-1 in T cell exhaustion and subsequent tumor immune evasion.
BTLA
Expression and function of BTLA
B and T lymphocyte attenuator (BTLA), i.e. CD272, was identified in 2003 as
an inhibitory receptor with structural similarities to CTLA-4 and PD-1.91 BTLA is
mainly expressed by immune cells, including T and B cells, DC and myeloid cells.92,93
In contrast to other B7/CD28 family members, BTLA binds a member of the tumor
necrosis factor receptor (TNFR) superfamily, namely herpes virus entry mediator
(HVEM).94 HVEM is part of an intricate signaling network as it has at least four
additional binding partners that distinctively mediate T cell responses: i.e. CD160,
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LIGHT (for lymphotoxin-like, exhibits inducible expression, and competes with HSV
glycoprotein D for HVEM, a receptor expressed by T lymphocytes), lymphotoxin-α
(LT-α) and herpes simplex virus glycoprotein D (gD).95 BTLA or CD160 signaling
upon HVEM binding result in T cell inhibition.94,96 However, HVEM present on T
cells acts as a co-stimulatory receptor,97 thereby constituting a bidirectional pathway.
Interestingly, na¨ıve T cells express both HVEM and BTLA, and these molecules form
a T cell intrinsic heterodimer complex.98 Due to this complex, HVEM is unavailable
for extrinsic ligands, and no co-stimulatory signal is transduced. Studies in BTLA-
deficient mice revealed a predisposition to experimentally induced autoimmune en-
cephalomyelitis.91 Furthermore, these mice develop late-onset spontaneous autoim-
mune hepatitis-like disease and multi-organ lymphocyte infiltration,99 implying the
involvement of BTLA in maintaining self tolerance. In humans, persistent expression
of BTLA was observed on EBV- and CMV-specific CD8+ T cells, negatively affecting
T cell function.100,101 Furthermore, in melanoma patients high BTLA expression cor-
related with impaired tumor-specific T cell function.37,100 These tumor-specific T cell
responses could be restored in vitro by interference with the BTLA-HVEM pathway
in combination with vaccination therapy. In addition, co-expression of PD-1, BTLA
and T cell immunoglobulin and mucin domain 3 (TIM-3) rendered melanoma-specific
CD8+ T cells highly dysfunctional, which could be restored by combined blockade of
all three co-inhibitory molecules.102
BTLA in hematological malignancies
A single administration of agonistic anti-BTLA antibody directly after alloSCT in
mice completely prevented GVHD, while this treatment did not hamper GVT re-
sponses.103,104 Moreover, when using an antibody that specifically blocked the in-
teraction of HVEM with BTLA, but not LIGHT, GVHD was attenuated.105 This
suggests that in this model the co-stimulatory function of HVEM was dominant over
its co-inhibitory activity. Since both HVEM and BTLA can be expressed by T cells,
bidirectional signaling can occur. Therefore, combining specific blocking antibodies
with cell-specific knockout models for these molecules will be necessary to further
unravel the intricate interactions between HVEM, BTLA, CD160 and LIGHT. In
addition, in Chapter 4 of this thesis we investigated the effect of a BTLA blocking
antibody on MiHA-specific T cell function in alloSCT patients.92 As shown for PD-
1, we observed that BTLA was also highly expressed on MiHA-specific TEM cells.
Moreover, in 7 out of 11 patients BTLA blockade resulted in increased outgrowth of
MiHA-specific TEM cells of transplanted patients. Interestingly, in 3 patients BTLA
blockade effects were more prominent than those of PD-1, indicating that BTLA
has a non-redundant function to PD-1, and therefore it holds promise in post-SCT
therapies.
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New co-inhibitory players
In addition to the afore discussed molecules, CD200R, TIM-3, LAG3 and PD-1H/
VISTA were recently shown to contribute to T cell inhibition and/or exhaustion in
hematological cancers.
CD200 Receptor (CD200R) is an inhibitory receptor previously thought to be
most important on myeloid cells, but is also expressed in the lymphoid lineage such
as NK, CD4+ and CD8+ T cells, especially upon stimulation.106 Its ligand, CD200
(OX2) is a glycoprotein expressed on a broad number of cell types, including solid
tumors and hematological malignancies.107,108 In addition to the previously discussed
co-inhibitory molecules, CD200R inhibits both T and NK cell functionality.109,110
Furthermore, CD200/CD200R interactions are involved in tumor immune evasion,
as CD200 expression on AML cells promoted tumor growth in mice.111 Interestingly,
patients with CD200+ AML cells displayed a lower number of activated NK cells, and
the effect on NK functionality was correlated to CD200 expression on the leukemia
cells.109 In concordance with this, blockade of CD200 enhanced IFN-γ release and
cytotoxicity by NK cells. Moreover, CD200 blockade restored T cell proliferation
and tumor control by immune cells for human CD200+ CLL both in vitro 110 and
in a humanized mouse model.112 However, in a follow-up report, treatment with
anti-CD200 antibody caused loss of T cell-mediated tumor control due to clearance
of the T cells.113 This was attributed to ADCC of CD200+ T cells caused by the
IgG1 variant of anti-CD200, which was not observed for the IgG4 isotype. Therefore,
blocking strategies should be carefully designed before proceeding to the clinic.
In addition, the co-signaling receptor TIM-3 is expressed on Th1 CD4+ and CD8+
T cells, and is involved in co-inhibition. In mice, the interaction of TIM-3 with its
ligand galectin-9 was demonstrated to be inhibitory in autoimmune diseases and ma-
lignancies.114 Furthermore, in HIV115 and melanoma patients,116 dysfunctional T
cells have been shown to co-express TIM-3. In this regard interference with TIM-3
signaling is an interesting treatment option, and enhanced tumor vaccine efficacy
has been observed by TIM-3 blockade.117 Interestingly, both TIM-3 and PD-1 were
expressed on a subset of exhausted CD8+ T cells in a murine AML model and expres-
sion increased during tumor progression.118 While either TIM-3 or PD-L1 blockade
alone was not sufficient to improve survival, a combination of the two antibodies
decreased tumor burden and enhanced survival. Furthermore, in human lymphoma
an interesting role for TIM-3 has been described on tumor endothelium.119 TIM-3
expressed on these endothelial cells mediated impaired CD4+ T cell responses, and
thereby promoted lymphoma onset, growth, and dissemination. In contrast, a stimu-
latory role for TIM-3 and galectin-9 has been reported in the interaction of CD8+ T
cells and DC.120 This discrepancy is reflected in research investigating its mechanism
of action, where T cell receptor stimulation is enhanced upon TIM-3 signaling.121
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This might be explained by the fact that T cell exhaustion could be caused by pro-
longed TCR signaling, and TIM-3 accelerates this process. Another explanation is
that depending on which ligand binds to TIM-3, different modes of signaling are
initiated. Therefore, TIM-3 may act as either a co-stimulatory or a co-inhibitory
factor, similar to BTLA.
Lymphocyte-activation gene 3 (LAG3; CD223) is a co-inhibitory receptor highly
similar to CD4 and binds HLA class II molecules.122,123 Importantly, LAG3 was
implicated to inhibit T cell function in HL patients.122,124 LAG3 seems to be non-
redundant from PD-1, as both are expressed on distinct populations of CD8+ T
cells.125 Recently, it was shown that in mice PD-1 and LAG3 act synergistically
in the onset of autoimmune diseases and tumor escape.126,127 Furthermore in HL,
both TREG and LAG3
+ CD4+ T cells were shown to be involved in tumor immune
evasion, since the expression of FoxP3 and LAG3 coincided with the impairment of
tumor-specific T cell responses.124 Therefore, LAG3 is an interesting candidate to
combine with therapies that utilize TREG depletion or PD-1 blockade.
Recently another immunoregulatory molecule with similarities to PD-1 as well as
to PD-L1 was simultaneously discovered by two groups: PD-1H (PD-1Homolog)128
or VISTA (V-domain Ig suppressor of T cell activation).129 This molecule is broadly
expressed on hematopoietic cells and is upregulated on APC and T cells upon acti-
vation. Mice treated with a single dose of PD-1H/VISTA-antibody did not develop
GVHD after alloSCT, however the mechanism of action was not elucidated.128 An-
other study identified PD-1H/VISTA as an inhibitory ligand on APC and tumor
cells.129 Here, PD-1H/VISTA Ig-fusion protein conveyed a lasting negative signal to
T cells, and expression of the protein on APC suppressed T cell proliferation. Impor-
tantly, PD-1H/VISTA expression on tumor cells resulted in diminished anti-tumor
immunity. The human ortholog was determined on the genomic level, and due to
the important role of this immunoregulatory molecule in GVHD and tumor escape,
PD-1H/VISTA is anticipated to be a potential therapeutic target.
Altogether, the pivotal role of co-inhibitory molecules in immune evasion of hema-
tological malignancies provides a rationale to include them in novel therapeutic
strategies. In the future, the interference with specific co-inhibitory receptors may
solve the conundrum of boosting GVT while limiting GVHD.
Organ-specific immunosuppression mechanisms
Although co-inhibitory receptors are important in the interaction of tumor cells and
the immune system, other factors in the microenvironment could also play a promi-
nent role in dampening anti-tumor immunity. One of the most important mecha-
nisms is the induction and recruitment of TREG, which can protect tumor cells by
suppressing tumor infiltrating cytolytic TEFF cells. Interestingly, it appears that
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these immunosuppressive factors are not only dependent on the tumor cells them-
selves, but also the organ location determines which mechanisms are being deployed.
Previously, it was shown that cytotoxic MiHA-specific CD4+ T cells were capable
of eliminating medullary MM, but could not eradicate tumor cells at extramedullar
locations, eventually leading to death.130 This emphasizes the fact that this dif-
ferential local immunosuppression may be responsible for fatal tumor outgrowth.
Interestingly, location-specific expression profiles of PD-1 have been shown before for
chronic viral infection, and the BM was also a less immunosuppressive environment
than the spleen.131 In Chapter 5 of this thesis, we have investigated the organ-
specific properties of several immunosuppressive mechanism in a MM mouse model.
A striking observation was that a stronger inflammation was present in BM com-
pared to spleen. In addition, while in spleen the percentage of NK cells dropped, this
did not take place in the BM. Furthermore, we found that TREG are differentially
regulated in these two organs. Whether or not a direct link exists between these
two mechanisms is not clear yet, but these results indicate that multiple suppressive
mechanisms can be present simultaneously dependent on the tumor organ location.
Therefore, attacking immunosuppression at different fronts may result in synergistic
boosting of clinical effective anti-tumor immunity.
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Scope of this thesis
Allogeneic stem cell transplantation is a potent therapy against hematological
malignancies. This thesis investigates the kinetics and functional properties of MiHA-
specific T cell responses after alloSCT, constituting the GVT effect. Although this is
a potentially curative anti-tumor immune effect, occurrence of detrimental GVHD,
suppression of robust MiHA T cell immunity and relapse of the malignancy are still
major impediments of this important anticancer treatment. Here, we investigated
the dynamics of these immune responses, and which immunosuppressive mechanisms
are involved in dampening anti-tumor MiHA-specific T cell immunity in relapsed
patients. Knowledge of these mechanisms will result in new treatment modalities
that optimize anti-tumor alloimmune responses, aiming to fully harness the power of
the GVT effect. In the end, the results described in this thesis may result in a better
curative rate of hematological malignancies, while decreasing adverse events such as
GVHD and infections.
In Chapter 2, we investigated alloreactive CD8+ T cells which specifically rec-
ognize the hemato-restricted MiHA LRH-1. Interestingly, immune responses against
this MiHA coincided with eradication of the malignancy. Furthermore, we showed
that these LRH-1-specific T cells can specifically lyse the progenitor CD34+ acute
and CML cells. Therefore, LRH-1 is an attractive target for immune therapy post
alloSCT. However, although MiHA responses constituted a powerful GVT effect,
relapses do occur despite the long-term presence of MiHA-specific CD8+ T cells.
Interestingly, we observed that escape from MiHA-specific CTL lysis during the ef-
fector response might be related to elevated levels of anti-apoptotic XIAP, especially
in the absence of IFN-γ and low E:T ratios. However, also intrinsic T cell inhibitory
mechanisms could play a important role. Therefore, in Chapter 3 we explored
whether the important co-inhibitory molecule PD-1 is involved in dysfunction of
MiHA-specific T cells in patients that relapse after alloSCT. Indeed, we showed that
PD-1 is present on alloreactive CD8+ T cells post-SCT and the PD-1 ligands are
expressed by myeloid leukemia cells. Most importantly, blockade of PD-1 increased
proliferation of MiHA-specific memory cells from relapsed patients, emphasizing the
role of this pathway in dysfunctional MiHA-responses and subsequent relapse. These
data render PD-1 an attractive target for post-SCT treatment, for instance by anti-
PD-1 monoclonal antibody administration, either as monotherapy or in combination
with DLI and MiHA-based vaccines. In addition to PD-1, in Chapter 4 we investi-
gated the role of BTLA, another major co-inhibitory molecule. Also for BTLA and
its ligand HVEM, we observed expression on MiHA-specific T cells and hematological
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tumor cells, respectively. Furthermore, blockade of BTLA enhanced the growth of
MiHA-specific T cells ex vivo, and in 3 out of 11 patients even stronger than PD-1
blockade. These results prove that T cell dysfunction is due to multiple co-inhibitory
receptors, and that between patients one or the other receptor may have the dominant
role. Furthermore, interfering with multiple co-inhibitory receptors at once may
result in a synergistic boost of anti-tumor immunity. In addition to receptors such as
PD-1 and BTLA, other extrinsic mechanisms are involved in tumor immune evasion.
Chapter 5 describes the different immunosuppressive mechanisms taking place in
mice with MM. Interestingly, differential effects are shown between the BM and the
spleen. More inflammation is shown in the BM, suggesting a higher anti-tumor effect
compared to the spleen. This is suggested by a decline of NK cells in spleen, while
in BM levels stay constant. One of the causative players for these differences may
be TREG, since a higher number and possibly more suppressive TREG are found in
the spleen. The results of this study show that immune evasion is an interplay of
different innate and adaptive components, which may differ between tumor location.
Since several factors such as NK cells and TREG are involved, multiple aspects can
be targeted, which most likely will affect the whole tumor microenvironment.
Altogether, in this thesis we investigated which mechanisms suppress the potential
curative power of GVT responses after alloSCT. One of the ways that its potency is
suppressed are co-inhibitory molecules like PD-1 and BTLA, which we can fortunately
alleviate by targeting these receptors. Furthermore, other factors such as tumor cell-
intrinsic anti-apoptotic properties or TREG are involved. Unraveling the role of all
these immunosuppressive mechanisms will lead to improved immunotherapies. This
holds great promise for the future, in which more strategies, e.g. the blockade of
co-inhibitory molecules, will be deployed to harness the full power of MiHA-specific
immune responses.
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Chapter 2: LRH-1 CTL target myeloid leukemic progenitor cells
Abstract
CD8+ T cells recognizing minor histocompatibility antigens (MiHA) on leukemic
stem and progenitor cells play a pivotal role in effective graft-versus-leukemia reac-
tivity after allogeneic stem cell transplantation (SCT). Previously, we identified a
hematopoiesis-restricted MiHA, designated LRH-1, which is presented by HLA-B7
and encoded by the P2X5 purinergic receptor gene. We found that P2X5 is signifi-
cantly expressed in CD34+ leukemic subpopulations from chronic myeloid leukemia
(CML) and acute myeloid leukemia (AML) patients. Here, we demonstrate that
LRH-1-specific CD8+ T cell responses are frequently induced in myeloid leukemia
patients following donor lymphocyte infusions. Patients with high percentages of cir-
culating LRH-1-specific CD8+ T cells had no or only mild graft-versus-host disease.
Functional analysis showed that LRH-1-specific cytotoxic T lymphocytes (CTL) iso-
lated from two different patients efficiently target LRH-1-positive leukemic CD34+
progenitor cells from both CML and AML patients, while mature CML cells are only
marginally lysed due to down-regulation of P2X5. Furthermore, we observed that
relative resistance to LRH-1-CTL-mediated cell death due to elevated levels of anti-
apoptotic XIAP could be overcome by IFN-γ pre-stimulation and increased CTL-
target ratios. These findings provide a rationale for use of LRH-1 as immunothera-
peutic target antigen to treat residual or persisting myeloid malignancies after allo-
geneic SCT.
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Introduction
Introduction
Allogeneic stem cell transplantation (SCT) followed by donor lymphocyte infusions
(DLI) is a curative treatment option for patients with chronic myeloid leukemia
(CML) or acute myeloid leukemia (AML).1,2 The therapeutic efficacy is attributed
to the graft-versus-leukemia (GVL) response mediated by donor-derived T cells rec-
ognizing minor histocompatibility antigens (MiHA) on malignant cells of the re-
cipient.3,4 However, a significant number of patients with advanced CML and AML
relapse due to persisting leukemic stem and progenitor cells.5 Adjuvant immunother-
apy targeting hematopoietic cell-restricted MiHA on these primitive leukemic cells
may permanently eradicate the malignancy without inducing graft-versus-host dis-
ease (GVHD).6,7
Previously, we identified a hematopoiesis-restricted MiHA, designated LRH-1,
which elicited an HLA-B7-restricted cytotoxic T lymphocyte (CTL) response in an
advanced CML patient treated with DLI.8 Using isolated LRH-1-specific CTL from
this patient we demonstrated that immunogenicity of LRH-1 resulted from differen-
tial expression of the P2X5 protein in recipient and donor cells as a consequence of a
single nucleotide frameshift polymorphism. Interestingly, tetramer analysis showed
a direct association between in vivo expansion of LRH-1-specific CD8+ T cells and
the disappearance of Bcr-Abl positive CML cells following DLI. Moreover, gene ex-
pression studies revealed thatP2X5 is not expressed in non-hematopoietic tissues,
including prominent GVHD target tissues such as skin, liver, colon and small intes-
tine.8 These findings illustrate that P2X5-encoded MiHA LRH-1 may play a signifi-
cant role in inducing GVL-specific immunity against myeloid leukemia. Although we
have shown that P2X5 mRNA is significantly expressed in leukemic CD34+CD38−
and CD34+CD38+ subpopulations from most CML and AML patients,8 it remained
to be investigated whether myeloid leukemic progenitor cells are susceptible to lysis
by LRH-1-specific CTL.
Here, we studied whether LRH-1-reactive CTL specifically and efficiently target
CD34+ leukemic progenitor cells from CML and AML patients. We demonstrate that
LRH-1-specific CD8+ T cell responses are frequently induced in myeloid leukemia
patients following DLI. In addition, LRH-1-specific CTL isolated from two different
patients efficiently lyse LRH-1-expressing malignant CD34+ progenitor cells from
both CML and AML patients. These findings illustrate that LRH-1 is an attractive
target for eradication of residual or persisting myeloid leukemic progenitor cells after
allogeneic SCT.
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Materials and Methods
Transplantation patients
Seven patients, five females and two males, aged 20 to 54 years (median 35) were
transplanted for acute lymphoblastic leukemia (ALL, n = 2), acute myeloid leukemia
(n = 2), chronic myeloid leukemia (n = 2) and multiple myeloma (n = 1). Donors
were HLA-identical siblings in five cases and non HLA-identical family members in
two cases. Conditioning for transplantation was with cyclophosphamide (120 mg/kg)
and total body irradiation (9 Gy) with the addition of idarubicin 42 mg/m2 in three
patients and anti-thymocyte globulin in two cases. All grafts were partially T cell-
depleted to 0.7 x 106 CD3+ cells/kg body weight of the recipient. DLI was given
pre-emptively in five patients and therapeutically in two patients.
Cell isolation and cell culture
Peripheral blood (PB) and bone marrow (BM) samples have been collected after
written informed consent in ongoing clinical stem cell transplantation protocols ap-
proved by the RUNMC and LUMC Institutional Review Boards. CD34+ CML and
AML cells were isolated from PB and BM, respectively, obtained at diagnosis, by
fluorescence activated cell sorting (FACS) on a Coulter Epics Elite Flow Cytometer
(Beckman Coulter, Fullerton, CA, USA). Primary T cell cultures were generated from
peripheral blood mononuclear cells (PBMC) obtained 2-6 months after DLI from 2
CML patients (Pt1 and Pt2) and 1 AML patient (Pt3) transplanted with stem cells
from an LRH-1 mismatched donor. After thawing, PBMC were partly used for LRH-
1/HLA-B7 tetramer staining. Remaining PBMC were cultured in Iscove’s modified
Dulbecco’s medium (IMDM) (Invitrogen, Carlsbad, CA, USA) supplemented with
10% human serum (HS) (PAA laboratories, Linz, Austria) and stimulated with irra-
diated (80 Gy) donor EBV-transformed lymphoblastoid cell line (LCL) pulsed with
10 µM LRH-1 peptide TPNQRQNVC at a ratio of 1:1. At day 1 and 4, 25 IU/ml IL-2
(Chiron, Emeryville, CA, USA) was added to the cell cultures. After 2 to 3 weekly
stimulations, these primary T cell cultures were analyzed for the presence of LRH-
1/HLA-B7-tetramer+ CD8+ T cells. LRH-1-specific CD8+ CTL culture TB1 was
enriched to a >95% LRH-1-tetramer+ population from PBMC of AML patient Pt3
by repeated LRH-1-specific stimulation. LRH-1-specific CD8+ CTL culture RP1 was
isolated from CML patient Pt1 who was successfully treated with DLI after allogeneic
SCT.8 Both CTL TB1 and RP1 recognize the 9-mer epitope TPNQRQNVC in the
context of HLA-B*0702. The HLA-B7-alloreactive CD8+ CTL culture KOR18 was
kindly provided by Prof. dr. E. Goulmy (Dept. of Immunohematology, LUMC, The
Netherlands). CTL RP1, TB1 and KOR18 (0.5*106) were cultured in IMDM/10%
HS containing irradiated (80 Gy) HLA-B7+ LRH-1+ EBV-LCL (0.5*106), irradi-
ated (60 Gy) allogeneic PBMC (0.5*106) from two donors, 100 IU/ml IL-2 and 1
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µg/ml PHA-M (Boehringer, Mannheim, Germany) in a total volume of 2 ml. Cell
lines were cultured in IMDM/10% fetal calf serum (FCS; Integro, Zaandam, The
Netherlands). KG1, KG1a and K562 AML cell lines were retrovirally transduced
with LZRS-HLA-B*0702-IRES-EGFP as described.8,9
Flow cytometry
PE-labeled LRH-1/HLA-B7 tetramers containing peptide TPNQRQNVC were pro-
duced as described.10 PBMC or CTL were incubated with 20 µg/ml HLA-B7/LRH-
1 tetramer for 20 min at room temperature. After washing with PBS/0.5% BSA,
cells were labeled with the appropriate concentration anti-CD8 (ProImmune, Oxford,
UK), anti-CD3, and anti-CD45 (Beckman Coulter) for 15 min at 4◦C. After washing,
cells were resuspended in PBS/0.5%BSA and 7-amino-actinomycin D (7AAD; Sigma,
St Louis, MO, USA) was added. Cells were analyzed using the Coulter FC500 flow
cytometer (Beckman Coulter). LRH-1-tetramer+ cells were further phenotyped using
IgG2A, anti-CD45RA, anti-CD27, anti-Fas (Beckman Coulter), IgG1, anti-CD45RO
(DAKO, Glostrup, Denmark), anti-CD127 (eBiosciences, San Diego, CA, USA), anti-
CD28 (Becton Dickinson, Franklin Lakes, NJ, USA), and anti-CCR7 (R&D Systems,
Minneapolis, MN, USA). Relapse samples from CML patient Pt1 were phenotyped
using anti-CD38, anti-CD117 (Becton Dickinson), anti-CD13, anti-CD33 (Beckman
Coulter), and anti-CD133 (Miltenyi Biotec, Bergisch Gladbach, Germany).
Real-time quantitative RT-PCR
Total RNA was isolated from cell samples using Trizol (Invitrogen) or the Zymo RNA
isolation kit II (Zymo Research Corporation, Orange, CA, USA). cDNA synthesis and
PCR amplification were performed as described.9,11,12 The hydroxymethylbilane syn-
thase (HMBS ) housekeeping gene was used to normalize gene expression. One µL of
cDNA was amplified in a 50-µl reaction mixture containing 1.25 U AmpliTaq Gold
(Applied Biosystems), 300 nM gene-specific forward and reverse primer, 150-300 nM
gene-specific Taqman probe (150 nM for P2X5, and 300 nM for HMBS ), 250 µM of
each dNTP, 5 mM MgCl2 and 1x Taqman PCR buffer (Applied Biosystems). Alter-
natively, 1x SYBRgreen buffer was used for the apoptosis-regulating genes caspase-
3, Smac, Bax, Bcl-xL, Bcl-2, Bak, and Bid. The following gene-specific primers
and Taqman probes were used: P2X5; P2X5-F 5’-TCCTGGCGTACCTGGTCGT-
3’, P2X5-R 5’-CTTCATTCTCAGCACAGACGTTC-3’ and P2X5-probe 5’-(TET)-
TGGGTGTTCCTGATAAAGAAGGGTTACCA-(TAMRA)-3’, HMBS; HMBS-F 5’-
GGCAATGCGGCTGCAA-3’, HMBS-R 5’-GGGTACCCACGCGAATCAC-3’ and
HMBS-probe 5’-(VIC)-CTCATCTTTGGGCTGTTTTCTTCCGCC-(TAMRA)-3’,
caspase-3; caspase-3-F 5’-GACAGACAGTGGTGTTGATGATGA-3’ and caspase-3-
R 5’-TTTGAATTTCGCCAAGAATAATAAC-5’, Smac; Smac-F 5’-CACAATGGC-
GGCTCTGAAG-3’ and Smac-R 5’-CCACAACAGGAACACACAAACA-3’, Bax;
Bax-F 5’-GAGCGGCGGTGATGGA-3’ and Bax-R 5’-TGGATGAAACCCTGAAG-
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CAAA-3’, Bcl-xL; Bcl-xL-F 5’-CCACTTACCTGAATGACCACCTAGA-3’, Bcl-xL-
R 5’-CAGCGGTTGAAGCGTTCC-3’, Bcl-2; Bcl-2-F 5’-TCGCCCTGTGGATGAC-
TGA-3’, Bcl-2-R 5’-CAGAGACAGCCAGGAGAAATCA-3’, Bak; Bak-F 5’-TGAGT
ACTTCACCAAGATTGCCA-3’ and Bak-R 5’-AGTCAGGCCATGCTGGTAGAC-
3’, and Bid; Bid-F 5’-CCTTGCTCCGTGATGTCTTTC-3, and Bid-R 5’-TCCGTT-
CAGTCCATCCCATTT-3’. Expression of apoptotic gene XIAP was determined us-
ing TaqMan gene expression assay Hs01597783 m1 (Applied Biosystems) with XIAP-
probe 5’-(FAM)-GCCGGCTGTCCTGGCGCGAAAAGGT-(TAMRA)-3’ according
to the manufacturers instructions. PCR amplification was performed using an ABI
Prism 7700 (Applied Biosystems) with the following PCR conditions: enzyme acti-
vation for 10 min at 95◦C, followed by 45 cycles of 95◦C for 15 s and 60◦C for 1 min.
P2X5 mRNA expression was quantified by determining calibration functions using
JVM-2 as reference cell line. The level of P2X5 expression was calculated relative
to the P2X5 expression in the JVM-2 cell line, which is susceptible to lysis by the
LRH-1-specific CTL. Previous experiments demonstrated that only target cells with
a relative P2X5 mRNA expression level higher than 0.4 could be recognized by LRH-
1-specific CTLs.8 Therefore, we arbitrarily set the cutoff level at 0.4 to discriminate
between LRH-1-positive and -negative cell types. mRNA expression of apoptosis
genes XIAP, caspase-3, Smac, Bax, Bcl-xL, Bcl-2, Bak, and Bid is shown in ∆∆Ct
values and was quantified relative to AML cell line KG1, which was set at 1 ∆∆Ct
value. ∆∆Ct was calculated as follows: 2(−[∆Ct sample]−[∆Ct KG1]), in which ∆Ct was
normalized for HMBS by calculating ∆Ct = Ctgene − CtHMBS per sample.
P2X5 genotyping
Genomic DNA was isolated from cell lines using the QIAamp DNA Blood mini kit
(Qiagen, Hilden, Germany). DNA was amplified as described 9, using the following
gene-specific primers and Taqman probes: P2X5; P2X5-EXON3-F 5-CCAAATCAA-
ACCTCAGCACAGAC-3, P2X5-EXON3-R 5-CTCAGTGCCTCTCTGGTTCCTT-
A-3, P2X5 5C allele-specific probe 5-(FAM)-ATTGTGACCCCCAACCA-(MGB)-3
and P2X5 4C allele-specific probe 5-(VIC)-TGTGACCCCAACCAG-(MGB)-3. After
PCR amplification an end-plate read was performed using ABI Prism 7700 allelic
discrimination software.
Cytotoxicity studies
Cytotoxicity assays were performed as described9,11,13 with some adaptations. Brie-
fly, CD34+ progenitor cells were sorted from thawed PB samples obtained from
chronic phase CML patients (Pt8-11). These samples contained 2-10% CD34+ leuke-
mic progenitor cells, of which 8-15% were negative for CD38. Purified chronic phase
CD34+ CML cells were either directly labeled with 0.75 µM carboxyfluorescein diac-
etate succimidyl ester (CFSE; Molecular Probes Europe, Leiden, The Netherlands)
and used in cytotoxicity assays, or first cultured for 1 week in the presence of a cy-
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tokine mixture (GM-CSF (100 ng/ml), G-CSF (100 ng/ml), IL-3 (50 ng/ml), SCF
(25 ng/ml), and EPO (2 IU/ml)). CD34+ accelerated phase CML relapse cells from
patient Pt1 were cultured overnight in medium containing GM-CSF (100 ng/ml),
G-CSF (100 ng/ml), IL-3 (50 ng/ml), SCF (25 ng/ml), and EPO (2 IU/ml) in the
absence or presence of 100 U/ml IFN-γ. Thereafter CD34+ cells were sorted, la-
beled with 0.625 µM CFSE and used in cytotoxicity assays in medium containing
GM-CSF, G-CSF, IL-3, SCF and EPO. PB or BM samples obtained from AML
M0/1/2 patients (Pt12-16) were cultured overnight in medium containing GM-CSF
(100 ng/ml), G-CSF (100 ng/ml), IL-3 (50 ng/ml), SCF (25 ng/ml) and Flt3L (20
ng/ml) in the absence or presence of 100 U/ml IFN-γ. Thereafter CD34+ cells were
sorted, labeled with 0.625 µM CFSE and used in cytotoxicity assays in medium con-
taining GM-CSF, G-CSF, IL-3, SCF and Flt3L. EBV-LCL were labeled with 1.5 µM
CFSE. Subsequently, CFSE-labeled target cells were co-cultured for three consecu-
tive days with unlabelled effector cells in IMDM/10% FCS containing 25 U/ml IL-2
and the above described cytokines. HLA-B*0702-IRES-EGFP-transduced AML cell
lines were used as targets without CFSE labeling. After co-culture, cells were har-
vested and 7AAD was added to identify the number of viable target cells. Target cell
survival was calculated as follows: % survival = [absolute no. viable target cells co-
cultured with CTL] / [absolute no. viable target cells cultured in medium] × 100%.
Specific lysis was calculated as follows: % lysis = 100 - [% survival]. To visualize
target cell lysis, cytospins were made from CD34+ CML progenitor cells and CD34−
cytokine-maturated CML cells on day 2 of co-culture with LRH-1-specific CTL. Cells
were morphologically examined after May-Gru¨nwald-Giemsa staining.
Results
CD34+ myeloid leukemia cell lines are efficiently lysed by LRH-1-specific
CTLs
To investigate potential CTL recognition of myeloid malignancies, P2X5 gene expres-
sion levels were measured by quantitative RT-PCR in a panel of malignant myeloid
cell lines. Interestingly, relatively high P2X5 mRNA levels were detected in the im-
mature CD34+CD38− myeloid cell line KG1 (0.71) and in the more undifferentiated
sub-line KG1a (1.08) (Figure 2.1A). Lower P2X5 expression levels were found in
U937 (0.39) and Kasumi (0.31). P2X5 expression was lowest in the more differenti-
ated myeloid leukemia cell lines, such as Lama, MonoMac6, NB4, K562, HL-60 and
THP-1. Next, we determined whether P2X5 mRNA expression in the KG1 cell lines
results in susceptibility to LRH-1-CTL-mediated lysis. Because target cell recogni-
tion by LRH-1-specific CTL is controlled by a single cytosine deletion polymorphism
(rs5818907) in exon 3 of the P2X5 gene, we first performed P2X5 genotyping anal-
ysis.
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Figure 2.1: P2X5 expression in KG1 AML cells results in recognition and lysis
by LRH-1 specific CTL. (A) P2X5 mRNA expression was determined by real-time quantitative
RT-PCR in a panel of AML cell lines. (B) Specific cytotoxicity of LRH-1-specific CTL RP1 against
AML cell lines KG1, KG1a and K562 with and without transduction of HLA-B*0702. Specific lysis
was determined after 2 days of co-culture in a flow cytometry-based cytotoxicity assay at an E:T
ratio of 0.5:1. (C) Survival up to 3 days of HLA-B*0702-transduced AML cell lines KG1 (N), KG1a
(H) and K562 () co-cultured with LRH-1-specific CTL RP1 at an E:T ratio of 0.5:1. Data are
displayed as mean plus or minus SD of triplicate wells.
This analysis revealed that KG1 and KG1a cells are homozygous positive for the
LRH-1-encoding allele (i.e. C/C genotype). Since these cell lines do not express
HLA-B7, they were retrovirally transduced with HLA-B*0702. Functional analy-
sis revealed that LRH-1-specific CTL efficiently kill HLA-B7-transduced KG1 and
KG1a cells at a very low E:T ratio of 0.5:1 (Figure 2.1B and 2.1C). No cytotoxic-
ity was observed against HLA-B7-transduced LRH-1-negative K562 cells (-/- geno-
type). By contrast, HLA-B7-transfected KG1 and K562 cell lines were effectively
lysed by allo-HLA-B7-specific CTL, indicating that HLA-B7 molecules were prop-
erly expressed (Figure 2.1B). These data demonstrate that P2X5 mRNA expression
in human CD34+ myeloid leukemia cell lines results in LRH-1-specific CTL lysis.
50
Results
Figure 2.2: Myeloid leukemic CD34+ progenitor cells from chronic phase CML
patients are efficiently lysed by LRH-1-specific CTLs. Survival of sorted CD34+
leukemic cells in flow cytometry-based cytotoxicity assays was determined from four HLA-B7+
patients after incubation with LRH-1-specific CTL RP1 (N), HLA-B7-specific CTL KOR18 (H; i.e.
positive control) or medium () in the presence of growth factors. Proliferation of viable CFSE-
labeled leukemic cells is shown from two LRH-1+ CML patients (A+B) and from two LRH-1− CML
patients (C+D) in the absence or presence of CTL at an E:T ratio of 0.5:1. Data are depicted as
mean plus or minus SD of triplicate wells.
LRH-1-specific CTL specifically target CD34+ CML and AML progenitor
cells
To investigate whether primary myeloid leukemic progenitor cells are susceptible to
LRH-1-CTL-mediated killing, we performed cytotoxicity assays with CD34+ cells
isolated from PB or BM of HLA-B7+ chronic phase CML patients Pt8-11 and of
HLA-B7+ AML patients Pt12-15. We observed that CD34+ progenitor cells from
two LRH-1+ CML patients (Pt8 and Pt9), which had a P2X5 mRNA expression
level of 4.68 and 1.86, respectively, were efficiently lysed by LRH-1-specific CTL.
Remarkably, targeting of CML progenitor cells by LRH-specific CTL at a very low
E:T ratio of 0.5:1 resulted in robust growth inhibition within 3 days (Figure 2.2A
and B). No cytotoxicity and growth inhibition of CD34+ cells from 2 LRH-1− CML
patients (Pt10 and Pt11) was observed, demonstrating specific targeting by LRH-
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Figure 2.3: Myeloid leukemic CD34+ progenitor cells from AML patients are
efficiently lysed by LRH-1-specific CTLs. Survival of sorted CD34+ leukemic cells in flow
cytometry-based cytotoxicity assays was determined from four HLA-B7+ patients after incubation
with LRH-1-specific CTL RP1 (N), HLA-B7-specific CTL KOR18 (H; i.e. positive control) or
medium () in the presence of growth factors. Proliferation of viable CFSE-labeled leukemic cells
is shown for two LRH-1+ AML patients (A+B) and for two LRH-1− AML patients (C+D) in the
absence or presence of CTL at an E:T ratio of 0.5:1. Data are depicted as mean plus or minus SD
of triplicate wells.
1-reactive CTL (Figure 2.2C and D). In addition, we observed that CD34+ cells
from two LRH-1+ AML patients (Pt12 and Pt13) were efficiently lysed by LRH-1-
specific CTL at a very low E:T ratio of 0.5:1 (Figure 2.3A and B). No cytotoxicity
and growth inhibition of CD34+ cells from two LRH-1− AML patients (Pt and Pt15)
was observed, again demonstrating specific targeting by LRH-1-reactive CTL (Figure
2.3C and D). By contrast, both LRH-1+ and LRH-1− CD34+ target cells of CML
and AML patients were efficiently killed by allo-HLA-B7-specific CTL.
Previously, we reported that mature myeloid cells such as monocytes and monocy-
te-derived DC have a relatively low P2X5 mRNA expression, which is insufficient
for recognition by LRH-1-specific CTL.8 Here, we studied the effect of differentia-
tion of CD34+ CML cells on LRH-1-CTL-mediated lysis. Therefore, CD34+ cells
from two LRH-1+ CML patients (Pt8 and Pt9) were cultured for 7 days in the
52
Results
presence of differentiation-inducing growth factors and used in cytotoxicity assays.
These cytokine-maturated CD34− CML cells from both patients were only marginally
lysed by LRH-1-specific CTL (Figure 2.4A and B). This decrease in responsiveness
was associated with >10 fold down-regulation of P2X5 mRNA expression from 4.68
to 0.42 and from 1.86 to 0.14 in LRH-1+ CML patient Pt8 and Pt9, respectively
(Figure 2.4C). Cytospin analysis confirmed this difference in susceptibility for cy-
totoxicity by LRH-1-specific CTL between primary CD34+ CML progenitor cells
and cytokine-maturated CML cells (Figure 2.4D). Allo-HLA-B7-specific CTL showed
equally effective lysis of both primitive and maturated CML cells. Together, these
data demonstrate that LRH-1-specific CTL effectively target primary leukemic pro-
genitor cells from chronic phase CML and AML patients, whereas mature myeloid
leukemic cells are not at all or only scarcely lysed.
LRH-1-CTL-mediated killing of CML blasts is enhanced by IFN-γ pre-
treatment
LRH-1-specific CTL were initially isolated from CML patient Pt1 after treatment
with DLI for relapse of the disease in accelerated phase.8 To determine whether CML
progenitor cells from this patient were responsive to LRH-1-CTL-mediated killing, we
performed cytotoxicity assays with CD34+ cells obtained at early relapse 11 months
after SCT and at late relapse 4 years after DLI.8 Phenotypic analysis of CD34+ cells
showed that these relapse samples were composed of different subpopulations based
on expression of CD38, CD117, CD33, CD13 and CD133 (Figure 2.5A). However,
both relapse samples similarly expressed P2X5 mRNA (i.e. 2.39 for relapse 1 and
2.88 for relapse 2), and the P2X5 mRNA levels were comparable to those observed
in CD34+ cells of chronic phase CML patients (Pt8 and Pt9). Unexpectedly, we
observed that CD34+ cells from accelerated phase CML patient Pt1 (Figure 2.5B)
were less efficiently lysed by LRH-1-specific CTL than CD34+ cells from chronic phase
CML and AML patients. Nevertheless, overnight stimulation of CD34+ cells of CML
patient Pt1 with 100 U/ml IFN-γ enhanced susceptibility to lysis by LRH-1-specific
CTL (Figure 2.5C). This improved killing was not associated with an increase of P2X5
mRNA levels, but correlated with up-regulation of HLA-B7 and adhesion molecules
such as CD54 at the cell surface of the leukemic blasts (Figure 2.6). Although
CD34+ CML cells from this patient were less susceptible to lysis by LRH-1-specific
CTL, targeting of IFN-γ-treated CML cells at a relatively high E:T ratio of 10:1
resulted in robust growth inhibition within 3 days (Figure 2.5D). Together, these data
indicate that lysis of myeloid leukemic progenitor cells that are relatively refractory
to alloreactive CTL can be further augmented by higher CTL-target ratios and in
the presence of inflammatory cytokines.
53
Chapter 2: LRH-1 CTL target myeloid leukemic progenitor cells
Figure 2.4: Cytokine-maturated LRH-1+ CD34− CML cells are not lysed by
LRH-1-specific CTLs. (A+B) Purified CD34+ CML cells were cultured for 1 week with growth
factors before incubation with LRH-1-specific CTL RP1 (N), HLA-B7-specific CTL KOR18 (H; i.e.
positive control) or medium () only. Survival of CFSE-labeled cytokine-maturated LRH-1+ CD34−
CML cells from two LRH-1+ CML patients was determined in the absence or presence of CTL at an
E:T ratio of 0.5:1. Data are depicted as mean plus or minus SD of triplicate wells. (C) P2X5 mRNA
expression was determined by real-time quantitative RT-PCR in sorted CD34+ CML cells (d0; black
bars) from two LRH-1+ CML patients and in the cytokine-matured CD34− progeny of these cells
(d7; gray bars). Cytokine-maturation of CD34+ CML cells results in a down-regulation of P2X5
expression, confirming the marginal susceptibility for LRH-1-CTL-mediated lysis. The arbitrary
threshold of 0.4 is indicated with a dashed horizontal line. (D) Cytospins of CD34+ progenitor
cells (upper panel) and cytokine-maturated CD34− cells (lower panel) from LRH-1+ CML Pt8.
Target cells were co-cultured with CTL at an E:T ratio of 0.5:1 for 2 days, after which the cells
were analyzed. Morphologically, the CD34+ progenitor cells consisted of myeloblasts, whereas
the cytokine-matured CD34− progeny of these cells consisted of promyelocytes, myelocytes and
granulocytes. The progenitor cells were clearly lysed by LRH-1-specific CTL RP1, whereas the more
differentiated cells were no longer attacked. In contrast, both cell populations were susceptible to the
allo-HLA-B7 control CTL KOR18. Imaging was performed with a Zeiss Axioskop microscope (Zeiss,
Sliedrecht, The Netherlands) equipped with a Sony 3CCD color video camera system. Pictures were
taken using a 40×/0.75 objective.
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Figure 2.5: Myeloid leukemic CD34+ progenitor cells from accelerated phase
CML patient Pt1 are efficiently lysed by LRH-1-specific CTL under inflamma-
tory conditions and with relatively high E:T ratios. (A) Subpopulations of CD34+
cells in relapse sample 1 and 2 from CML patient Pt1 were phenotyped with antibodies directed
against CD38, CD117, CD33, CD13 and CD133. (B) Survival of sorted CD34+ leukemic cells from
relapse 1 and 2 from patient Pt1 was determined in flow cytometry-based cytotoxicity assays af-
ter incubation with LRH-1-specific CTL RP1 (N), HLA-B7-specific CTL KOR18 (H; i.e. positive
control) or medium () in the presence of growth factors. Proliferation of viable CFSE-labeled
leukemic cells is shown in the absence or presence of CTL at an E:T ratio of 3:1. Data are depicted
as mean plus or minus SD of triplicate wells. (C) Pre-treatment with IFN-γ increases susceptibility
to LRH-1-CTL-mediated lysis. Percentage survival of CD34+ cells from relapse 2 with or without
pre-incubation with inflammatory cytokine IFN-γ in the presence of LRH-1-specific CTL RP1 was
determined in flow cytometry-based cytotoxicity assays. Survival is calculated compared to medium
after co-culture at an E:T ratio of 10:1. Data are depicted as mean plus or minus SD of triplicate
wells. (D) Higher E:T ratios result in improved lysis of IFN-γ pre-treated CD34+ cells from relapse
2. Survival of sorted CD34+ leukemic cells from relapse 2 from patient Pt1 was determined in flow
cytometry-based cytotoxicity assays after incubation with LRH-1-specific CTL RP1 at E:T ratios
10:1 (square), 3:1 (triangle), and 0.5:1 (circle) or medium (diamond) in the presence of growth
factors. Data are depicted as mean plus or minus SD of triplicate wells.
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Figure 2.6: Pre-incubation with IFN-γ induces an upregulation of CD54 and
HLA-B7 expression on myeloid leukemic progenitor cells. Expression of CD54 and
HLA-B7 on CD34+ relapse CML cells from patient Pt1 was measured by flow cytometry after o/n
incubation in the absence (grey plot) or presence (black plot) of 100 U/ml IFN-γ. The dotted line
represents the IgG1 isotype control.
Elevated XIAP expression counteracts LRH-1-CTL-mediated cell death
of leukemia progenitor cells
To gain insight into mechanisms that could explain the relative resistance of CML
relapse cells from Pt1 to LRH-1-CTL-mediated lysis, we determined expression levels
of several apoptosis-regulating genes in CD34+ leukemia cells from CML and AML
patients by quantitative RT-PCR. Interestingly, expression of the anti-apoptotic gene
XIAP in CD34+ cells from patient Pt1 was much higher than in CD34+ cells from
other CML patients (Figure 2.7). By contrast, we observed relatively low levels of
caspase-3 and the XIAP-inhibitor Smac in the CD34+ cells from patient Pt1 com-
pared to the other samples (Figure 2.7). For Bid, Bcl-xL, and Bcl-2, the expression
levels measured in CD34+ cells from patient Pt1 were in the same range as found in
CD34+ CML cells from other patients (Figure 2.7).
The levels of pro-apoptotic genes Bax and Bak were relatively high in the CD34+ cells
from patient Pt1, but this seems not to result in higher susceptibility to LRH-1-CTL-
mediated lysis. These results suggest that elevated expression of the downstream
anti-apoptotic mediator XIAP could be involved in inhibiting apoptotic cell death of
CD34+ CML cells from patient Pt1 targeted by LRH-1-specific CTL. By contrast,
elevated XIAP expression has no effect on HLA-B7 CTL-mediated killing. This may
be explained by the difference in the avidity of the CTL-target interaction between
LRH-1-specific CTL and HLA-B7-specific CTL in conjunction with differences in
antigen-density between specific LRH-1.B7 complexes and all HLA-B7 molecules on
CD34+ cells. Our observation that hardly any IFN-γ is produced by LRH-1-specific
CTL upon recognition of CML relapse cells from Pt1, while significant IFN-γ is
released by HLA-B7-specific CTL, supports this hypothesis (Figure 2.8A). In addition
to CML samples, we also assessed expression of apoptosis mediators in CD34+ cells
from AML patients. In general, higher levels of pro- as well as anti-apoptotic genes
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Figure 2.7: Anti-apoptotic gene XIAP is highly expressed in CD34+ CML re-
lapse cells from Pt1 compared to CML and AML cells from other patients. Ex-
pression of apoptosis-regulating genes was determined by real-time quantitative RT-PCR in CML
cells from Pt1 obtained at relapse 1 and relapse 2, and a panel of CML and AML samples. Expres-
sion is depicted as ∆∆Ct values and was quantified relative to AML cell line KG1, which was set
at 1 ∆∆Ct, and normalized for the expression of housekeeping gene HMBS.
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Table 2.1: Genotype and allele frequencies of LRH-1
Allele Number Percentage
Genotype frequency
-/- 41 46%
C/- 45 50%
C/C 4 4%
Allele frequency
- 127 71%
C 53 29%
were found in CD34+ AML cells compared to CD34+ CML cells. Furthermore, the
expression was more heterogeneous, which might be due to a more diverse genetic
background of the AML patients.
LRH-1-specific CD8+ T cells are frequently expanded in myeloid leukemia
patients after DLI
Immunogenicity of LRH-1 is controlled by a single cytosine deletion polymorphism
(rs5818907) located in exon 3 of the P2X5 gene.8 Hence, CD8+ T cells from a
homozygous LRH-1− (-/- genotype) donor can elicit an allogeneic CTL response
directed against P2X5 -expressing cells from homozygous (C/C genotype) or het-
erozygous (C/- genotype) LRH-1+ patients. To determine the population frequency
of the LRH-1-positive and -negative alleles, we genotyped 90 unrelated individuals
by allele-specific PCR. The genotype frequencies were 4% C/C, 50% C/- and 46%
-/-, and the LRH-1+ and LRH-1− alleles were present at frequencies of 0.29 and 0.71,
respectively (Table 2.1). Using the formula pxq3 + 0.75xp2xq2, where p and q repre-
sent allele frequencies,14 we calculated that between siblings the recipient disparity
for the LRH-1+ allele is 13.6% (p = 0.29 and q = 0.71), whereas recipient disparity
for the LRH-1− allele is 4.9% (p = 0.71 and q = 0.29). In addition, we experimentally
determined the LRH-1 disparity in 51 HLA-B7-matched SCT donor-recipient pairs
by genotyping analysis. In these 51 donor-recipient pairs, we identified 11 LRH-1+
patients (= 22%) that had received a transplant from a LRH-1− donor.
Next, we investigated the in vivo immunogenicity of LRH-1 in these mismatched
patients following DLI. PBMC from 7 of in total 11 LRH-1-mismatched recipients,
including CML patient Pt1, could be analyzed for the presence of circulating LRH-1-
specific CD8+ T cells using tetramer staining (Table 2.2). Remarkably, we detected in
3 out of 7 patients a significant percentage of LRH-1-specific CD8+ T cells between 10
to 25 weeks post-DLI (Table 2.2). These LRH-1-tetramer+ cells could not be detected
(≤0.01%) before DLI (data not shown). Previously, we reported that in CML patient
Pt1 emergence of LRH-1-specific CD8+ T cells coincided with the disappearance of
Bcr-Abl positive CML cells.8 Here, we report that in addition to this CML patient,
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Figure 2.8: IFN-γ production by LRH-1-specific CTL and HLA-B7-specific
CTL. (A) IFN-γ production by LRH-1-specific CTL and HLA-B7-specific CTL upon overnight
stimulation with different target cells at an E:T ratio of 0.5:1 was measured by ELISA. (B) LRH-
1+ EBV-LCL stimulate IFN-γ production by CTL RP1 and TB1, whereas LRH-1+ CML relapse
samples and LRH-1+ AML do not. CTL KOR18 produces IFN-γ in response to all HLA-B7+
targets.
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Table 2.2: Characteristics of HLA-B7+ LRH-1+ patients transplanted with an
LRH-1− donor
Pt1 Pt2 Pt3 Pt4 Pt5 Pt6 Pt7
Diagnosis CML CML AML AML B-ALL T-ALL MM
Type of DLI T T P P P P P
Sample data (weeks
post-DLI)
25 11 10 18 11 19 12
Presence of LRH-1
specific CD8+ T cells
+ + + - - - -
LRH-1-specific CD8+
T cells (%) in sample
1.6 0.1 6.9 <0.01 <0.01 <0.01 <0.01
LRH-1-specific CD8+
T cells (%) after 2
weeks of culture
12.8 0.7 15.4 <0.01 <0.01 n.d. <0.01
T: Therapeutic; P: Pre-emptive; n.d.: not determined
LRH-1-tetramer+ CD8+ T cells could be detected in two other myeloid leukemia
patients following treatment with DLI. One of these patients was also a CML patient
(Pt2) who was treated with imatinib mesylate (Glivec) in combination with low-
dose DLI (5x106 CD3+ cells/kg body weight) for relapsed disease 4.5 years after
allogeneic SCT. A PBMC sample obtained at 11 weeks post-DLI contained a relative
low frequency of 0.1% LRH-1-tetramer+ CD8+ T cells (Table 2.2). Specific detection
of LRH-1-specific CTL in this patient was verified after in vitro stimulation of the
PBMC sample with peptide-pulsed donor EBV-LCLs. After 2 rounds of stimulation,
the percentage of LRH-1-tetramer+ CD8+ T cells increased up to 0.7% (Table 2.2).
The other patient was an AML patient (Pt3) who was treated with pre-emptive
DLI (0.1 × 108 CD3+ cells/kg body weight) at 5 months after allogeneic SCT. Strik-
ingly, at 10 weeks after DLI a peak level of 6.9% LRH-1-specific CD8+ T cells could be
detected in the PB (Table 2.2, Figure 2.9A). These in vivo expanded LRH-1-specific
CD8+ T cells had predominantly (∼ 90%) a CD45RA−CD45RO+CD27+CCR7−Fas+
effector/effector-memory phenotype (Figure 2.9A). A subfraction (43%) of the LRH-
1 tetramer+ CD27+ T cells expressed CD28, which is indicative for the presence of
early antigen-primed CD8+ T cells according to the differentiation model proposed
by Appay et al.15 Most LRH-1-specific CD8+ T cells lacked IL-7Rα(CD127) expres-
sion at this time point. After the peak response, the number of circulating LRH-1
tetramer+ cells declined to 2.9% at 15 weeks and 0.9% at 20 weeks (Figure 2.9B).
Thereafter, a small memory population of around 0.05% remained detectable in the
PB for many years. Importantly, despite the presence of these very high numbers of
LRH-1-specific CD8+ T cells the patient did not develop GVHD, which correlates
with the hematopoietic-restricted expression of the P2X5 target gene. Furthermore,
the patient remained in complete clinical and cytogenetic remission for years after
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pre-emptive DLI. However, 33 months after DLI, the patient developed a chloroma
in the left upper eyelid. Remarkably, the patient remained in continuous cytogenetic
remission in the BM. The patient was treated with local radiotherapy and DLI at
a dose of 0.7 × 108 CD3+ cells/kg body weight. The chloroma disappeared and
the DLI did not elicit GVHD. However, three years later (i.e. 6 years after SCT)
the patient developed a second chloroma paravertebrally, again without leukemic in-
volvement in the BM. Despite successful treatment with high-dose cytarabine, DLI
(1.4 × 103 CD3+ cells/kg body weight) and local radiotherapy a third chloroma in
the gut was demonstrated 8 months later. She was given a second allogeneic SCT
from an HLA-identical sister but developed GVHD grade III and died from infec-
tious complications. During this period of extramedullary relapses and concomitant
treatment, LRH-1-specific CD8+ memory T cells were present but did not respond
(Figure 2.9B).
P2X5-expressing AML and CML cells are efficiently lysed by LRH-1-
specific CTL isolated from two different patients
To investigate whether LRH-1-specific CTL present in AML patient Pt3 showed
similar cytotoxicity as the LRH-1-specific CTL generated from CML patient Pt1,
we have isolated LRH-1 tetramer+ T cells from patient Pt3. After antigen-specific
stimulation, tetramer analysis revealed that more than 95% of CD8+ T cells were
LRH-1 tetramer positive (data not shown). This CD8+ CTL culture, termed TB1,
mediated efficient lysis against LRH-1+ EBV-LCL, but not against LRH-1− donor
EBV-LCL, demonstrating specific recognition of the LRH-1-epitope (Figure 2.9C).
Targeting of HLA-B7+ LRH-1+ CD34+ AML cells from patient Pt16 by CTL TB1
at a low E:T ratio of 0.5:1 resulted in efficient lysis (Figure 2.9C). Similar strong
lysis of AML cells is shown for the CML patient Pt1-derived CTL RP1. CD34+
CML cells from patient Pt1 were again less susceptible to LRH-1-CTL-mediated
lysis, although CTL TB1 displayed somewhat more efficient lysis than CTL RP1.
For both CTL, lysis could be improved by pre-treatment of the CD34+ CML cells
with IFN-γ similar to previous results. Furthermore, CTL TB1 as well as CTL RP1
did not produce IFN-γ upon recognition of AML cells or CML relapse cells from
Pt1, irrespective of IFN-γ-treatment, whereas IFN-γ was produced upon co-culture
with LRH-1+ EBV-LCL (Figure 2.8B). Analysis of the phenotypical properties of
both CTL cultures showed that RP1 and TB1 were both negative for CD27, CD28,
CD62L, CCR7 and CD127 (IL-7Rα), and expressed similar levels of perforin (data
not shown). Furthermore, we compared IFN-γ production by CTL RP1 and TB1
upon recognition of various concentrations of the LRH-1 peptide loaded on HLA-
B*0702-transduced K562 cells. We observed that IFN-γ production by CTL TB1
was slightly higher than by CTL RP1, suggesting a somewhat higher avidity of CTL
TB1 for LRH-1+ target cells (Figure 2.10). These observations are in agreement with
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Figure 2.9: LRH-1-specific CTL TB1 of AML patient Pt3 efficiently recognizes
LRH-1+ CD34+ AML and CML progenitor cells. (A) LRH-1-tetramer+ CD8+ T cells
from patient Pt3 were phenotyped for their expression of CD45RA, CD27, Fas, CD127, CD28,
CD45RO and CCR7. (B) Longitudinal follow up of LRH-1-tetramer+ CD8+ T cells in vivo from
patient Pt3 in relation to clinical outcome. Depicted is the percentage of LRH-1-tetramer+ T cells
in the CD8+ T cell population (left y axis) and the lymphocyte count (right y axis) together with
treatments and the occurrence of chloromas. (C) Specific lysis of CD34+ leukemic progenitor cells
with or without pre-incubation with IFN-γ in the presence of LRH-1-specific CTL TB1 (black bars)
or RP1 (gray bars) was determined in flow cytometry-based cytotoxicity assays. Lysis is calculated
compared to medium after two days of co-culture at an E:T ratio of 0.5:1. Data are depicted as
mean plus or minus SD of triplicate wells.
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Figure 2.10: CTL TB1 produces relatively more IFN-γ than CTL RP1 upon
recognition of the LRH-1 epitope. (A) IFN-γ production by CTL RP1 and TB1 was
compared upon recognition of various concentrations of LRH-1 peptide loaded on HLA-B*0702-
transduced K562 cells. A culture of CTL RP1 with >95% LRH-tetramer+ cells was compared
to a culture of CTL TB1 with ∼33% LRH-1-tetramer+ cells at an E:T ratio of 1:3 corrected for
the tetramer+ T cell content. Depicted are duplicate ELISA-measurements of IFN-γ production
by each CTL after overnight stimulation. We observed that IFN-γ production by CTL TB1 was
slightly higher than by CTL RP1, suggesting a somewhat higher avidity of CTL TB1 for LRH-1+
target cells. (B) Overnight stimulation of CTL with LRH-1+ EBV-LCL showed high levels of IFN-γ
production, which was similar for CTL RP1 and TB1 compared with HLA-B7-specific CTL KOR18.
the slightly better lysis of CD34+ CML relapse cells from patient Pt1 by CTL TB1
(Figure 2.9C).
Collectively, these results illustrate that LRH-1-specific T cell responses can be
induced in vivo in both CML and AML patients, and that these LRH-1-reactive CTL
are involved in targeting CD34+ AML and CML progenitor cells.
Discussion
Hematopoietic cell-restricted MiHA are crucial targets for selective induction of a
GVL response in the absence of GVHD after HLA-identical allogeneic SCT. In a pre-
vious study, we described the identification of a hematopoietic cell-restricted MiHA,
designated LRH-1, which is derived from the polymorphic P2X5 protein.8 Interest-
ingly, LRH-1 elicited an allogeneic CTL response in a patient with advanced CML
treated with DLI, which was associated with clinical remission. Moreover, gene ex-
pression studies showed that the LRH-1-encoding P2X5 gene is selectively expressed
by lymphoid cells and by normal and malignant CD34+ progenitor subpopulations.
Importantly, no significant P2X5 gene expression was found in prominent GVHD tar-
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get organs, such as skin, liver, colon and small intestine. These results suggest that
LRH-1 may contribute to induction of GVL immunity in leukemia patients treated
with allogeneic SCT in the absence of GVHD. In this study, we investigated suscepti-
bility of CD34+ myeloid leukemic progenitor cells to LRH-1-CTL-mediated lysis and
the applicability of LRH-1 as a target for immunotherapy of myeloid leukemia.
It has been recognized that for complete eradication of leukemia after SCT, in-
duction of effective alloreactive T cell responses against leukemic stem and progenitor
cells is essential.16,17 Several studies have demonstrated a correlation between the
presence of T cells recognizing leukemic CD34+ progenitor cells and the occurrence
of complete remissions in vivo.18–21 Therefore, MiHA which are expressed on CD34+
leukemic progenitor cells are highly relevant targets for immunotherapy. Previously,
we reported that LRH-1 elicited a profound CTL response in a CML patient treated
with DLI which was associated with the disappearance of Bcr-Abl positive tumor cells
(i.e. Pt1 in this study). Although we observed that LRH-1-specific CTL efficiently
recognized and lysed lymphoid cells, bulk CML mononuclear cells of the patient from
whom this CTL culture RP1 was originally isolated were not recognized.8 However,
the majority of CML cells are mature myeloid cells that express very low levels of
P2X5. In this study, we therefore investigated whether CD34+ leukemic progenitor
cells are potential targets of LRH-1-specific CTL. Significant P2X5 expression was
detected in both CD34+CD38− and CD34+CD38+ subpopulations from most CML
and AML patients.8 Based on the results of previous expression and CTL recognition
studies, these expression levels are expected to be sufficient for LRH-1-CTL-mediated
lysis.8 To determine whether primary leukemic progenitor cells are susceptible for
LRH-1-CTL-mediated lysis, we performed cytotoxicity assays with CD34+ progen-
itor cells isolated from PB or BM of CML and AML patients. In these assays,
we clearly demonstrated that leukemic CD34+ progenitor cells from chronic phase
LRH-1+ CML patients as well as from LRH-1+ AML patients were efficiently lysed
by LRH-1-specific CTL. On the other hand, mature myeloid leukemic cells were not
at all or only scarcely lysed, which was in concordance with a strong decrease in P2X5
gene expression levels after cytokine maturation. In addition to the LRH-1-specific
CTL from CML Pt1 (i.e. RP1), we isolated a second LRH-1-specific CTL (i.e. TB1)
from AML patient Pt3, in whom a high level of LRH-1-specific CD8+ T cells was
induced at 10 weeks post-DLI. Interestingly, we observed that both CTL displayed
similar cytotoxicity against primary CD34+ CML and AML progenitor cells. These
results show that LRH-1-specific T cell responses can be induced in vivo in both
CML and AML patients and that these LRH-1-specific CTL can recognize and lyse
both AML and CML progenitor cells.
Despite the effective cytotoxicity by LRH-1-specific CTL observed in flow cytome-
try-based cytotoxicity assays, no IFN-γ production could be measured for both CTL
after stimulation with myeloid leukemic progenitor cells. By contrast, LRH-1-specific
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CTL efficiently produced IFN-γ upon recognition of LRH-1+ EBV-LCL. This may
be explained by differences in antigen concentration at the cell surface and strength
of CTL-target interactions between myeloid leukemic progenitor cells and EBV-LCL.
It has been well established that dual activation thresholds are present for cytotoxi-
city and cytokine production in CTL upon antigen-specific interactions with its tar-
get.22,23 At low antigen concentrations a lytic immunological synapse can be formed,
while for production of IFN-γ higher antigen concentrations and the formation of a
mature immunological synapse is needed.22–24 Similar results were previously ob-
served in the recognition of P2X5-expressing LRH-1+ lymphoid malignancies by
LRH-1-specific CTL.9
Although efficient lysis of most CD34+ CML and AML samples was observed,
accelerated phase CD34+ relapse CML cells from patient Pt1 were less efficiently
lysed by LRH-1-specific CTL. However, lysis could be improved by increase of the
E:T ratio and pre-incubation of CML cells with inflammatory cytokine IFN-γ. The
observed lysis of CML relapse cells from patient Pt1 confirms the previously shown
correlation between expansion of LRH-1-specific CD8+ T cells and the disappear-
ance of CML.8 Pre-incubation of CD34+ cells with IFN-γ induced an increase of
HLA-B7 and CD54, which probably resulted in more effective lytic immunological
synapses. A similar effect of IFN-γ pre-treatment on the expression of HLA-B7 and
CD54, resulting in improved CTL-mediated lysis, was previously observed for solid
tumor cells.11 Therefore, the presence of IFN-γ may have a beneficial effect on the
LRH-1-specific GVL response. However, we observed that LRH-1-specific CTL did
not produce IFN-γ in vitro upon recognition of myeloid leukemic progenitor cells.
Nevertheless in vivo, IFN-γ could be supplied by co-existing CD8+ cytotoxic T cells
for other MiHA on leukemic cells.
Studies by Ravi et al. showed that coexistence of specific mitochondrial signaling
defects, such as decreased expression of Smac, together with expression of XIAP
decreases the sensitivity of cancer cells to CTL-mediated apoptosis.25 To elucidate
whether this mechanism could play a role in the relative resistance to lysis of CML
relapse cells from Pt1, we compared expression levels of apoptosis-regulating genes
between CD34+ cells from Pt1 and a panel of CML and AML samples from other
patients. Interestingly, we observed elevated expression of the anti-apoptotic gene
XIAP in CD34+ cells from patient Pt1. Moreover, the levels of pro-apoptotic genes
caspase-3 and Smac were relatively low, while expression levels of pro-apoptotic
genes Bax and Bak were relatively high. However, XIAP-mediated inhibition of
effector caspases may have a more dominant effect on CTL-mediated apoptosis than
increased expression of Bax and Bak, which exert their function more upstream
in the apoptosis pathway. In addition, we observed relatively low levels of XIAP-
inhibitor Smac, which might result in more prominent resistance of XIAP-expressing
leukemia cells of CML patient Pt1 following targeting by LRH-1 CTL. We showed
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that pre-treatment with IFN-γ and increased CTL-target ratios largely corrected
the anti-apoptotic balance and significantly improved lysis by LRH-1-specific CTL.
However, this mechanism could have played a role in evasion of leukemia cells in
accelerated phase CML Pt1 eventually resulting in uncontrollable disease.8
At present, several MiHA have been identified that can induce allogeneic T cell
responses in patients. Of these molecularly defined MiHA, LRH-1,8 HB-1,26 HA-
1,27 HA-2,28 PANE-1,29 LB-ECGF-1,30 ACC-1,31 ACC-2,31 and ACC-632 have a
hematopoietic restricted expression. The applicability of these MiHA as targets for
immunotherapy depends on the disparity of the MiHA+ allele in the recipient direc-
tion and on the population frequency of the HLA-restriction molecule in which the
MiHA is presented.33 Here, we determined the population frequencies of the LRH-1+
and LRH-1− alleles by genotyping 90 unrelated individuals, which revealed a recipi-
ent disparity for the LRH-1+ allele of 13.6%. Consequently, the overall applicability
of LRH-1-based immunotherapy is estimated around 2.3% based on the recipient dis-
parity for the LRH-1+ allele (13.6%) and the HLA-B7 phenotype frequency (∼17% in
the Caucasian population).34 Therefore, LRH-1 belongs to the most suitable MiHA
for immunotherapy, together with MiHA HA-1, ACC-1, and ACC-2, which have an
overall applicability of 10.6%, 5.8%, and 2.7%, respectively.33 Interestingly, the nine
amino acid-disparity between donor and recipient cells caused by the frameshift poly-
morphism in the P2X5 protein may give rise to additional antigenic epitopes that
are presented by other frequent HLA class I or class II alleles. Currently, we are
investigating whether other putative peptides are derived from P2X5 that act as
immunogenic T cell epitopes. This may further increase the overall applicability of
P2X5 as an immunotherapeutic target.
To determine the immunogenicity of LRH-1 in different patients, we investigated
the occurrence of LRH-1-specific T cells responses in LRH-1+ patients treated with
DLI. Seven LRH-1+ patients who received DLI from an LRH-1− donor were analyzed
for the presence of LRH-1-specific CD8+ T cells by tetramer staining. LRH-1-specific
CD8+ T cells could be detected in 3 out of 7 (43%) LRH-1+ recipients within 10 to
25 weeks after DLI. These results suggest that LRH-1 is a relatively immunogenic
epitope. In the CML patient (Pt1) from whom the LRH-1-specific CD8+ CTL cul-
ture RP1 was originally isolated, we detected 1.6% LRH-1-tetramer+ CD8+ T cells
at 25 weeks after therapeutic DLI. Although LRH-1 has a hematopoietic-restricted
expression, this patient developed mild chronic GVHD. However, since it has been
demonstrated that allogeneic T cell responses against multiple MiHA can be elicited
after DLI,19 the mild GVHD may be due to the presence of T cells directed against
MiHA with ubiquitous expression. Remarkably, 6.9% LRH-1-specific CD8+ T cells
in the total CD8+ T cell population were present in an AML patient (Pt3) treated
with pre-emptive DLI, whom did not develop GVHD. This patient remained in com-
plete cytogenetic remission for 33 months. However, years after the LRH-1 CTL
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response this patient developed relapses at sanctuary sites in the absence of leukemic
involvement in the BM. Similar cases of extramedullary relapses in the presence of
continuous BM remission have been described, suggesting disparate GVL effect at
different sites in the body.35–37 In these patients, certain leukemic cells have mi-
grated to immune-protected sites where they escaped from GVL immunity due to
diminished T cell homing to these tissues, evasion of immune recognition and/or
development of an immunosuppressive network at the tumor site. Finally, a lower
amount of 0.1% LRH-1-specific CD8+ T cells was detected in a CML patient (Pt2)
who was treated with imatinib mesylate (Glivec) in combination with low-dose DLI
for relapsed disease. This low percentage of LRH-1-specific T cells may be caused
by the presence of imatinib mesylate, which has been demonstrated to interfere with
T cell activation and proliferation.38 The absence of severe GVHD in these three
patients together with the presence of significant numbers of LRH-1-specific T cells
emphasizes the hematopoietic-restricted expression of LRH-1 and its potential to in-
duce GVL without inducing GVHD. Together with our in vitro cytotoxicity data, the
observed molecular remission in CML Pt1 after therapeutic DLI and the prolonged
BM remission in AML Pt3 after pre-emptive DLI, indicate that LRH-1-specific T cell
responses can be induced in vivo in LRH-1+ patients treated with an LRH-1− donor
and that these LRH-1-specific CD8+ T cells can play an important role in specific
lysis of CD34+ leukemic progenitor cells.
In conclusion, we demonstrate that MiHA LRH-1 is an attractive GVL-specific
antigen, which induces CD8+ T cell responses in multiple patients after DLI. We
show that CD34+ leukemic progenitor cells, but not mature myeloid cells are sus-
ceptible to lysis by in vivo induced LRH-1-specific CTL. These results indicate that
LRH-1-based immunotherapy following allogeneic SCT may be a potent treatment
for CML and AML patients. Recently, we demonstrated that P2X5 is highly ex-
pressed in a broad range of lymphoid malignancies and several solid tumors which
results in susceptibility to LRH-1-CTL-mediated lysis.9,11 Collectively, these findings
illustrate that LRH-1 represents a highly relevant target for post-transplant vaccina-
tion or adoptive T cell therapy to induce GVL-specific immunity in a broad range of
hematological malignancies.
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Chapter 3: PD-1 signaling impairs MiHA-specific CD8+ T cells
Abstract
Tumor relapses remain a serious problem after allogeneic stem cell transplantation
(alloSCT), despite the long-term persistence of minor histocompatibility antigen
(MiHA)-specific memory CD8+ T cells specific for the tumor. We hypothesized that
these memory T cells may lose their function over time in transplanted patients. Here,
we offer functional and mechanistic support for this hypothesis, based on immune
inhibition by programmed death-1 (PD-1) expressed on MiHA-specific CD8+ T cells
and the associated role of the PD-1 ligand PD-L1 on myeloid leukemia cells, especially
under inflammatory conditions. PD-L1 was highly upregulated on immature human
leukemic progenitor cells, whereas co-stimulatory molecules such as CD80 and CD86
were not expressed. Thus, immature leukemic progenitor cells seemed to evade the
immune system by inhibiting T cell function via the PD-1/PD-L1 pathway. Blocking
PD-1 signaling using human antibodies led to elevated proliferation and IFN-γ pro-
duction of MiHA-specific T cells co-cultured with PD-L1-expressing leukemia cells.
Moreover, patients with relapsed leukemia after initial MiHA-specific T cell responses
displayed high PD-L1 expression on CD34+ leukemia cells and increased PD-1 lev-
els on MiHA-specific CD8+ T cells. Importantly, blocking PD-1/PD-L1 interactions
augments proliferation of MiHA-specific CD8+ memory T cells from relapsed pa-
tients. Taken together, our findings indicate that the PD-1/PD-L pathway can be
hijacked as an immune escape mechanism in hematological malignancies. Further-
more, they suggest that blocking the PD-1 immune checkpoint offers an appealing
immunotherapeutic strategy following alloSCT in patients with persistent or relapsed
disease.
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Introduction
Alloreactive CD8+ T cells play a crucial role in the graft-versus-tumor (GVT) re-
sponse following allogeneic stem cell transplantation (alloSCT) and donor lympho-
cyte infusion(DLI).1 In HLA-matched alloSCT, these alloreactive CD8+ T cell re-
sponses are directed against minor histocompatibility antigens (MiHA).2 Previously,
we have characterized CD8+ T cell immunity toward a hematopoietic-restricted
MiHA, designated LRH-1, which is presented by HLA-B7 and encoded by the P2X5
purinergic receptor gene.3 LRH-1-specific CD8+ T cell responses can be frequently
detected in myeloid leukemia patients following DLI, and has been associated with
leukemic remission.3,4 Moreover, we showed that CD34+ myeloid leukemia progeni-
tor cells can be efficiently targeted in vitro by LRH-1-specific CD8+ CTLs, indicating
that these CTLs play a significant role in graft-versus-leukemia (GVL)-specific immu-
nity. However, we have observed that despite the presence of LRH-1-specific CD8+
memory T (TMEM) cells for many years, late relapses do occur in patients with ad-
vanced myeloid leukemia. Furthermore, we noted that LRH-1-specific CD8+ TMEM
cells do not always efficiently expand with recurrence of leukemia cells, suggesting
that these T cells become functionally impaired.
Mechanisms exploited by tumor cells to inhibit CD8+ T cell-mediated immunity
include disruption of antigen presentation, downregulation of HLA molecules, and in-
duction of immunosuppressive components such as programmed death-1 (PD-1) sig-
naling.5,6 PD-1 plays a crucial role in T cell regulation in various immune responses
and is involved in peripheral tolerance, autoimmunity, infection, and anti-tumor im-
munity.7 Elevated PD-1 expression on antigen-specific CD8+ T cells in chronic viral
infection has been recognized as a hallmark for T cell exhaustion resulting in dimin-
ished cytokine production, proliferation, and cytolytic activity upon antigen restimu-
lation.8 PD-1 binds 2 ligands, PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC; CD273).7
Although PD-L2 expression is mainly restricted to antigen presenting cells (APC)
like dendritic cells (DC) and macrophages, PD-L1 is also expressed by many non-
hematological cell types.7 Furthermore, PD-L1 can be expressed on multiple tumor
types and its expression is elevated following IFN-γ exposure.9 PD-L1 molecules
on tumor cells can deliver negative signals through PD-1 to tumor-reactive CTL,
thereby inhibiting anti-tumor immunity.10 In agreement, PD-L1 expression has been
associated with poor prognosis in various cancers including hepatocellular carcinoma
and melanoma.9,11 Notably, studies in models of murine myeloid leukemia have also
shown that PD-1/PD-L1 interactions play an important role in immune evasion.12,13
Interestingly, PD-L1 is also able to bind CD80, resulting in T cell inhibition.14 There-
fore, PD-L1 molecules on human leukemia cells may restrain CD8+ T cell responses
involved in GVL immunity after alloSCT.
In this study, we examined the role of PD-1/PD-L1 interactions in functional
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impairment of MiHA-specific CD8+ T cells. We observed that PD-L1 on myeloid
leukemia cells is induced following IFN-γ and TNF-α exposure. Furthermore, we ob-
served that activated LRH-1-specific CD8+ T cells express PD-1 during the course of
the immune response. Importantly, we showed that blockade of PD-1/PD-L1 inter-
actions using clinical grade human antibodies increases the proliferation and IFN-γ
production of MiHA-specific CD8+ T cells when stimulated with PD-L1-expressing
acute myelogenous leukemia (AML) cells and DC. Together, these findings indicate
that the PD-1 signaling pathway suppresses MiHA-specific CD8+ T cell responses
and PD-1 blockade may be an attractive approach to boost GVL immunity in pa-
tients with persistent or relapsed disease.
Material and Methods
Patient and donor material
Peripheral blood (PB) and bone marrow (BM) samples of leukemia patients have
been collected after written informed consent in ongoing clinical SCT protocols ap-
proved by the RUNMC Institutional Review Board. We used PB mononuclear cells
(PBMC) obtained from transplanted patients who developed MiHA-specific CD8+
T cell responses. Patient 1 (Pt 1) suffered from accelerated phase (AP) chronic
myeloid leukemia (CML) and was successfully treated with therapeutic DLI after
alloSCT.3 However, the patient relapsed 4 years after DLI. Patient 2 (Pt 2) suffered
from AML and developed an LRH-1-specific CD8+ T cell response upon pre-emptive
DLI, but developed extramedullary relapses without leukemic involvement in BM.4
Characteristics of these and other transplanted patients are included in Table 3.2.
DCs were generated from monocytes isolated from PBMC of healthy donors
by plastic adherence. Immature DCs (iDC) were generated by culturing adherent
monocytes in X-VIVO 15 medium (Lonza) supplemented with 2% HS, 500 U/mL in-
terleukin (IL)-4, and 800 U/mL Granulocyte macrophage colony-stimulating factor
(GM-CSF) (both Immunotools). After 3 days, cells were harvested, used for T cell
stimulations experiments or further cultured as described before.15 At day 8, mature
DCs (mDC) were harvested and used in T cell stimulation experiments. LRH-1-
specific CD8+ CTL culture RP1 was isolated from CML-AP Pt 1 and was cultured
as described previously.4 Before use in T cell stimulation experiments, leukemia sam-
ples and DCs were cultured overnight with or without 100 U/mL IFN-γ and 1.25
ng/mL TNF-α (both Immunotools).
Mixed lymphocyte AML reactions and CTL stimulation assays
After culturing and pre-incubation, AML cells and DCs were washed, counted, and
seeded in 96-well round bottom plates (Corning Costar). In lymphocyte AML reac-
tion assays, allogeneic CD3+ T cells were isolated by direct magnetic labeling with the
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appropriate MicroBeads (Miltenyi Biotec) following the manufacturer’s instructions.
Subsequently, 104 CD3+ T cells were added to AML cells and mDCs at different E:T
ratios. In MiHA-specific T cell expansion assays, PD-L1+ iDCs were loaded with
10 µmol/L LRH-1 peptide TPNQRQNVC for 30 minutes at room temperature and
co-cultured with LRH-1-specific CTL RP1 at a stimulation ratio of 10:1.
Blocking antibodies were added at a final concentration of 10 µg/mL. Antibodies
to PD-1 (BMS-936558; MDX-1106; ONO-4538) and PD-L1 (BMS-936559; MDX-
1105) and a matching immunoglobulin (Ig) G4 isotype control were kindly provided
by Dr. A. Korman (Bristol-Myers Squibb, Biologics Discovery). BMS-936558 and
BMS-936559 are genetically engineered, fully human IgG4 antibodies currently evalu-
ated in clinical trials for selected tumor treatments.16 All co-cultures were performed
in a total volume of 200 mL Iscove’s modified Dulbecco’s medium (IMDM)/10% HS.
After 5 days of co-culture, supernatant was harvested for cytokine analysis. At day
5, 0.5 µCi [3H]-thymidine (Perkin Elmer) was added to each well. After overnight in-
cubation, [3H]-thymidine incorporation was measured using a 1205 Wallac Betaplate
counter (Perkin Elmer).
MiHA-specific TMEM-cell proliferation assays
MiHA-specific CD8+ T cells present in PBMC from patients Pt 1, 2, and 15 to 21
(Table 3.2) were stimulated for 1 to 3 consecutive weeks ex vivo with either MiHA
peptide alone or with MiHA peptide-loaded PD-L1+ iDC or PD-L1+ PD-L2+ mDC
as described previously.15 PD-1 and PD-L1 blocking antibodies were added at a final
concentration of 10 µg/mL. After 5 days, 500 mL supernatant was removed and
fresh IMDM/10% HS containing 50 U/mL IL-2 and 5 ng/mL IL-15 (Immunotools)
was added. At day 7, cells were harvested, counted, and the percentage of MiHA-
tetramer+ CD8+ T cells was determined.
Flowcytometry
Expression of co-signaling ligands on myeloid leukemia cells and DCs was analyzed by
staining with the following fluorochrome-conjugated antibodies: CD14 (Dako), CD3,
CD34, CD117, CD54, CD80, CD83, CD86 (all from Beckman Coulter), anti-PD-L1,
anti-PD-L2 (both from Becton Dickinson), and isotype controls IgG1 FITC/PE dual-
color control (Dako) and IgG2b PE (Beckman Coulter). PD-1 expression on and the
percentage of MiHA-specific CD8+ T cells were determined as described previously15
using anti-PD-1(Becton Dickinson). Cells were analyzed using the Coulter FC500
flow cytometer (Beckman Coulter).
Immunohistochemistry staining
Paraffin-embedded chloroma tissues were stained as previously described.17 Briefly,
antigen retrieval was done using 10 minutes of boiling in 0.01 mol/L of sodium
citrate pH 6.0 followed by incubation with primary antibodies anti-PD-L1 (eBio-
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science), anti-PD-L2 (eBioscience), anti-CD8 (DAKO), anti-CD34 (Klinipath), and
anti-FoxP3 (ITK Diagnostics). Staining was visualized either by 3,3-diaminobenzi-
dine (DAB) or aminoethyl carbazole (AEC) staining.
IFN-γ and granzyme B ELISA
Production of IFN-γ and granzyme B by stimulated T cells was determined by
enzyme-linked immunosorbent assay (ELISA; IFN-γ: Pierce Endogen; granzyme B:
Mabtech) according to manufacturer’s protocol.
Real-time quantitative reverse transcription PCR and microarray analysis
Total RNA was isolated from cell samples using Trizol (Invitrogen). cDNA synthe-
sis and PCR amplification were carried out as described.18 The hydroxymethylbilane
synthase (HMBS) housekeeping gene was used to normalize PD-L1 and PD-L2 ex-
pression. PD-L1 and PD-L2 mRNA expression is shown in ∆∆Ct values and was
quantified relative to cell line U266, which was set at 1 ∆∆Ct value. ∆∆Ct was
calculated as follows: 2(−[∆Ct sample]−[∆Ct U266]), in which ∆Ct was normalized for
HMBS by calculating ∆Ct = Ctgene − CtHMBS per sample.
For microarray analysis, LRH-1-tetramer+ human CD8+ T cells were sorted (me-
dian sorted cell number 1,300; range 200-15,000 cells) on an Epics Elite sorter (Beck-
man Coulter), resulting in a more than 96% pure product, and resuspended in Trizol.
RNA extraction, amplification, cDNA generation, and microarray analysis were done
as described previously.19
Statistical analysis
Paired 1-tailed student t test or 1-way ANOVA followed by a Bonferroni post-hoc
test was used when appropriate.
Results
Myeloid leukemia progenitor cells differentially express PD-L1 compared
to CD80 and CD86
To investigate whether myeloid leukemia cells in relapsed patients after alloSCT
express PD-L1 under inflammatory conditions, we analyzed leukemia samples from
2 patients who relapsed despite circulating LRH-1-specific CD8+ T cells (Table 3.1).
We found that CD34+ CML-AP cells from a relapsed patient (Pt 1) at 4 years after
DLI express PD-L1 upon stimulation with IFN-γ (Figure 3.1A), whereas expression
of co-stimulatory molecules CD80 and CD86 on these CD34+ CML-AP cells was
low. Furthermore, we observed high PD-L1 expression on CD34+ leukemia cells in
a chloroma biopsy of an AML patient (Pt 2) who relapsed 3 years after DLI (Figure
3.1B).
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Figure 3.1: Myeloid leukemia cells express PD-L1 under inflammatory condi-
tions. Expression of co-signaling ligands on leukemia cells was determined by
FCM, immunohistochemistry, and RT-PCR. (A) FCM analysis of PD-L1, PD-L2, CD80
and CD86 expression on CD34+ progenitor cells of CML-AP Pt 1 at time of relapse, 4 years after
DLI. Leukemia cells were exposed to 100 IU/mL IFN-γ and 1.25 ng/mL TNF-α 16 hour before
analysis. (B) Expression of PD-L1 and PD-L2 by CD34+ AML cells in a chloroma biopsy of Pt
2 at time of relapse, 3 years after DLI, was determined by immunohistochemistry. Staining was
visualized using DAB (CD34) or AEC (PD-L1, PD-L2, and isotype control). Magnification 1,000×.
(C) CD33+ AML cells from 9 to 12 different patients were incubated with 100 IU/mL IFN-γ and
1.25 ng/mL TNF-α for 16 hours, after which PD-L1 and PD-L2 mRNA expression with (+) and
without (-) IFN-γ and TNF-α was measured. (D) Expression of co-stimulatory ligands on CD33+
AML cells, in the absence (-) or presence (+) of IFN-γ and TNF-α, was determined by FCM. (E)
Expression of PD-L1, PD-L2, CD80, CD86 and CD54 on CD33+CD117+CD14− progenitor AML
cells from 8 patients. Expression is depicted as mean + SD. Paired 1-tailed student t test was
performed. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 3.2: High numbers of CD8+ cells have infiltrated the extramedullary
AML, whereas only minimal numbers of FoxP3+ regulatory T cells are present.
Staining was visualized using DAB. Magnification CD8 100x, FoxP3 400x.
Again, we found that these extramedullary AML cells expressed low levels of CD80
and CD86 (data not shown). Staining of specific T cell markers revealed that CD8+
T cells extensively infiltrated the chloroma, whereas FoxP3+ regulatory T cells were
hardly detectable (Figure 3.2).These data suggest that selective expression of PD-L1
on these relapsed leukemia cells could have been involved in evading LRH-1-specific
CD8+ T cell immunity.
To determine whether selective induction of PD-L1 expression under inflamma-
tory conditions is a general phenomenon in leukemia, we analyzed a panel of 12 pri-
mary AML samples for expression of co-signaling ligands following treatment with
IFN-γ and TNF-α (Table 3.1). Indeed, these cytokines induced a 137-fold and 31-fold
upregulation of PD-L1 and PD-L2 mRNA, respectively (Figure 3.1C). Furthermore,
consistent with the findings in the 2 relapsed leukemia patients, PD-L1 cell surface
expression was significantly upregulated (>20% PD-L1− cells) on AML cells of 7
out of 10 newly diagnosed patients, whereas expression of PD-L2 was only slightly
induced (Figure 3.1D). Notably, PD-L1-expressing AML cells displayed very low ex-
pression of CD80 and a variable expression of CD86, which was not influenced by
IFN-γ/TNF-α treatment.
Because AML clones comprise heterogeneous populations of malignant cells, we
studied whether different AML populations exhibited differential expression of co-
signaling molecules. By using multicolor flowcytometry (FCM), we defined 3 dis-
tinct AML populations defined as CD33+CD117+-CD14− AML progenitor cells,
CD33+CD117−CD14− AML myelo/monoblasts, and CD33+CD117−CD14+ AML
promonocytes (Figure 3.3A and B). A panel of 9 AML patients with different French
American British (FAB) classifications was used for analyzing expression of co-
signaling ligands upon IFN-γ ± TNF-α stimulation. Interestingly, the most im-
mature CD33+CD117+CD14− AML cells exhibited high PD-L1 expression (range:
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Figure 3.3: Subpopulation distribution and expression of co-signaling molecules
within AML. (A) The total AML population was identified by CD33 expression, and AML subsets
were further defined by CD14 and CD117 expression. Example of the gating strategy of different
AML subpopulations using a bone marrow samples of AML-M2 patient 5. (B) Distribution of
leukemic subpopulations within 9 AML samples of morphologically diagnosed FAB classification
M0, M1, M2, M4 and M5. Expression of co-stimulatory molecules after overnight incubation with
IFN-γ and TNF-α on (C) CD117−CD14− intermediate AML cells or (D) CD117−CD14+ AML
promonocytes.
46%-94% PD-L1+ cells) in combination with almost absent or very low expres-
sion of PD-L2, CD80, and CD86 under inflammatory conditions (Figure 3.1E). The
CD33+CD117−CD14− AML myelo/monoblasts showed slightly more upregulation
of PD-L1 and CD80 expression and higher CD86 expression (Figure 3.3C). Mature
CD33+CD117−CD14+ AML promonocytes display combined upregulation of PD-L1,
PD-L2, CD80, and CD86 expression (Figure 3.3D).
Collectively, these data show that immature AML cells which contain the puta-
tive leukemic stem cells selectively upregulate PD-L1 expression following short-term
exposure to IFN-γ and TNF-α, enabling these leukemia progenitor cells to inhibit T
cell-mediated attack via the PD-1/PD-L1 pathway.
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Effect of PD-L1-expressing AML cells on allogeneic T cells
To investigate whether PD-L1 expression on AML cells can dampen allogeneic T
cell responses, we performed mixed lymphocyte reactions between PD-L1-expressing
AML cells and allogeneic CD3+ T cells in the absence or presence of anti-PD-1/BMS-
936558 and anti-PD-L1/BMS-936559 blocking antibodies. Blocking with either anti-
PD-1 or anti-PD-L1 antibody significantly increased the proliferation of CD3+ T
cells upon stimulation with allogeneic PD-L1+ AML cells from AML-M4 Pt 9 (Figure
3.4A), whereas allogeneic T cell proliferation stimulated with PD-L1+ and PD-L2+
mDCs could only be inhibited with anti-PD-1 (Figure 3.4B). This difference can be
explained by the high PD-L2 expression on mDC resulting in insufficient interference
of PD-1 signaling by the PD-L1 antibody. In agreement with the T cell proliferation
data, IFN-γ production was also increased by blocking of PD-1 interactions between
T cells and PD-L1+ AML cells (Figure 3.4C) or PDL1+/L2+ mDC (Figure 3.4D).
These results show that PD-L1 expression on AML cells decreases T cell proliferation
and cytokine production.
MiHA-specific CTL expansion and function is enhanced by PD-1 blockade
To elucidate the role of PD-L1 on AML cells in inhibiting the recognition by MiHA-
specific CD8+ T cells, we performed antigen restimulation experiments using CTL
clone RP1 that recognizes the hematopoietic-restricted MiHA LRH-1 on AML pro-
genitor cells.4 RP1, as well as CTLs against other MiHA, upregulates the expression
of PD-1 upon coculture with MiHA+ AML (Figure 3.5 and data not shown). Anti-
body blockade of PD-1 signaling using human antibodies resulted in improved prolif-
eration and IFN-γ production by CTL RP1 upon engagement of PD-L1-expressing
primary AML cells from Pt 11 loaded with MiHA peptide (Figure 3.4E and G). As
hypothesized, we found that PD-1 blockade strongly elevated the proliferation and
IFN-γ production by CTL RP1 when stimulated with peptide-loaded PD-L1+ iDC
(Figure 3.4F and H). Cytotoxicity of CTL versus AML was also enhanced after PD-1
and PD-L1 blockade (Figure 3.4I), whereas no cytoxicity was observed versus iDC
(Figure 3.4J). These data indicate that MiHA-specific CD8+ effector T cells can be
inhibited via the PD-1/PD-L1 pathway either by AML or resident APC populations
that selectively express PD-L1 in the leukemia microenvironment.
PD-1 is highly expressed by circulating MiHA-specific CD8+ T cells in
vivo
Next, we investigated whether PD-1 is expressed by LRH-1-specific T cells in CML-
AP Pt 1 and AML-M0 Pt 2 who relapsed 4 and 3 years, respectively, after the
initial DLIs that induced long-lasting LRH-1-specific CD8+ T cell responses in these
patients. PD-1 expression could be detected on LRH-1-specific CD8+ T cells during
the complete course of the immune response after DLI which peaked at week 28
for CML-AP Pt 1 and at week 10 for AML-M0 Pt 2 (Figure 3.6A). We observed
81
Chapter 3: PD-1 signaling impairs MiHA-specific CD8+ T cells
82
Results
Figure 3.4: PD-1 blockade enhances T cell responses to stimulation by primary AML cells
and DCs. Allogeneic CD3+ T cells were cocultured with PD-L1-expressing leukemia cells of AML
Pt 9 (A) and (C) or PD-L1+PD-L2+ mDC (B) and (D) with addition of blocking anti-PD-1 or
anti-PD-L1 antibodies. Proliferation was measured on day 5 (A) and (B) and IFN-γ production
was evaluated (C) and (D). LRH-1-specific CTL RP1 was cocultured with peptide loaded primary
leukemic cells of AML Pt 11 (E), (G), and (I) or peptide-loaded PD-L1+ iDC (F), (H), and (J),
combined with blockade of PD-1 or PD-L1. Subsequently, proliferation was measured (E) and (F)
in addition to IFN-γ production (G) and (H). Cytotoxicity was measured by granzyme B secretion
(I) and (J). One representative experiment of 3. One-way ANOVA was performed compared with
isotype antibody as control. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
relatively elevated expression of PD-1 on LRH-1 tetramer-positive T cells compared
with tetramer-negative CD8+ T cells in the same patient (Figure 3.6A and B). After
DLI, PD-1 levels at the cell surface of LRH-1-specific CD8+ T cells gradually declined,
but more than 95% of the tetramer-positive T cells remained PD-1 positive during
the contraction phase. To determine PD-1 expression of the apparently impaired
LRH-1-specific CD8+ TMEM cells in the relapsed patients several years after DLI,
we sorted LRH-1-specific CD8+ TEFF cells (Pt 1: 1.8% at week 28; Pt 2 2.9% at
week 15) and low frequencies of LRH-1-specific CD8+ TMEM cells (Pt 1: 0.08% at
week 225; Pt 2 0.05% at week 151) and performed microarray analysis using amplified
cDNA. PD-1 mRNA levels of LRH-1-specific CD8+ TMEM cells at the time of relapse
were elevated or similar compared with LRH-1-specific CD8+ TEFF cells at the peak
of the response for Pt 1 and Pt 2, respectively (Figure 3.6C). These data indicate
that LRH-1-specific CD8+ T cells express elevated levels of PD-1 on the cell surface,
which remain present during the contraction and late memory phase of the immune
response following DLI.
Figure 3.5: LRH-1-specific CTL line expresses and upregulates PD-1 during
co-culture with primary AML cells. (A) During 6 days of co-culture of CTL with CD33+
AML Pt11 cells, expression of PD-1 on LRH-1-specific CTL was monitored by FCM. (B) Expression
of PD-1 on CD8+ LRH-1-specific CTLs on day 6.
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Figure 3.6: MiHA-specific T cells express elevated levels of PD-1 in vivo.
(A) PD-1 expression of LRH-1-specific T cells in CML-AP Pt 1 and AML-M0 Pt 2 was determined
by FCM. Time post DLI is indicated in weeks, and percentage of LRH-1-specific T cells of total
CD8+ T cells in brackets and MFI of LRH-1-specific T cells is displayed. (B) PD-1 expression of
LRH-1-specific T cells compared with total CD8+ T cells in the same patient. (C) LRH-1-specific
T cells were isolated by FCM-assisted sorting. Subsequently, RNA was isolated and PD-1 mRNA
levels were determined at the peak of the response, and in LRH-1-specific TMEM cells 4.5 or 3 years
after initial response. Raw intensity values measured from microarray analysis are depicted.
PD-1 blockade augments proliferation of MiHA-specific CD8+ T cells
To further elucidate the role of PD-1 in impairment of LRH-1-specific CD8+ TMEM
cells, we performed functional assays using PBMCs from CML-AP Pt 1 containing
0.05% to 0.10% LRH-1-specific CD8+ TMEM cells several years after the initial re-
sponse. Stimulation of PBMC of Pt 1 with peptide alone in the presence of IL-2
and IL-15 did not result in an increase of LRH-1-specific T cells (data not shown).
Notably, PD-1 or PD-L1 blockade resulted in a 2- to 4-fold increase in the number of
LRH-1-specific T cells (Figure 3.7A). However, peptide stimulation in the presence
of PD-1 blockade, but in the absence of professional APCs, resulted in insufficient T
cell outgrowth. Therefore, we stimulated PBMCs containing LRH-1-specific TMEM
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Table 3.2: Characteristics of transplanted patients and effect of PD-1 blockade
on MiHA-specific T cell profileration
Pt Disease MiHA T
cell
response
Sample date
(months)
Effect PD-1
blockade
Clinical outcome
1 CML-AP LRH-1 52 post-tDLI 19.8 Hematologic relapse at
47 mo post-tDLI
2 AML LRH-1 7 post-pDLI 15.4 Chloroma relapse at
33, 70, and 78
post-pDLI
2 AML LRH-1 36 post-pDLI 2.8 Chloroma relapse at
33, 70, and 78
post-pDLI
15 CML-BC HA-1 9 post-pDLI 1.5 Remission; death due
to GVHD at 11 mo
post-pDLI
16 MM HA-1 6 post-SCT 5.5 Active disease at 6 mo
post-SCT, plasma cells
5%; M-protein 7g/L
17 Pre-T ALL HA-2 12 post-SCT 2.5 Remission; alive at 174
mo post-SCT
18 CML SP110 20 post-SCT 8.7 Cytogenetic relapse at
14 mo post-SCT
19 AML HA-8 12 post-SCT 0.7 Remission; alive at 213
mo post-SCT
20 NHL HA-1 12 post-SCT 5.9 Remission; alive at 165
mo post-SCT
21 MM HA-1 6 post-SCT 3.3 Remission; alive at 31
mo post-SCT
Characteristics of patients with hematological malignancies displaying MiHA-specific T cell re-
sponses. Pt, patient; CML-AP, chronic myeloid leukemia accelerated phase; CML-BC, chronic
myeloid leukemia blast crisis; MM, multiple myeloma; T-ALL, T cell acute lymphoid leukemia;
NHL, non-Hodgkin lymphoma; pDLI, preemptive DLI; tDLI, therapeutic DLI; MiHA-specific
response: MiHA for which a response was observed; Effect PD-1 blockade, ratio absolute num-
ber of tet+ cells DC+ peptide + aPD-1/absolute number of tet+ cells DC+ peptide + isotype
control; Mo, months; GVHD, graft-versus-host disease.
cells with peptide-loaded PD-L1-expressing iDC in the presence of PD-1 blockade.
Blockade with anti-PD-1 antibody resulted in a 20 times higher number of LRH-1-
specific CD8+ T cells after 3 stimulations with peptide-loaded PD-L1+ iDCs (Figure
3.7B). Consistently, we observed a specific increase to 4.4% LRH-1-specific CD8+ T
cells compared with 0.6% with the isotype control after repeated DC stimulations
using blockade with anti-PD-1 (Figure 3.7C).
Similar assays were performed with PBMC obtained 7 and 36 months post-DLI
containing low numbers of LRH-1-specific TMEM cells from AML-M0 Pt 2. In these
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Figure 3.7: PD-1 blockade increases ex vivo proliferation of MiHA-specific CD8+
TMEM cells.(A) PBMC of CML-AP Pt 1 containing low levels of LRH-1-specific TMEM cells years
after initial responses were stimulated by addition of LRH-1 peptide in the presence of blocking
antibodies against PD-1 or PD-L1. Numbers of LRH-1-specific cells were enumerated by FCM,
and numbers at isotype control were set to 1. Results are from 3 independent experiments from a
sample 225 weeks after DLI (N,  and •) and 1 sample taken 275 weeks after DLI (H). (B) IDCs
were loaded with LRH-1 peptide and added weekly to PBMC containing LRH-1-specific TMEM
cells for 3 weeks, combined with blocking antibodies. (C) LRH-1-specific T cell percentages of total
CD8+ were identified by FCM. iDC stimulation assays with Pt 1 are representative of 3 seperate
experiments. (D) mDCs loaded with LRH-1 peptide were used to stimulate LRH-1-specific TMEM
cells of AML-M0 Pt 2. Subsequently, the percentage of LRH-1-specific T cells after 1 week was
determined by FCM. (E) mDCs loaded with HA-1 peptide were used to stimulate HA-1-specific
TMEM cells of relapsed MM Pt 16. Subsequently, the percentage of HA-1-specific T cells after 1
week was determined by FCM.
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assays, we used mDC to prevent repetitive T-cell stimulation. At 7 months post-DLI,
blocking with anti-PD-1 and anti-PD-L1 antibody resulted in increased outgrowth
of LRH-1-specific CD8+ T cells up to 8.1% and 6.4%, respectively, compared with
2.0% in the presence of an isotype control (Figure 3.7D). In addition, during relapse
at 36 months post-DLI, upon PD-1 and PD-L1 blockade LRH-1-specific CD8+ T
cells increased to 1.16% and 0.86%, respectively, compared with 0.59% for isotype
control (Table 3.2). To confirm effect of PD-1/PD-L1 blockade on the proliferative
capacity of other MiHA-specific T cells, we stimulated PBMC from a relapsed multi-
ple myeloma (MM) patient (Pt 16) containing HA-1-specific T cells. In concordance
with results obtained with LRH-1-specific CD8+ T cells, blockade of PD-1/PD-L1
interactions leads to enhanced mDC-stimulated proliferation of HA-1-specific CD8+
T cells (Figure 3.7E). In addition, we investigated whether PD-1 blockade increased
the absolute amount of MiHA-specific T cells. For AML Pt 2 and MM Pt 16, we
observed a robust absolute increase of MiHA-specific T cells upon PD-1 and PD-L1
blockade (Figure 3.8A).
Next, we investigated whether the effect of PD-1/PD-L1 is exclusive for dysfunc-
tional MiHA-specific T cells in relapsed patients, or that it also affects potential
non-impaired T cells in patients with remission after alloSCT. Therefore, we inves-
tigated the effect of PD-1/PD-L1 blocking in CML-BC Pt 15 and pre-T ALL Pt 17
(Table 3.2). PD-1 and PD-L1 blockade does enhance the absolute number of MiHA-
specific T cells, but the effect is moderate (Figure 3.8B). Finally, we compared the
effect of PD-1 blockade on MiHA-specific T cells from relapsed patients to those from
patients in remission. Importantly, we showed that PD-1 blockade has a significantly
superior effect on dysfunctional MiHA-specific T cells from relapsed patients (Figure
3.8C).
Collectively, these results show that PD-1 signaling impairs the proliferative ca-
pacity of MiHA-specific CD8+ T cells upon antigen stimulation prior to or during
relapse, and this functional impairment can be abrogated by PD-1/PD-L1 immune
checkpoint blockade.
Discussion
AlloSCT is a potentially curative treatment for advanced myeloid leukemia.1 The ef-
fect largely depends on alloreactive CD8+ T cells targeting MiHA on leukemic blasts
and progenitor cells.20 However, MiHA-specific CD8+ T cell responses induced after
transplantation are in many patients not sufficient to sustain complete remission.
Distinct mechanisms are involved in reducing anti-tumor T cell responses, allowing
malignant cells to escape immune destruction. Among these mechanisms, T cell inhi-
bition or even exhaustion due to signaling of the PD-1/PD-L pathway may diminish
immune responses by limiting the expansion and functionality of CD8+ T cells.12,21
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Figure 3.8: The effect of PD-1 blockade on proliferation of MiHA-specific T
cells in relapsed patients is higher than in patients in remission. PBMCs containing
MIHA-specific T cells were stimulated with DC containing their cognate peptide with or without
anti-PD-1 or anti-PD-L1. (A) PD-1/PD-L1 blockade enhances the expansion of MiHA-specific T
cells in relapsed patients. Pt 2 and 16 experienced relapse after initial MiHA-specific responses.
PBMCs prior to additional therapy to treat relapse were investigated. (B) PD-1/PD-L1 blockade
moderately enhances the expansion of MiHA-specific T cells in patients in long-term remission. Pt
15 and 17 remained in remission after initial immune responses. (C) the effect of PD-1 blockade is
significantly higher on MiHA-specific T cells in relapsed patients. Ratio was calculated by dividing
the absolute number of tet+ T cells in the presence of anti-PD-1 antibody by the absolute number
of tet+ T cells in the presence of isotype control. One tailed student t test was performed. *, P <
0.05.
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Recently, we showed that LRH-1+ leukemia can relapse without inducing secondary
LRH-1-specific CD8+ TMEM cell expansion, suggesting that these TMEM cells are
either suppressed or not activated.3,4 In this study, we examined the role of PD-
1/PD-L1 interactions in functional impairment of LRH-1-specific CD8+ T cells reac-
tive to myeloid leukemia. Interestingly, we showed that PD-L1 and, to some extent,
PD-L2 was expressed by CD34+ progenitor myeloid leukemia cells of 2 patients with
relapses after initial efficient T cell responses. Furthermore, we confirmed expression
of PD-L1 on a broader panel of AML samples at diagnosis. Previously, it has been
shown that PD-L1 expression is elevated on relapse AML compared with diagnosis
material.22 We investigated this in 1 CML patient, and indeed, PD-L1 expression
was higher on relapse tumor cells than cells at diagnosis (Table 3.1). Especially,
CD117+CD14− early progenitor myeloid leukemia cells, which contain the leukemic
stem cells, highly expressed PD-L1. PD-L1 expression increased upon exposure to
inflammatory cytokines, whereas expression of CD80 and CD86 remained low. Con-
sequently, prolonged PD-1/PD-L1 interactions may lead to functional exhaustion of
LRH-1-specific TMEM cells, and relapse of the leukemia may occur without induction
of a secondary immune response. To investigate whether LRH-1-specific T cells dis-
play an impaired phenotype, we analyzed T cells of 2 patients with LRH-1-specific
responses. It is known that PD-1 is elevated on T cells specific for viral epitopes
in chronic viral infections.23 Also, during CML disease, PD-1 levels of the total
population of CD8+ T cells are elevated.12 Here, we showed for the first time that
MiHA-specific TMEM cells can have an elevated level of PD-1. Both patients with the
nonresponding TMEM cells had leukemia relapses following a robust initial LRH-1-
specific T cell response. Whether or not elevated PD-1 expression on MiHA-specific
T cells correlates with immune escape and subsequent relapse of meyoloid leukemia
needs to be determined in a larger cohort of patients. However, we found that the
PD-1/PD-L1 pathway negatively influences the function of PD-1-expressing LRH-1-
-specific CTL. Most importantly, we show that blocking PD-1/PD-L1 interactions
with human blocking antibodies resulted in increased outgrowth of MiHA-specific
TMEM cells. We also observed a stimulatory effect of PD-1 blockade on MiHA-
specific T cells from patients in remission, which is not unexpected due to the role of
PD-1 in regulation of T cell activation. However, the abrogation of PD-1 signaling
had a significantly stronger effect on the proliferation of MiHA-specific T cells in
relapsed patients than those in patients in remission. Besides PD-1, several other in-
hibitory receptors play a role in functional T cell exhaustion, such as CTLA-4, LAG-3,
BTLA, TIM-3, CD160 and CD244.24 In future years, the influence of this array of
co-inhibitory receptors will be further elucidated. Perhaps, combinations of blocking
antibodies to PD-1 and LAG-3 will result in highly reactivated MiHA-specific T cell
responses.25 But, as PD-1 is involved in peripheral tolerance, autoimmune events
following PD-1 blockade therapy may occur.26 In a recent phase I study, the clinical
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grade anti-PD-1 antibody BMS-936558, also used in our study, was administered
to patients with solid tumors. Anti-PD-1 was well tolerated and only 1 serious ad-
verse event, inflammatory colitis, was observed in a melanoma patient. Remarkably,
1 durable complete response and 2 partial responses were observed.16 Our current
in vitro data illustrate that PD-1 blockade is an attractive approach to reinvigo-
rate impaired MiHA-specific T cells in patients with persisting or relapsed leukemia.
However, in the setting of alloSCT, PD-1 blockade could aggravate GVHD. For op-
timal boosting of selective GVT immunity in the post-SCT setting, we would like
to combine active immunotherapy by DC vaccination using hematopoietic-restricted
MiHAs with PD-1 blockade. By inducing a time-limited alleviation of PD-1 signal-
ing combined with an antigen-specific stimulus, we aim to resuscitate the impaired
MiHA-specific T cells, without causing autoimmune effects or GVHD. Another strat-
egy is to specifically knock down PD-L1 and/or PD-L2 on MiHA-loaded DC vaccines
by siRNA. In a recent article, we showed that stimulation with PD-L1/2 knockdown
DCs resulted in specific outgrowth of initially unresponsive MiHA-specific T cells.15
This strategy would minimize myeloid leukemia off-target stimulatory effects, because
the hyperstimulatory DCs are loaded with hematopoietic-restricted MiHA. Results
of clinical trials being performed with BMS-936558 and BMS-936559 in parallel with
preclinical mouse models using blocking antibodies in a post-SCT setting will de-
termine the ideal therapy combination. In conclusion, we showed PD-L expression
on myeloid leukemia cells, especially under inflammatory conditions. Interestingly,
CD117+ early progenitor myeloid leukemia cells express high levels of PD-L1, but
low CD80 and CD86 expression. Furthermore, we showed that blockade by human
anti-PD-1 or anti-PD-L1 increases proliferation and IFN-γ and granzyme B produc-
tion by LRH-1-specific CTL incubated with PD-L1+ leukemia cells. In addition,
LRH-1-specific CD8+ T cells exhibit elevated PD-1 expression in vivo. Most impor-
tantly, we could specifically resuscitate initially unresponsive MiHA-specific TMEM
cells by PD-1/PD-L1 blockade. Therefore, we postulate that PD-1 blockade could be
a powerful addition to post-SCT therapy. Combining MiHA-specific DC vaccination
with PD-1 blockade may reinvigorate impaired MiHA-specific TMEM cells and restore
immune control, thereby preventing or attacking leukemia relapses.
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Chapter 4: BTLA blockade enhances MiHA-specific T cell function
Abstract
Allogeneic stem cell transplantation (alloSCT) can cure hematological malignancies
by inducing alloreactive T cell responses targeting minor histocompatibility antigens
(MiHA) expressed on malignant cells. Despite induction of robust MiHA-specific T
cell responses and long-term persistence of alloreactive memory T cells specific for
the tumor, often these T cells fail to respond efficiently to tumor relapse. Previously,
we demonstrated the involvement of the co-inhibitory receptor programmed death-1
(PD-1) in suppressing MiHA-specific CD8+ T cell immunity. In this study, we in-
vestigated whether B and T lymphocyte attenuator (BTLA) plays a similar role in
functional impairment of MiHA-specific T cells after alloSCT. In addition to PD-1,
we observed higher BTLA expression on MiHA-specific CD8+ T cells compared with
that of the total population of CD8+ effector-memory T cells. In addition, BTLA’s
ligand, herpes virus entry mediator (HVEM), was found constitutively expressed by
myeloid leukemia, B cell lymphoma, and multiple myeloma cells. Interference with
the BTLA-HVEM pathway, using a BTLA blocking Ab, augmented proliferation
of BTLA+PD-1+ MiHA-specific CD8+ T cells by HVEM-expressing dendritic cells.
Notably, we demonstrated that blocking of BTLA or PD-1 enhanced ex vivo prolifer-
ation of MiHA-specific CD8+ T cells in respectively 7 and 9 of 11 alloSCT patients.
Notably, in 3 of 11 patients, the effect of BTLA blockade was more prominent than
that of PD-1 blockade. Furthermore, these expanded MiHA-specific CD8+ T cells
competently produced effector cytokines and degranulated upon Ag re-encounter.
Together, these results demonstrate that BTLA-HVEM interactions impair MiHA-
specific T cell functionality, providing a rationale for interfering with BTLA signaling
in post-stem cell transplantation therapies.
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Introduction
Allogeneic stem cell transplantation (alloSCT) can be a curative treatment for hema-
tological malignancies.1 The therapeutic effectiveness is attributed to the graft-
versus-tumor (GVT) effect, which is constituted by donor T cells targeting minor
histocompatibility antigens (MiHA) expressed by tumor cells.2 Recipient dendritic
cells (DC) present MiHA to donor-derived MiHA-specific CD8+ T cells, whereupon
these cells get activated and expand. Subsequently, they migrate to the tumor sites
and lyse the cancer cells.3 Adaptive immune responses, including alloreactive re-
sponses, terminate in a contraction phase, leaving a small pool of long-lived MiHA-
specific memory cells.4 Unfortunately, despite the presence of these memory cells,
many patients with a hematological malignancy relapse post-transplant,5,6 suggest-
ing that MiHA-specific T cell functionality is affected. Tumor cells are known to evade
immune attack via multiple mechanisms,7 among which is interference with T cell
activation. This is a tightly coordinated event, involving TCR-mediated recognition
of the cognate peptide, ligation of co-signaling receptors, and cytokine signaling.8
In recent years, the distinct role of co-inhibitory receptors in this process has been
extensively investigated.9,10 Expression of these receptors has been linked to func-
tional impairment of T cells in various diseases, such as chronic viral infections11,12
and cancer.13–15
We recently investigated whether MiHA-specific T cells in patients after alloSCT
are functionally impaired by signaling of co-inhibitory receptors and demonstrated
that blockade of the programmed death-1 (PD-1; CD279) pathway augmented prolif-
eration and cytokine production of MiHA-specific T cells.16 PD-1 is involved in T cell
exhaustion, a phenomenon characterized by the gradual loss of T cell functionality
(i.e., diminished cytokine production, proliferative capacity and cytolytic activity).17
In addition, it was observed that concurrent expression of multiple co-inhibitory re-
ceptors determines the functional state of T cells.18 One of these co-inhibitory recep-
tors is B and T lymphocyte attenuator (BTLA; CD272).19 This receptor is a member
of the CD28/B7 family, but in contrast to PD-1 and CTLA-4, BTLA binds to a mem-
ber of the TNF receptor superfamily, herpes virus entry mediator (HVEM).20 Other
binding partners of HVEM are CD160 and LIGHT (lymphotoxin-like, exhibits in-
ducible expression, and competes with HSV glycoprotein D for HVEM, a receptor
expressed by T lymphocytes).21 HVEM ligation to the receptors BTLA and CD160
was shown to be inhibitory, whereas the interaction of HVEM with LIGHT medi-
ates T cell stimulation.22 Recently, a role for BTLA was implicated in the escape of
melanoma cells from T cell immunity.23 The authors demonstrated that high BTLA
expression on Melan-AMART−1-specific CD8+ T cells correlated with inhibition of
Ag-specific cytokine production in melanoma patients. Therefore, we investigated
the role of BTLA in the functional impairment of MiHA-specific T cells in alloSCT
97
Chapter 4: BTLA blockade enhances MiHA-specific T cell function
patients. In this study, we demonstrated that these alloreactive cells had high expres-
sion of both BTLA and PD-1. Moreover, we showed that HVEM and BTLA were
constitutively expressed by hematological cancer cells, suggesting a role of the BTLA-
HVEM pathway in tumor immune evasion in alloSCT patients. Most importantly,
we showed augmented proliferation of MiHA-specific T cells upon ex vivo stimulation
after anti-BTLA blockade. Together, these results demonstrate that BTLA interac-
tions contribute to the functional impairment of MiHA-specific T cells, providing a
rationale for incorporation of BTLA interference in post-stem cell transplantation
therapies.
Material and Methods
Patient and donor material
Mononuclear cells were isolated from healthy donor buffy coats (Sanquin, Nijmegen,
The Netherlands) or from blood and bone marrow samples of patients with hemato-
logical malignancies. To examine primary tumor cells, bone marrow samples of eight
acute myeloid leukemia (AML) patients and 10 multiple myeloma (MM) patients
obtained at diagnosis were used. Furthermore, we used PBMC from transplanted
patients who developed MiHA- or CMV-specific CD8+ T cell responses. These were
obtained 3-13 mo after alloSCT. Characteristics of these patients are described in Ta-
ble 4.1. Because no apheresis material of the corresponding donors was available, DC
were cultured from apheresis material of allogeneic HLA-A2+ or HLA-B7+ donors.
All cells of healthy donors and patients were obtained after written informed consent.
Cell culture
Hematopoietic tumor cell lines were cultured in IMDM (Invitrogen, Carlsbad, CA)
supplemented with 10-20% FCS (Integro, Zaandam, The Netherlands). UM-6 cells
were cultured in IMDM-10% FCS with 22.5 ng/ml IL-6 (Immunotools, Friesoythe,
Germany). AML-193 cells were cultured in IMDM-20% human serum (HS; PAA
Laboratories, Pasching, Austria) containing 2 ng/ml IL-3 (Cellgenix, Freiburg, Ger-
many) and 2 ng/ml GM-CSF (Immunotools).
Generation of monocyte-derived DC
Healthy donor monocytes were isolated from PBMC via plastic adherence in tissue
culture flasks (Greiner Bio-One, Alphen a/d Rijn, The Netherlands). Immature DC
were generated by culturing monocytes in X-VIVO-15 medium (Lonza, Verviers,
Belgium) supplemented with 2% HS, 500 U/ml IL-4 (Immunotools), and 800 U/ml
GM-CSF. After 3 days, cells were harvested and cultured in 6-well plates (Corning
Costar, Lowell, MA) at 1 x 106 DC/well in X-VIVO-15-2% HS containing 500 U/ml
IL-4, and 800 U/ml GM-CSF. Maturation of DC was induced at day 6 by culturing
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in X-VIVO-15/2% HS containing 500 U/ml IL-4, 800 U/ml GM-CSF, 5 ng/ml IL-1β,
15 ng/ml IL-6, 20 ng/ml TNF-α (all Immunotools), and 1 µg/ml PGE2 (Pharmacia
& Upjohn, Bridgewater, NJ). At day 8, mature DC were harvested and used in T
cell stimulation assays.
Flow cytometry
BTLA and PD-1 expression on CD8+ T cell subsets of healthy donors and alloSCT
patients was analyzed by staining PBMC with Abs against CCR7 (clone 150503;
R&D Systems, Abingdon, U.K.), CD45RA (clone H100; BioLegend, Antwerp, Bel-
gium), CD3 (clone UCHT1; Beckman Coulter, Fullerton, CA), and CD8 (clone 3B5;
Invitrogen) in combination with BTLA (clone J168-340), PD-1 (clone MIH4; both BD
Biosciences, Franklin Lakes, NJ), or IgG1 isotype control (Dako, Glostrup, Denmark).
In case of PBMC containing MiHA-specific, CMV-pp65-specific, or influenza virus
(FLU)-specific CD8+ T cells, cells were first labeled with 1.5-2 µg allophycocyanin-
conjugated tetramer containing the corresponding peptide. Tetramers were kindly
provided by Prof. Dr. Frederik Falkenburg (Department of Hematology, Leiden
University Medical Center, Leiden, The Netherlands).
Human AML and MM cell lines, primary patient samples, and healthy donor
leukocytes were phenotyped by staining the cells with Abs recognizing HVEM (clone
122; BioLegend), BTLA, CD160 (clone BY55; Beckman Coulter), LIGHT (clone
7-3(7); eBioscience, Vienna, Austria), or IgG1 FITC/PE dual-color isotype control
(Dako). Primary AML cells were gated on CD33+ cells using a CD33 Ab (clone
D3HL60.251; Beckman Coulter). Primary MM cells were gated on CD38+CD138+
cells using Abs against CD38 (clone HIT2; BD Biosciences) and CD138 (clone B-
A38; Beckman Coulter). Healthy donor leukocytes were labeled with Abs recognizing
CD3 (clone UCHT1), CD8 (clone SFCI21Thy2D3; Beckman Coulter), CD14 (clone
HCD14; BioLegend), and CD19 (clone HD37; Dako).
MiHA-specific T cell cultures were incubated with PE-labeled tetramer and,
subsequently, labeled with FITC-conjugated CD8 (clone LT8; ProImmune, Oxford,
U.K.) and PE-Cy7-conjugated CD3. After washing with PBS/0.5% BSA (Sigma, St.
Louis, MO), cells were resuspended in washing buffer containing 0.1% 7-aminoactino-
mycin D (Sigma). Cells were analyzed using the Coulter FC500, Navios, or the
Cyan-ADP flow cytometer (all Beckman Coulter).
BTLA and PD-1 blocking Abs
Mouse anti-human BTLA IgG1 blocking Ab, BTLA-8.2, was kindly provided by Prof.
Dr. Daniel Olive (INSERM Unite´ Mixte de Recherche 891, Institut Paoli Calmettes,
Marseille, France). Mouse IgG1 isotype control (clone MOPC21) was obtained from
BioXCell (West Lebanon, NH). Human PD-1 blocking Ab (BMS-936,558; MDX-1106;
ONO-4538) and a matching IgG4 isotype control were kindly provided by Dr. Alan
Korman (Bristol-Myers Squibb, Biologics Discovery, Milpitas, CA).
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Table 4.1: Characteristics of transplanted patients and effect of BTLA and/or
PD-1 blockade on MiHA-specific CD8+ T cell proliferation
Patient number
1 2 3
Disease Pre-T ALL AML AML
MiHA T Cell Responsea HA-2 LRH-1 HA-8
Sample Date (mo) 12 post-SCT 12 post-SCT 12 post-SCT
DLI Prior to Sample Date No Yes No
Disease Status at Sample
Date
Complete
remission
Complete
remission
Complete
remission
GVHD at Sample Date Limited cGVHD No Limited cGVHD
ISD at Sample Date CSA, Prednisone No No
Clinical Outcome Remission; alive
at 174 mo
post-SCT
Chloroma relapses
at 39, 76, 84 mo
post-SCT
Remission; alive
at 213 mo
post-SCT
Effect Anti-BTLAb 2.6 1.1 9.0
Effect Anti-PD-1 2.5 6.5 0.7
Effect Combination 1.8 5.7 3.4
Patient number
4 5 6
Disease AML CML CML-AP
MiHA T Cell Responsea LRH-1 HA-8 LRH-1
Sample Date (mo) 6 post-SCT 11 post-SCT 13 post-SCT
DLI Prior to Sample Date No Yes Yes
Disease Status at Sample
Date
Complete
remission
Complete
remission
Partial remission
GVHD at Sample Date Limited cGVHD No No
ISD at Sample Date No No No
Clinical Outcome Remission; alive
at 136 mo
post-SCT
Remission; alive
at 171 mo
post-SCT
Hematologic
relapse at 57 mo
post-SCT
Effect Anti-BTLAb 2.1 0.5 2.5
Effect Anti-PD-1 12.5 5.4 7.0
Effect Combination 18.5 2.6 71.7
Characteristics of patients with hematological malignancies displaying MiHA-specific CD8+
T cell responses.
aMiHA-specific response: MiHA for which a response was observed.
bEffect anti-BTLA: ratio of absolute number of tetramer+ CD8+ cells after stimulation with
DC plus peptide plus anti-BTLA/absolute number of tetramer+ CD8+ cells after stimula-
tion with DC plus peptide plus isotype control.
cGVHD, Chronic graft versus-host disease; CML-AP, chronic myeloid leukemia-accelerated
phase; CML-BC, chronic myeloid leukemia-blast crisis; CSA, cyclosporin A; DLI, donor lym-
phocyte infusion given at 4-10 mo after stem cell transplantation; ISD, immunosuppressive
drugs; NHL, non-Hodgkin lymphoma; pre-T ALL, pre-T cel acute lympoblastic leukemia;
SCT, stem cell transplantation.
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Table 4.2: Characteristics of transplanted patients and effect of BTLA and/or
PD-1 blockade on MiHA-specific CD8+ T cell proliferation (continued)
Patient number
7 8 9
Disease CML-BC MM MM
MiHA T Cell Responsea HA-1 HA-1 HA-1
Sample Date (mo) 13 post-SCT 6 post-SCT 5 post-SCT
DLI Prior to Sample Date Yes No No
Disease Status at Sample
Date
Complete
remission
Complete
remission
Partial remission
GVHD at Sample Date Extensive
cGVHD
Limited cGVHD No
ISD at Sample Date CSA No No
Clinical Outcome Remission; death
due to GVHD at
15 mo post-SCT
Remission; alive
at 31 mo
post-SCT
Activ disease at
6 mo post-SCT.
Plasma cells 5%;
M-protein 7g/L
Effect Anti-BTLAb 1.2 3.6 1.0
Effect Anti-PD-1 3.8 4.6 8.7
Effect Combination 4.4 4.0 9.4
Patient number
10 11
Disease NHL NHL
MiHA T Cell Responsea HA-1 HY.A2
Sample Date (mo) 12 post-SCT 3 post-SCT
DLI Prior to Sample Date No No
Disease Status at Sample
Date
Complete
remission
Relapse
GVHD at Sample Date No No
ISD at Sample Date No Prednisone
Clinical Outcome Remission; alive
at 165 mo
post-SCT
Hematologic
relapse at 3 mo
post-SCT
Effect Anti-BTLAb 11.7 2.6
Effect Anti-PD-1 5.3 1.6
Effect Combination 8.4 5.8
Characteristics of patients with hematological malignancies displaying MiHA-specific CD8+
T cell responses.
aMiHA-specific response: MiHA for which a response was observed.
bEffect anti-BTLA: ratio of absolute number of tetramer+ CD8+ cells after stimulation with
DC plus peptide plus anti-BTLA/absolute number of tetramer+ CD8+ cells after stimula-
tion with DC plus peptide plus isotype control.
cGVHD, Chronic graft versus-host disease; CML-AP, chronic myeloid leukemia-accelerated
phase; CML-BC, chronic myeloid leukemia-blast crisis; CSA, cyclosporin A; DLI, donor
lymphocyte infusion given at 4-10 mo after stem cell transplantation; ISD, immunosuppresive
drugs; NHL, non-Hodgkin lymphoma; pre-T ALL, pre-T cel acute lympoblastic leukemia;
SCT, stem cell transplantation.
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Ex vivo Ag-specific T cell expansion and degranulation assays
CMV-pp65-specific or MiHA-specific CD8+ memory T cells present in PBMC from
respectively healthy donors or patients (patients 1-11, Table 4.1) were stimulated for
1 wk ex vivo with peptide-loaded DC in the presence of BTLA and/or PD-1 block-
ing Ab. Mature allogeneic DC, cultured from apheresis material of HLA-A2+ or
HLA-B7+ donors, were loaded with or without 10 µM MiHA or CMV-pp65 peptide
(LRH-1: TPNQRQNVC; HA-1: VLHDDLLEA; HA-2: YIGEVLVSV; HA-8: RTLD-
KVLEV; HY.A2: FIDSYICQV; CMV-pp65: NLVPMVATV or RPHERNGFTVL)
for 30 min at 37◦C. PBMC were preincubated for 30 min with 10 µg/ml BTLA and/or
PD-1 blocking Ab and, subsequently, stimulated with DC at a ratio of 1:0.1 in 1 ml
IMDM-10% HS in 24-well plates (Corning Costar). After 5 days, 1 ml IMDM-10%
HS supplemented with 50 U/ml IL-2 and 5 ng/ml IL-15 (Immunotools) was added.
At day 7, cells were harvested, counted, and the percentage of Ag-specific CD8+ T
cells was determined using flow cytometry. To visualize proliferation of CMV-pp65-
specific and MiHA-specific CD8+ T cells present in PBMC, cells were labeled prior to
T cell stimulation with CFSE (Molecular Probes Europe, Leiden, The Netherlands).
Briefly, PBMC were washed with PBS and resuspended to 10 x 106 cells/ml. Cells
were labeled with 1.25 µM CFSE for 10 min at room temperature. The reaction was
stopped by adding an equal volume of FCS, followed by incubation at room temper-
ature for 2 min, and washing. CFSE-labeled PBMC were used in T cell proliferation
assays as described earlier. At day 7, cells were overnight restimulated with 5 µM Ag
peptide in the presence of CD107a Ab (clone H4A3; BD Biosciences). The following
day, Ag-specific CD8+ T cell proliferation and degranulation was determined by ana-
lyzing CFSE dilution and CD107a staining of the tetramer+ CD8+ T cell population,
respectively.
Intracellular cytokine staining
CMV-pp65-specific or MiHA-specific CD8+ memory T cells present in PBMC were
stimulated with DC loaded with 10 µM peptide, as described earlier. After 7 days,
cells were restimulated with 5 µM peptide. After 1.5 h, brefeldin A (BD Biosciences)
was added to inhibit protein transport within the cell. The next day, cells were first
labeled with allophycocyanin-conjugated tetramer, CD3 PE-Cy7, and CD8 Alexa
Fluor 700, as described previously. After washing in PBS-0.5% BSA, cells were fixed
during 15 min at room temperature with Reagens A (Life Technologies, Grand Island,
NY). Cells were washed, resuspended in Reagens B (Life Technologies), and stained
for 20 min at room temperature with IFN-γ FITC Ab (clone B27) and TNF-α PE
Ab (clone MAb11; both BD Biosciences) or IgG1 FITC-PE isotype control (Dako).
Finally, cells were washed and analyzed using flow cytometry.
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Statistics
To determine statistical differences, a two-sample two-tailed t test assuming indepen-
dent samples, one-way ANOVA with a Bonferroni post-hoc test, or a Kruskal-Wallis
analysis followed by a Dunn’s post-hoc test was used, as indicated. The p values
<0.05 were considered significant.
Results
MiHA-specific CD8+ EM T cells show high BTLA and PD-1 expression
Flow cytometric analysis was performed on CD8+ T cells from alloSCT patients and
healthy donors to determine BTLA and PD-1 expression levels on MiHA-, CMV-,
and FLU-specific CD8+ T cells in comparison with distinct CD8+ T cell differentia-
tion stages. CD8+ T cell subset composition was analyzed by gating on CCR7 and
CD45RA (Figure 4.1A, 4.1B). In healthy donors, the total CD8+ T cell pool was
composed of na¨ıve, effector-memory (EM), and central-memory (CM) cells. alloSCT
patients, on the contrary, had very low numbers of na¨ıve and CM CD8+ T cells,
and their CD8+ T cells predominantly consisted of EM cells (84.2 ± 2.3%). Similar
to CMV-pp65-specific CD8+ T cells in healthy donors (94.1 ± 3.0%), MiHA-specific
and CMV-pp65-specific CD8+ T cells in alloSCT patients were mainly of EM pheno-
type (95.7 ± 2.1% and 95.7 ± 1.3%, respectively). However, the FLU-specific CD8+
T cell population in healthy donors comprised both CM (35.0 ± 9.8%) and EM (62.9
± 10.3%) cells.
In healthy individuals, BTLA was highly expressed on na¨ıve CD8+ T cells and
gradually decreased on more differentiated T cells, with EM CD8+ T cells showing
markedly lower BTLA levels than the other T cell subsets (Figure 4.1C, 4.2A). When
comparing CD8+ T cell subsets of healthy donors with those of alloSCT patients,
the number of na¨ıve BTLA+ T cells was significantly lower in alloSCT patients. In
contrast to BTLA, PD-1 expression by na¨ıve T cells was low and markedly increased
upon T cell differentiation into effector and memory cells (Figure 4.1C, Figure 4.2).
In alloSCT patients, the percentage of PD-1+ cells within each CD8+ T cell subset
was significantly higher than that in healthy individuals.
As most of the MiHA-specific and CMV-specific CD8+ T cells displayed an EM
phenotype, we compared the expression of BTLA and PD-1 within the EM subset of
tetramer+ and total CD8+ T cells (Figure 4.1D, Figure 4.2B, 4.2C). Both in healthy
donors and alloSCT patients, the percentage of BTLA+ cells was significantly higher
for CMV-specific CD8+ EM T cells than for total CD8+ EM T cells. The percentage
of BTLA-positive FLU-specific T cells was similar to that in the total CD8+ EM T
cell population of healthy donors, although BTLA levels on these T cells were slightly
lower (Figure 4.2C). Notably, MiHA-specific CD8+ T cells of alloSCT patients highly
expressed both BTLA and PD-1. Also CMV-specific and FLU-specific T cells in
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Figure 4.1: BTLA and PD-1 are highly expressed by MiHA-specific CD8+ T
cells. CD8+ T cell subsets of healthy donors and alloSCT patients were examined for BTLA and
PD-1 expression using flow cytometry. (A and B) T cell subset composition was analyzed by gating
on CCR7 and CD45RA expression within the total or Ag-specific CD3+CD8+ T cell populations.
na¨ıve (N), CCR7+CD45RA+; CM, CCR7+CD45RA−; EM, CCR7−. (A) Representative examples
of the CD8 subset composition in one healthy donor (HD) and one alloSCT patient (Pt) are given.
(B) Combined data on CD8 subset composition for healthy donors and alloSCT patients is shown
(HD CD8, n = 8; HD CMV and FLU, n = 5; Pt CD8, n = 6; Pt CMV and MiHA, n = 5). Data are
expressed as mean + SEM. (C) Percentage of BTLA+ and PD-1+ cells was examined within the
different CD8+ T cell subsets. (D) Within the EM subset of the total or Ag-specific CD3+CD8+
T cell population, the percentage of BTLA+ and PD-1+ cells was examined. Statistical analysis
was performed using a two-sample two-tailed t test assuming independent samples (C) or one-way
ANOVA followed by a Bonferroni post-hoc test (D). White bars, healthy donors; gray bars, alloSCT
patients. * P < 0.05; ** P < 0.01; *** P < 0.001.
healthy donors showed increased PD-1 expression, however to a lesser extent than
in alloSCT patients. Collectively, these data demonstrate that MiHA-specific EM T
cells of alloSCT patients have elevated BTLA and PD-1 expression.
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Figure 4.2: BTLA and PD-1 are highly expressed by MiHA-specific CD8+ T
cells. CD8+ T cell subsets of healthy donors (HD) and alloSCT patients (pt) were examined
for BTLA and PD-1 expression using flow cytometry. T cell subsets were analyzed by gating on
CCR7 and CD45RA expression within the total or antigen-specific CD3+CD8+ T cell populations.
Na ive(N), CCR7+CD45RA+; Central memory (CM), CCR7+CD45RA−; Effector memory (EM),
CCR7−. (A) Median fluorescence intensity (FI) of BTLA and PD-1 was examined within the
different T cell subsets of the total CD8+ T cell population. (B) Surface expression of BTLA and
PD-1 (filled black) as compared to isotype control (filled grey) on total CD8+ and antigen-specific
EM T cells is depicted for the same donors and patients as in Figure 4.1A. The numbers in the plots
represent the median FI. (C) BTLA and PD-1 surface expression levels were analyzed within the
EM subset of the total or antigen-specific CD3+CD8+ T cell populations for all donors and patients.
HD CD8: n=8, HD CMV and FLU: n=5, Pt CD8: n=6, Pt CMV and MiHA: n=5. Statistical
analysis was performed using a two-sample two-tailed t-test assuming independent samples, or One-
way ANOVA followed by a Bonferroni post-hoc test, if appropriate. * P < 0.05; ** P < 0.01. CMV,
cytomegalovirus; FLU, influenza virus; MiHA, minor histocompatibility antigen.
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HVEM and BTLA are highly expressed by human hematopoietic tumor
cells
To determine the expression of HVEM, BTLA, CD160, and LIGHT on hematopoietic
malignancies, we analyzed various tumor cell lines, patient bone marrow samples,
and healthy donor leukocytes for cell surface expression using flow cytometry. First,
we analyzed myeloid leukemia (both AML and chronic myeloid leukemia (CML)),
B cell non-Hodgkin lymphoma (B-NHL), and MM cell lines (Figure 4.3A). HVEM
levels were constitutively high on all of these malignancies, although the membrane
expression was slightly lower on the immature (FAB type M0-M2) leukemia cell
lines compared with the more mature (FAB type M5) leukemia cell lines (Table 4.1,
Figure 4.4A). In contrast to HVEM, BTLA was restricted to the B cell malignancies
and showed a more heterogeneous expression pattern. No expression of CD160 was
observed for any of the tumor cell lines examined. LIGHT expression levels, in
contrast, were highest on some leukemic cell lines and modest in B-NHL and MM
tumor cell lines. To confirm these expression patterns in primary human tumor cells,
we analyzed bone marrow samples of 8 AML and 10 MM patients obtained at time of
diagnosis. AML and MM cells were gated on the CD33+SSClow and CD38+CD138+
populations, respectively. Similar expression patterns were found for HVEM and
LIGHT in the primary tumor samples compared with the tumor cell lines (Figure
4.3B, 4.3C, Table 4.2, Figure 4.4B). Although CD160 was again not expressed by the
malignant cells, BTLA expression was substantially higher on the primary AML and
MM cells than on the corresponding tumor cell lines. We also examined healthy donor
control cells and observed high HVEM and BTLA expression on T cells, monocytes,
and B cells (Figure 4.3D). However, expression levels were significantly higher on
the monocytes and B cells (Figure 4.4C). Furthermore, monocytes also displayed
significantly higher LIGHT expression than the other cell types. Together, these
data show that human AML and MM cells display high levels of HVEM, whereas
BTLA is highly expressed on MM cells and moderately on AML cells.
PD-1 blockade augments the proliferative capacity of fully functional
CMV-specific CD8+ T cells
First, we investigated the effect of BTLA and/or PD-1 blockade on CMV-specific
T cell responses. As in healthy donors, a high level of PD-1 and BTLA on pp65-
specific T cells was observed. Therefore, we stimulated PBMC of three healthy
donors with CMV-pp65 peptide-loaded DC in the presence or absence of blocking
Ab. After 1 week, CMV-specific CD8+ T cell proliferation and function was ana-
lyzed. In Figure 4.5A, the percentage of tetramer+ CD8+ T cells is shown for one
representative healthy donor. Blockade of BTLA resulted in a slightly higher per-
centage of CMV-specific T cells after 1 week. In contrast, PD-1 blockade clearly
boosted the percentage and absolute number of CMV-specific CD8+ T cells (Figure
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Figure 4.3: Hematopoietic tumor cells highly express HVEM and BTLA. Surface
expression of HVEM, BTLA, CD160, and LIGHT on hematopoietic tumor cells and healthy donor
control cells was analyzed using flow cytometry. (A) For each protein, the percentage of positive
cells was determined in various hematopoietic tumor cell lines. (B) HVEM, BTLA, and LIGHT
(black lines) protein expression by primary tumor cells as compared with isotype control (filled
gray). Data of one representative AML and one MM patient are shown, respectively patient 19 and
24 of Table 4.3. The numbers in the plots represent the mean fluorescence intensity. (C and D) The
percentages of HVEM, BTLA, CD160, and LIGHT positive cells were determined in bone marrow
samples of 8 AML patients and 10 MM patients and PBMC samples of 5 healthy donors. (C) AML
and MM cells were gated on the CD33+ SSClow and CD38+CD138+ populations, respectively. (D)
Healthy donor CD4+ T cells were gated as CD3+CD82, CD8+ T cells as CD3+CD8+, monocytes
as CD14+, and B cells as CD19+ cells. Lines indicate the mean. Statistical analysis was performed
using a two-sample two-tailed t test assuming independent samples (C) or one-way ANOVA followed
by a Bonferroni post-hoc test (A, D). * P < 0.05; ** P < 0.01; *** P < 0.001.
4.5B). The combination of BTLA and PD-1 blockade had no synergistic effects in this
donor. To combine data of all healthy donors, the fold expansion was calculated as
the absolute number of MiHA-specific CD8+ T cells in the presence of Ab blockade
relative to isotype control treatment (Figure 4.5C). Notably, only PD-1 blockade and
the combination with anti-BTLA treatment significantly enhanced the expansion of
CMV-specific CD8+ T cells. To visualize the proliferation of the CMV-specific T
cells, we labeled PBMC of donor 2 with CFSE and performed a 1-week stimulation
assay. After overnight restimulation with 5 µM CMV peptide in the presence of
anti-CD107a Ab, the proliferation and degranulation capacity of the CMV-specific
CD8+ T cells was analyzed. Upon stimulation in the presence of PD-1 blocking Ab,
more cells had a CFSE− phenotype compared with isotype control-treated cells (Fig-
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Figure 4.4: Hemapoietic tumor cells highly express HVEM and BTLA. Surface
expression of HVEM, BTLA, CD160 and LIGHT on hematopoietic tumor cells and HD control
cells was analyzed using flow cytometry. For each protein the mean fluorence intensity (MFI)
was determined on (A) various hematopoietic tumor cell lines, (B) primary tumor cells, and (C)
healthy donor control cells. (B) AML (n=8) and MM (n=10) cell were gated on CD33+ and
CD38+CD138+ populations respectively. (C) HD CD4+ T cells were gated as CD3+CD4+, CD8+
T cells as CD3+CD8+, monocytes as CD14+ and B cells as CD19+ (n=5). Statistical analysis was
performed using a two-sample two-tailed t-test assuming independent samples, or One-way ANOVA
followed by a Bonferoni post-hoc test. * P < 0.05; ** P < 0.01; *** P < 0.001.
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Table 4.2: HVEM, BTLA, CD160 and LIGHT expression levels on hematopoi-
etic tumor cell lines
Cell line Type HVEM+ BTLA+ CD160+ LIGHT+
(%) (%) (%) (%)
KG1a AML-M0 85.0 8.9 3.6 6.8
KG1 AML-M1 59.1 10.0 2.1 5.3
Kasumi AML-M2 28.1 8.0 0.8 27.0
HL-60 AML-M2 93.9 10.1 1.2 9.2
AML-193 AML-M5 95.9 6.8 1.5 11.0
Mono-Mac-6 AML-M5 99.7 5.8 0.7 6.3
THP1 AML-M5 88.8 8.2 1.1 ND
LAMA-84 CML 47.6 10.3 1.1 41.9
K-562 CML 81.9 12.8 1.2 51.3
Raji B-NHL 54.9 8.2 0.7 2.3
BJAB B-NHL 90.1 7.3 0.2 1.9
RAMOS B-NHL 89.9 94.1 0.1 4.7
HS-Sultan B-NHL 88.9 60.9 3.2 5.1
RPMI-1788 B-NHL 88.7 74.6 1.1 43.0
U-698-M B-NHL 63.3 60.9 0.1 2.7
SU-DHL-6 B-NHL 80.8 53.9 1.1 11.1
L-363 MM 74.4 16.9 0.3 3.2
U266 MM 61.9 8.8 0.7 8.7
RPMI-8226 MM 89.6 24.4 4.2 2.1
UM1 MM 77.7 54.7 0.9 34.9
UM3 MM 97.8 2.3 0.1 1.1
UM6 MM 99.8 92.5 50.5 7.7
UM9 MM 99.7 39.7 1.1 6.4
Various hematopoietic tumor cell lines were analyzed for percentage of
HVEM, BTLA, CD169 and LIGHT positive cells.
AML, acute myeloid leukemia; CML, chronic myeloid leukemia; B-NHL, B-
cell non-Hodgkin lymphoma; MM, multiple myeloma; ND, not determined.
ure 4.5D). Furthermore, >66% of the tetramer+ CD8+ T cells showed high CD107a
staining upon overnight restimulation with CMV peptide (Figure 4.5E). Notably in
this donor, BTLA blockade did not further increase the degranulation capacity of the
CMV-specific CD8+ T cells, but blocking of PD-1 resulted in a higher percentage of
CD107a+ Ag-specific T cells. Moreover, combined BTLA and PD-1 blockade further
boosted CMV-specific T cell degranulation. Finally, we examined the production of
effector cytokines IFN-γ and TNF-α of 1-week expanded CMV-specific T cells. Af-
ter overnight restimulation, most of the CMV-specific CD8+ T cells produced either
IFN-γ alone or in combination with TNF-α (Figure 4.5F). Blockade of BTLA did not
improve the percentage of Ag-specific T cells producing cytokines. On the contrary,
blockade of PD-1 alone or in combination with BTLA enhanced the percentage of
IFN-γ+ and IFN-γ+ TNF-α+ cells within the CMV-specific CD8+ T cell population
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Table 4.3: HVEM, BTLA, CD160 and LIGHT expression levels on primary
AML and MM cells.
Patient Type Malignant HVEM+ BTLA+ CD160+ LIGHT+
Patient Type cells∗ (%) (%) (%) (%) (%)
12 AML-M0 40 84.3 21.4 8.3 10.2
13 AML-M1 91 60.9 23.8 0.2 7.5
14 AML-M1 54 61.7 29.6 0.2 4.7
15 AML-M2 64 99.0 29.3 0.7 6.8
16 AML-M2 69 52.2 32.7 0.2 23.7
17 AML-M2 30 69.9 65.7 0.3 1.4
18 AML-M4 48 89.0 33.1 0.2 2.9
19 AML-M4 22 91.0 23.5 0.3 10.4
20 MM stage 1A 16 91.0 76.2 0.2 ND
21 MM stage 1A 19 93.9 98.7 1.2 ND
22 MM stage 3A 36 71.9 56.9 0.7 0.5
23 MM stage 3A 43 85.0 63.3 0.9 ND
24 MM stage 3A 13 90.6 98.6 1.5 17
25 MM stage 3A 21 92.2 88.3 0.4 30.7
26 MM stage 3A 15 96.8 95.2 1.6 32.6
27 MM stage 3A 38 97.3 30.1 0.1 20.5
28 MM stage 3B 36 97.3 95.7 0.3 1.5
29 MM stage 3B 73 99.5 99.9 0.6 ND
Peripheral blood samples of AML and MM patients, obtained at time of diagnosis, were ana-
lyzed for percentage of HVEM, BTLA, CD160 and LIGHT positive cells. AML cells were gated
as CD33+SSlow cells. MM cells were gated as CD38+CD138+ cells.
∗ The percentage of blasts was defined by morphological analysis.
AML, acute myeloid leukemia; MM, multiple myeloma; ND, not determined.
of this donor. These results indicate that blockade of PD-1, but not of BTLA, results
in increased proliferation of CMV-specific CD8+ T cells of healthy donors and that
these Ag-specific T cells are highly functional upon restimulation with the cognate
peptide.
Both BTLA blockade and PD-1 blockade augment expansion of MiHA-
specific CD8+ T cells ex vivo
To investigate the role of BTLA in the inhibition of MiHA-specific CD8+ T cell re-
sponses, we performed functional assays using PBMC from 11 patients with a hema-
tological malignancy who developed MiHA-specific T cell responses after alloSCT.
Previously, we demonstrated that reinvigoration of MiHA-specific CD8+ T cell re-
sponses requires mature DC loaded with the cognate MiHA.16,24 Therefore, we first
analyzed expression levels of HVEM and its binding partners on mature monocyte-
derived donor DC (Figure 4.6A). Similarly to hematological tumor cells, mature DC
displayed high HVEM expression and moderate levels of BTLA and LIGHT. CD160,
in contrast, was not expressed. Subsequently, these DC were pulsed with MiHA
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Figure 4.5: Blockade of PD-1 results in enhanced proliferation of functional
CMV-specific CD8+ T cells in healthy donors. PBMC of healthy donors containing
CMV-pp65-specific CD8+ T cells were stimulated for 1 week with mature DC loaded with the
CMV peptide at a ratio of 1:0.1. To block the inhibitory interactions, cells were preincubated
with 10 µg/ml anti-BTLA and/or anti-PD-1. CMV-specific T cell expansion and function was
subsequently analyzed using flow cytometry. (A) One week after stimulation, cells were analyzed
for tetramer+ CD8+ T cells using flow cytometry. Data of one representative healthy donor out
of three donors is shown. (B) Total number of CMV-pp65-specific CD8+ T cells of donor 1 after
1 week of stimulation with CMV peptide-loaded DC in the presence or absence of blocking Ab.
(C) The effect of BTLA blockade on CMV-specific T cell expansion was calculated by dividing the
absolute number of tetramer+ T cells after BTLA and/or PD-1 blockade with the absolute number
of tetramer+ T cells treated with isotype control Ab. Data of three different donors are shown. (D-
F) To visualize T cell proliferation and function after 1-week stimulation in the presence of BTLA
and/or PD-1 blockade, PBMC labeled with or without 1.25 µM CFSE were restimulated overnight
with 5 µM Ag peptide in the presence of CD107a Ab or brefeldin A. The following day, CFSE
dilution (D), CD107a staining (E), and intracellular IFN-γ and TNF-α levels (F) were analyzed
within the CMV-specific CD8+ T cell population. Numbers in the plot indicate the percentage of
cells in each quadrant. Data of one out of two donors is shown. Statistical analysis was performed
using a Kruskal-Wallis analysis followed by a Dunn’s post-hoc test. * P < 0.05. MFI, Mean
fluorescence intensity.
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peptide and used for ex vivo stimulation of MiHA-specific memory T cells in the
presence of BTLA and/or PD-1 blocking Ab. In Figure 4.6B, results of three rep-
resentative patients are shown. At start, PBMC of patients 4, 8, and 10 contained
0.09, 0.76, and 0.11% CD8+ T cells recognizing either the MiHA LRH-1 or HA-1. In
these patients, we observed augmented percentages of MiHA-specific CD8+ T cells
after blockade of BTLA and/or PD-1 compared with isotype control-treated cells.
To combine data of all patients, the fold expansion was calculated as the absolute
number of MiHA-specific CD8+ T cells after Ab blockade relative to isotype con-
trol treatment. In 7 of 11 patients, BTLA blockade augmented MiHA-specific T cell
expansion >2-fold (range, 2.1- to 11.7-fold; Figure 4.6C, Table 4.1). Furthermore,
PD-1 blockade enhanced MiHA-specific T cell numbers >2-fold in 9 of 11 patients
(range, 2.5- to 12.5-fold; Figure 4.6D). Notably, in 3 of the 7 BTLA responders, the
effect of BTLA blockade was more prominent than that of PD-1 blockade. However,
no significant difference was observed when comparing the effects of BTLA and PD-1
blockade for all patients. Moreover, combined blockade of BTLA and PD-1 boosted
MiHA-specific CD8+ T cell expansion, although when compared with single receptor
blockade, no additive effect was observed.
Finally, we examined CFSE dilution, degranulation, and cytokine production by
the expanded MiHA-specific CD8+ T cells after overnight restimulation with the
cognate peptide. After 1 wk of stimulation with peptide-loaded DC, >90% of the
MiHA-specific CD8+ T cells were CFSE− (Figure 4.7A). However, no differential
effect of BTLA or PD-1 blockade could be observed. Furthermore, these expanded
Figure 4.6: BTLA blockade increases ex vivo expansion of MiHA-specific CD8+
memory T cells. PBMC of patients containing MiHA-specific CD8+ T cells were stimulated for
1 week with mature DC loaded with the cognate peptide at a ratio of 1:0.1. To block the inhibitory
interactions, cells were preincubated with 10 µg/ml anti-BTLA and/or anti-PD-1. DC phenotype
and MiHA-specific T cell expansion was subsequently analyzed using flow cytometry. (A) Surface
expression of HVEM, BTLA, CD160, and LIGHT (black lines) compared with isotype control (filled
gray) was measured on mature monocyte-derived DC from healthy donors. The numbers in the plots
represent the mean fluorescence intensity. Data of one representative donor is shown. (B) After 1
week, MiHA-specific T cell expansion was analyzed using tetramers. The numbers in the FACS plots
represent the percentage of HA-1- or LRH-1-specific CD8+ T cells of each patient within the total
CD3+CD8+ T cell population. (C) The effect of BTLA blockade on MiHA-specific T cell expansion
was calculated by dividing the absolute number of tetramer+ T cells after BTLA blockade with the
absolute number of tetramer+ T cells treated with isotype control. Data of 11 different patients is
shown. (D) The effect of PD-1 and combined BTLA/PD-1 blockade on MiHA-specific CD8+ T cell
proliferation was calculated relative to isotype control-treated cells. Data of 11 different patients
is shown. Statistical analysis was performed using a Kruskal-Wallis analysis followed by a Dunn’s
post-hoc test. P < 0.05; *** P < 0.001.
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MiHA-specific EM T cells efficiently degranulated upon Ag re-encounter, as demon-
strated by CD107a staining (Figure 4.7B). This is in contrast to the tetramer− CD8+
T cell population, of which <5% of the cells stained positive for CD107a (data not
shown). In some patients, single PD-1 blockade resulted in somewhat increased per-
centages of CD107a+ Ag-specific T cells; however, this was not observed for the
other treatments. In Figure 4.7C, intracellular IFN-γ and TNF-α expression lev-
els by MiHA-specific T cells of one representative patient (patient 2) are shown.
After Ag restimulation, >90% of the Ag-specific CD8+ T cells produced the effec-
tor cytokines IFN-γ and/or TNF-α (Figure 4.7C-E). Although the percentage of
cytokine-producing T cells did not further increase, the expression levels of IFN-γ
and TNF-α within the MiHA-specific CD8+ T cells seemed to be higher after prior
BTLA and/or PD-1 blockade. Especially, TNF-α seemed differentially upregulated
in MiHA-specific T cells treated with BTLA blocking Ab. In conclusion, we demon-
strate that next to PD-1, BTLA is also involved in MiHA-specific T cell inhibition
and that the relative contribution of these two receptors to functional impairment
differs between patients.
Discussion
Alloreactive MiHA-specific CD8+ T cells play a pivotal role in GVT responses after
alloSCT and donor lymphocyte infusion.24,25 Unfortunately, many patients develop
relapses despite the long-term presence of MiHA-specific memory T cells, suggesting
that these cells become functionally impaired. Tumor cells deploy distinct mecha-
nisms to evade immune attack,7 including expression of ligands for co-inhibitory re-
ceptors on T cells.26 Previously, we demonstrated that the co-inhibitory PD-1/PD-L
pathway is involved in the functional impairment of MiHA memory responses after
alloSCT and that these could be reinvigorated by DC stimulation in combination
with PD-1 blockade.16 Another co-inhibitory receptor, BTLA, was recently shown
to be involved in dysfunction of melanoma-specific T cells.23 This prompted us to
investigate the potential inhibitory role of BTLA on MiHA-specific T cells in cancer
patients after alloSCT.
First, we investigated BTLA and PD-1 expression on the different CD8+ effec-
tor/memory subsets in healthy donors and alloSCT patients. In concordance with
the work from Derre´ et al.,23 we found that BTLA expression in healthy donors is
highest on na¨ıve CD8+ T cells and is gradually reduced in CM and EM cells. This
phenomenon was similar for CD8+ T cells of patients, although overall BTLA ex-
pression was lower. In contrast, PD-1 expression shows a reversed profile, with low
expression on na¨ıve T cells and high presence on CM and EM cells, which was also
reported by Duraiswamy et al.27 In alloSCT patients, PD-1 levels in the distinct sub-
sets were evidently higher than those in corresponding healthy donor T cells. This
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Figure 4.7: Expanded MiHA-specific CD8+ memory T cells are highly func-
tional. PBMC of patients containing MiHA-specific CD8+ T cells were stimulated for 1 week with
mature DC loaded with the cognate peptide at a ratio of 1:0.1. To visualize the effect on T cell
proliferation and function by BTLA and/or PD-1 blockade, PBMC labeled with or without 1.25 µM
CFSE were after 1 week restimulated overnight with 5 µM Ag peptide in the presence of CD107a
Ab or brefeldin A. The following day, the percentage of CFSE− (A) and CD107a+ (B) cells within
the MiHA-specific CD8+ T cell population was analyzed. Data are depicted as mean + SEM, n =
3. (C) Intracellular IFN-γ and TNF-α levels within the MiHA-tetramer+ CD8+ T cell population
of one representative patient (patient 2) out of three patients. Numbers in the plot indicate the
percentage of cells in each quadrant. (D and E) Intracellular IFN-γ (D) and TNF-α (E) levels
within the tetramer+ CD8+ T cell population. Data are depicted as mean + SEM, n = 2 to 3.
is probably because of the presence of a long-lasting inflammatory milieu due to the
pre-SCT conditioning regimen,28 development of alloreactive T cell responses,29 oc-
currence of graft-versus-host disease (GVHD), and reactivation of viruses and subse-
quent immune responses.30,31 The differential expression profiles of BTLA and PD-1
indicate that there is a distinct role for these molecules to exert their physiological
function. Because peripheral blood of alloSCT patients predominantly contains EM
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CD8+ T cells with very low numbers of na¨ıve and CM T cells, analysis of BTLA
and PD-1 expression was limited to the EM subset. Skewing of the CD8+ T cell
population to the EM subset is a common phenomenon after alloSCT, as many T
cells become activated as mentioned before. When focusing on the MiHA-specific T
cells, these are also mainly of the EM type, as expected due to in vivo allogeneic
activation.
Subsequently, we investigated BTLA and PD-1 expression specifically on CMV-,
FLU-, and MiHA-specific T cells of healthy donors and alloSCT patients, respec-
tively. In accordance with findings by others,23,32 healthy donor CMV-specific T
cells showed relative increased BTLA and PD-1 expression, which is probably due
to frequent activation by latent CMV. On the contrary, lower BTLA expression was
observed in case of cleared viral infections, like influenza. In general, BTLA levels on
total CD8+ T cells in patients were slightly lower compared with those in healthy in-
dividuals. Notably, CMV- and MiHA-specific T cells of alloSCT patients were highly
BTLA positive despite their EM phenotype. PD-1 levels, on the contrary, were al-
ready high on the total CD8+ T cell pool, as well as on CMV- and MiHA-specific EM
T cells. These data confirm our recent observations6 and can be attributed to the
high numbers of activated alloreactive and microbial-reactive T cells as mentioned
before. Notably, MiHA-specific T cells of alloSCT patients showed high expression
levels of both PD-1 and BTLA.
To investigate whether BTLA ligation could be a potential evasion mechanism,
we next examined ligand expression levels on tumor cells. Therefore, we analyzed
hematopoietic tumor cells for the presence of BTLA, HVEM, CD160, and LIGHT.
Notably, both HVEM and its binding partner BTLA were expressed on primary
leukemia and myeloma cells, whereas LIGHT and CD160 were barely present. Our
data correspond with the literature describing HVEM to be constitutively expressed
on primary myeloma cells.33 Furthermore, we report here for the first time, to our
knowledge, that primary AML cells highly express HVEM. Notably, in contrast to
the ligands for PD-1,16 HVEM is constitutively expressed, and further upregulation
under inflammatory conditions was not observed (data not shown). Because BTLA
can also be expressed on the tumor cells, we also investigated whether T cells were
positive for HVEM. Indeed, HVEM was observed on human T cells, indicating that
a bi-directional HVEM-BTLA signaling route between tumor cell and T cells can
occur. As yet, the effect of BTLA signal transduction into the tumor cell is un-
known. Furthermore, besides BTLA, HVEM itself has been reported to function as
a receptor as well.34,35 Altogether, this results in a complex network of interactions
for BTLA, HVEM, and their binding partners,36 which needs to be elucidated in
future experiments.
The concurrent expression of BTLA on MiHA-specific T cells and HVEM by ma-
lignant cells suggested that this co-inhibitory pathway contributed to the functional
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inhibition of MiHA-specific T cells in vivo. Therefore, we performed ex vivo blocking
experiments using DC as APCs. Based on their strong stimulatory potential, DC
are attractive vaccines for ex vivo 37 and in vivo 38 stimulation of MiHA-specific T
cell responses. Importantly, DC also express HVEM, BTLA, and to some extent
LIGHT, providing a rationale for combined DC stimulation and BTLA blockade.
In addition, by interfering with the ligation of HVEM to BTLA, an additive effect
could be realized by increased interaction of HVEM with LIGHT,22 yielding a more
co-stimulatory signal. After blockade of BTLA interactions, we observed enhanced
proliferation of MiHA-specific T cells in 64% of the patients, indicating that BTLA
ligation also contributes to impairment of alloreactive T cells in transplanted cancer
patients. On the basis of our previous findings, where we identified the involvement
of PD-1 in MiHA-specific T cell dysfunction, we next compared the relative contri-
bution of both co-inhibitory receptors in this process. Compared to BTLA blockade,
PD-1 blockade exerted evident boosting of Ag-specific T cell expansion in 82% of
the patients. Notably, some patients responded better to BTLA blockade, whereas
others showed more pronounced effects after PD-1 blockade. Whether the increase
in number of cells is due to enhanced cell cycling was investigated in a CFSE dilution
assay. For CMV-specific CD8+ T cells, we observed a higher percentage of CFSE-
diluted dividing cells after PD-1 blockade. However, we did not observe these effects
in MiHA-specific CD8+ memory T cells. The increased number of Ag-specific T
cells may here be attributed to less apoptosis after BTLA and/or PD-1 blockade. In
addition, we examined whether the boosted Ag-specific T cells exhibited competent
functionality. Upon Ag re-encounter, both CMV- and MiHA-specific CD8+ T cells
efficiently degranulated and produced effector cytokines. Notably, blocking of BTLA
seemed to mediate increased TNF-α production in MiHA-specific T cells.
Possibly, the differences observed between PD-1 and BTLA blocking can be at-
tributed to inherent differences between the Abs. The anti-PD-1 Ab is fully hu-
manized and has proved its functionality in phase I clinical trials,39 whereas the
anti-BTLA Ab is murine and still in the preclinical stage. Although few immunere-
lated adverse events have been reported for PD-1 blockade, dosing and timing of the
BTLA blocking Ab has to be carefully examined in clinical trials, as both molecules
are involved in the maintenance of self tolerance. Especially, in the alloSCT setting,
interference with co-inhibitory molecules could deteriorate GVHD. In mouse models,
however, BTLA has been reported to have a differential role in GVT responses, and
not in GVHD.40,41 Although we found high expression of both BTLA and PD-1 on
MiHA-specific CD8+ T cells, we could not correlate their expression levels to the
effect on T cell proliferation upon blocking of either of these pathways (data not
shown). Perhaps the impairment via these receptors depends more on the amount
of signaling it has experienced than on the expression of the receptor as such, as
has been suggested previously for PD-1.17,42 Furthermore, no evident correlation in
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BTLA effect and disease status could be observed, although patients in long-term
remission after alloSCT seemed to respond better. This is in contrast to PD-1,
which was shown to be more involved in the impairment of MiHA T cell responses
in relapsed patients.16 It could be that the inhibitory effect of BTLA and PD-1 on
MiHA-specific T cells has been influenced by the treatment with immunosuppressive
drugs; however, in our study only few patients received immunosuppressive drugs at
time of analysis, and no firm conclusions could be drawn. As the reversed expression
profiles of BTLA and PD-1 on normal T cells already demonstrate, these molecules
are likely to have distinct roles in hampering MiHA-specific T cell responses. Finally,
we examined whether an additive effect could be observed by combined blockade of
BTLA and PD-1. However, we did not observe an unambiguous additive effect on
MiHA-specific T cell proliferation. This might suggest that the two receptors share
common intracellular signaling pathways. It has been reported that both PD-1 and
BTLA relay their co-inhibitory signal via SHP-1 and SHP-2.43,44 Nonetheless, a third
interactor with the intracellular domain of BTLA has been described, Grb-2.45
Altogether, we have demonstrated that BTLA and PD-1 levels are elevated on
MiHA-specific T cells post-transplantation and that BTLA’s ligand HVEM is present
on hematological tumors as well as DC. Importantly, blocking of BTLA results in
enhanced outgrowth of MiHA-specific cells upon DC stimulation. Moreover, oth-
ers reported a differential role of BTLA in the induction of GVHD and GVT re-
sponses,40,41 making it an interesting target to prevent adverse alloreactive effects.
This prompts BTLA as a novel target in combination with DC vaccination. We did
not observe additive effects of simultaneous PD-1 and BTLA blockade and could not
predict effects of either blocking Ab. Therefore, further research into the distinct
roles of BTLA, PD-1, and other co-inhibitory molecules is important to understand
the functional state of impaired T cells. This will result in more targeted therapy
by applying blocking Abs to the appropriate receptors. In conclusion, we showed
that BTLA interactions impair functionality of MiHA-specific T cells, providing a
rationale for the incorporation of BTLA blockade in post-stem cell transplantation
therapies.
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Chapter 5: Immunosuppressive mechanisms in multiple myeloma
Abstract
Although the B cell malignancy multiple myeloma (MM) is primarily found in the
bone marrow (BM), tumor cells can also disseminate to and proliferate in extra-
medullary locations. Since extramedullary sites can be relatively resistant to im-
munotherapy as compared to medullary sites, we examined if differential immune
reactions exist between the BM and the spleen. Therefore we determined the ex-
pression of inflammatory mediators and the presence of immune cell populations
in the BM and spleen of control mice or mice with MM. We observed that while
IFN-γ and IFN-γ-induced chemokines increased in the BM of mice with MM, they
remained constant or decreased in the spleen. Simultaneously, the percentage of NK
cells remained constant in the BM, while declining in the spleen. Interestingly, we
found that upon MM challenge a smaller proportion of splenic NK cells produced
IFN-γ upon activation compared to those in the BM. To investigate the factors in-
volved in organ-specific immunosuppression, we analyzed the number and phenotype
of regulatory T cells (TREG) in the BM and the spleen. In the spleen a significant
increase in TREG content occurred, which altered the balance between TREG and NK
cells. Moreover, the TREG found in spleen displayed a higher level of FoxP3 than
those in BM, suggesting a stronger suppressive capacity. In conclusion, our data
indicate numerical and potentially functional differences between BM and splenic
TREG populations in mice with MM. These differences could explain the reduced in-
flammation associated with extramedullary MM growth, as compared to medullary
growth. Therefore, interference with site-specific immunosuppression may lead to
better therapy of extramedullary MM.
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Introduction
Multiple myeloma (MM) is a common malignancy originating from transformed
plasma cells. The natural niche of these cells is the bone marrow (BM), and here
most of the symptoms are caused, such as bone pain, bone fractures and loss of
hematopoiesis. However, during disease progression, MM cells also disseminate to
extramedullary sites.1 Common sites include spleen, lymph nodes, liver and kidneys.2
The presence of MM at extramedullary sites is correlated with poor prognosis,3 and in
a mouse model it was found that at these sites an inferior anti-MM immune response
occurred compared to the BM.4 MM can be targeted by immune cells, indicated
by the fact that allogeneic stem cell transplantation (alloSCT) followed by donor
lymphocyte infusion can induce long-term disease free survival.5,6 In addition, the
drugs Lenalidomide and Bortezomib are known to have immunomodulatory effects,
and part of the efficacy against MM may be due to their stimulatory effect on T cells
and NK cells.7–9 However, several mechanisms of immune evasion can be exploited
by MM, such as the induction and recruitment of regulatory T cells ( TREG).
10 In
this study, we have used the MM cell line 5T33 in a non-transplanted and an allo-
geneic bone marrow transplantation (BMT) mouse model to study medullary and
extramedullary immunological reactions against MM. We found that the presence
of MM cells induced immune reactions in the BM, while immunosuppression was
provoked in the spleen. Moreover, MM growth resulted in numerical and functional
differences between BM and splenic NK cells and TREG. These data show a di-
chotomy between immune reactions in intra- and extramedullary tumor sites that
might have implications for the treatment of MM.
Material and Methods
Mice
C3.SW-H2b/SnJ (H-2b, Ly9.1+) mice were originally purchased from The Jackson
Laboratory. C57Bl/KaLwRij.hsd mice were purchased from Harlan. All mice were
kept on standard lab chow and sterile water, and housed under specific pathogen free
conditions at the Central Animal Laboratory at the Radboud University Nijmegen
Medical Centre. All animal experiments were approved by the Animal Experimental
Committee of the Radboud University Nijmegen Medical Centre, and were performed
in accordance with institutional and national guidelines.
AlloBMT, DLI and MM challenge
KaL mice, 8-20 weeks of age, were irradiated with a linear particle accelerator in two
treatments of 6 Gy at one and two days before BMT. Irradiated mice received 5 x
106 T cell-depleted C3 bone marrow cells intravenously. T cells were depleted using
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anti-CD4 and anti-CD8 IMag magnetic beads (BD Biosciences). Between day -7
and 7 post alloBMT mice received ciprofloxacine and sugar in their drinking water.
Following a reconstitution period of 2 months, mice were intravenously injected with
106 5T33-GFP MM cells11 plus DLI in the form of 2 x 107 mononuclear cells from
C3 spleens and peripheral lymph nodes. In additional experiments, non-transplanted
Kal mice, 10-20 weeks of age, were challenged with 106 5T33-GFP MM cells.
Cell isolation and ELISA
Cells and soluble material from tissues were isolated essentially as described.12 In
brief, BM (2 femurs and 2 tibias) and spleen single-cell suspensions were prepared
in PBS with proteinase cocktail inhibitor (P8340; Sigma-Aldrich). Supernatant was
collected for several ELISA assays. A sandwich ELISA for mouse CXCL9 was per-
formed according to the manufacturer’s description (R&D Systems). We performed
ELISAs for mouse IFN-γ and CXCL16 as described previously.13 The detection limit
of these ELISAs is ∼16 pg/ml for IFN-γ, ∼60 pg/ml for CXCL9, and ∼24 pg/ml for
CXCL16.
Flow cytometry, cell sorting and antibodies
Staining of cell-surface proteins was performed as described previously.13 Except
when noted, antibodies were purchased from BD Biosciences. Prior to staining, all
cells were treated for 15’ on ice with unlabeled anti-CD16/32 (eBioscience) to prevent
Fc receptor staining. The following antibodies were used, with matching isotype con-
trols: FITC-conjugated CD4 and CD62L (ImmunoTools); PE-conjugated CD4, PD-1
(eBioscience) and PD-L1 (eBioscience); CD3-biotin followed by QD605-streptavidin
(Invitrogen); CD44-PE-Cy5 (BD Biosciences); APC-conjugated NK1.1 (eBioscience)
and CD25 (ImmunoTools); PE-Cy7-conjugated CD4 and CD8. To determine IFN-γ
production by the different cell subsets, cell stimulation was performed. PBMCs
were stimulated with phorbol myristate acetate (PMA; BD) and ionomycin (BD) for
5 hours with Brefeldin A (BD) present for the final 3.5 hours. Cells were stained
for membrane markers as described, and subsequently fixated, permeabilized and
stained for IFN-γ-PE and FoxP3-PE or isotype control as described by the manufac-
turers protocol (eBioscience). TREG were identified as CD25
HIGHFoxP3+. All flow
cytometry was performed on an FC500 cytometer (Beckman Coulter).
RNA isolation and RT-PCR
RNA was isolated and amplified by quantitative RT-PCR (qPCR) as described ear-
lier.13 Primer and probe sequences are included in Table 5.1. Expression was normal-
ized against the reference gene porphobilinogen deaminase (PBGD) using the 2−∆Ct
method, where ∆Ct represents the threshold cycle (Ct) of the sample gene minus the
Ct of PBGD.
126
Results
Table 5.1: Primer and probe sequences
Name Type Dye Gene Sequence 5’ to 3’
mPBGD-F1 primer - Pbgd gtggaagtccgagccaagga
mPBGD-F2 primer - Pbgd tggttgttcactccctgaagg
mCXCL9-F primer - Cxcl9 ctggagcagtgtggagttcg
mCXCL9-R primer - Cxcl9 agtgtagcaatgatttcagttttgttg
mCXCL10-F primer - Cxcl10 ctgggtctgagtgggactcaa
mCXCL10-R primer - Cxcl10 cattctttttcatcgtggcaatg
mCXCL12-F primer - Cxcl12 cactccaaactgtgcccttca
mCXCL12-R primer - Cxcl12 gatccactttaatttcgggtcaat
mCXCL16-F primer - Cxcl16 tccattctttatcaggttccagttg
mCXCL16-R primer - Cxcl16 tgaaaactcttcccatgaccagt
mPBGD probe VIC Pbgd tgtgcctaccatactacctcctggctttactattg
mCXCL9 probe TET Cxcl9 aaccctagtgataaggaatgcacgatgctcc
mCXCL10 probe TET Cxcl10 cctctcgcaaggacggtccg
mCXCL12 probe TET Cxcl12 tgcacggctgaagaacaacaacagacaa
mCXCL16 probe TET Cxcl16 tccgtgaactagtggactgctttgagcg
Cxcl, chemokine ligand; Pbgd, porphobilinogen deaminase
Statistical analysis
All statistical analyses were performed in Graphpad Prism 4.0. Linear regression was
applied to investigate correlations in curve fitting models, and significant deviation
from zero for the slope was analyzed. In addition, the student t-test or the one-
way analysis of variance (ANOVA) were used to determine significance differences
between two or more than two groups, respectively. P -values of less than 0.05 were
considered significant.
Results
MM cells induce inflammatory factors in the BM, but not in the spleen
To investigate organ-specific immune effects in MM-bearing mice, we examined allo-
geneic BMT mice with and without MM challenge (Figure 5.1A ’BMT’ and ’BMT
+ MM’) and analyzed the immune processes present in BM and spleen. First, we
investigated the mRNA level of the inflammatory chemokines CXCL9, CXCL10 and
CXCL16 (Figure 5.2A) and the inflammatory cytokine IFN-γ (Figure 5.2B). In the
BM, the presence of MM cells induced the expression of the inflammatory chemokines
and the release of IFN-γ, while the homeostatic chemokines CXCL4 and CXCL12
remained similar (Figure 5.2C). In addition, protein levels of CXCL9 and CXCL16
detected in the tissues were elevated (Figure 5.2D). In contrast, a reverse situa-
tion was observed in the spleen. No increase was observed in IFN-γ, CXCL9 and
CXCL10, and CXCL16 was even significantly lower in MM-containing spleens, for
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Figure 5.1: Percentage and number of MM cells and survival in BMT and non-
transplanted mice. (A) Mice which received 106 MM cells after BMT survived ∼28 days. MM
cells were present both in BM and spleen in varying numbers. (B) non-transplanted mice succumbed
to MM challenge ∼40 days after administration.
both secreted protein and mRNA level. These effects were not due to a difference in
the percentage of MM cells, since an analysis with a selected data set of similar MM
cell percentages for the spleen and the BM resulted in similar data (data not shown).
In addition, the MM cells did not produce the inflammatory chemokines themselves
(data not shown). This striking dichotomy between the BM and the spleen prompted
us to analyze if the MM load had a differential effect on local chemokine expression
levels. For the three inflammatory chemokines which were upregulated in the MM-
bearing BM, the expression levels were positively correlated with the percentage of
MM cells in the BM, with a significant correlation for CXCL9 (Figure 5.3A). How-
ever, the same analysis indicated an inverse correlation in the spleen, especially for
CXCL16 (Figure 5.3B). These data demonstrate that MM cells induce inflammatory
signals in the BM but not in the spleen. To extend these findings in the alloBMT
mouse model, we investigated the growth of MM cells and immune cell dynamics in
non-transplanted mice.
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Figure 5.2: Inflammatory chemokines were increased in the BM of MM-bearing
BMT mice, in contrast to a decrease in the spleen. (A) mRNA expression of CXCL9,
CXCL10, and CXCL16 in total cell lysate. Cut-off levels for expression were 0.01 AU. (B) IFN-γ
levels of supernatant of BM and spleen from BMT mice by ELISA. (C) mRNA levels of the homeo-
static chemokines CXCL4 and CXCL12. (D) CXCL9 and CXCL16 protein levels were investigated
by ELISA. Significance was investigated by student-t test. * P < 0.05; ** P < 0.01; *** P < 0.001.
Differential immune cell kinetics between BM and spleen upon MM pres-
ence
As observed in the transplanted mice, tumor cells in non-transplanted mice grew both
in the BM and in the spleen (Figure 5.1). Subsequently, we examined whether the
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Figure 5.3: Chemokine expression correlated to tumor load in BM and spleen.
By a linear regression curve fitting model we analyzed the correlation between CXCL9, CXCL10
and CXCL16 expression and tumor load in BM and spleen. R2 is depicted and significant deviations
from zero from the slope were determined. * P < 0.05; ** P < 0.01.
expression of inflammatory chemokines showed a similar profile as in the transplanted
mice. Although the chemokine levels were somewhat lower than in alloBMT mice,
we indeed detected higher expression in MM-bearing BM for CXCL10, and especially
for CXCL16 (Figure 5.4). In contrast, the levels in the spleen were equal to non-MM
bearing mice. To further investigate differential immune reactions taking place in
these two organs, we analyzed the presence of T cells and NK cells (Figure 5.5). In
MM-bearing mice, the percentages of CD3+ T cells decline in the spleen, and also in
the BM, despite its more inflammatory milieu. Next, we examined the composition of
these CD3+ T cells. Interestingly, there was a significant increase in the percentage
of CD4+ T cells in the BM, while this was not seen in the spleen. In addition,
we investigated the percentage of NK cells in both BM and spleen. No change was
observed in the level of CD8+ T cells. Notably, the level of NK cells in the spleen
of MM mice declined as compared to the healthy situation, while the percentage
remained the same in the BM.
Frequency and function of NK cells and TREG are differently regulated in
BM versus spleen
To investigate the capability of NK cells to secrete cytokines, cells were stimulated
and subsequently stained for intracellular IFN-γ. We detected a decrease of IFN-γ
producing NK cells in the spleen, but not in the BM (Figure 5.6A). Subsequently, we
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Figure 5.4: CXCL16 expression upon MM differed between BM and spleen in
non-transplanted mice. Cut-off levels for expression were 0.01 AU. Significance was investi-
gated by student-t test. ** P < 0.01.
investigated which mechanism could be responsible for the reduced NK cell function-
ality. In Figure 5.4, we observed that the relative number of CD4+ T cells increased
in the BM. Since this could be due to either immunosuppressive TREG or immune
stimulatory helper T cells (TH) , we performed a staining for the TREG-associated
transcription factor FoxP3 (Figure 5.6B). Interestingly, despite the increasing frac-
tion of CD4+ T cells in the BM, this was not due to a higher proportion of TREG. In
the spleen the percentage of TREG increased in tumor-bearing mice (Figure 5.6B).
Furthermore, we examined the FoxP3 expression level, since expression may be cor-
related with suppressive capacity.14 For TREG, both in the BM and the spleen, the
FoxP3 expression was upregulated in MM-bearing mice compared to healthy mice
(Figure 5.6C). However, the levels observed in the spleen, with or without the pres-
ence of MM, were significantly higher compared to those in the BM. In view of the
results described above, we analyzed the ratio of TREG to NK cells. Interestingly,
the ratio increased significantly in the spleen, but not in the BM (Figure 5.6D). Al-
together, these data show a reduced level of inflammatory chemokines and IFN-γ
upon MM challenge in an extramedullary site as compared to the the BM, combined
Figure 5.5: Immune cell populations changed differentially in BM and spleen
in MM-bearing mice. The presence of CD3+ T cells, subdivided by CD4+ and CD8+, and of
NK cells was analyzed. Significance was investigated by student-t test. * P < 0.05; ** P < 0.01.
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Figure 5.6: TREG and IFN-γ-producing NK cells in spleen and BM. (A) The
percentage of IFN-γ producing NK cell was measured after stimulation. (B) TREG were identified
by FoxP3 staining. (C) FoxP3 mean fluorescence intensity (MFI) of TREG. (D) TREG/NK cell
ration, in which the absolute number of TREG was devided by the absolute number of NK cells.
Significance was investigated by student-t test (A,B,D) or ANOVA (C). * P < 0.05; P < 0.01.
with less IFN-γ-producing NK cells. This may be linked to the observed increased
induction of TREG, and therefore these suppressive cells might be responsible for a
lower susceptibility to anti-tumor immunity of extramedullary MM.
Discussion
In this study, we observed that depending on their intra- or extramedullary locations,
MM cells induce differential immune responses. More specifically, reduced induction
of IFN-γ and inflammatory chemokines were observed in extramedullary sites com-
pared to the BM, while TREG induction was higher. Previously it was shown that
cytotoxic CD4+ T cells were capable of eliminating medullary MM, but could not
eradicate tumor cells at extramedullary locations, including subcutaneous sites and
the ovaries.4 Our data nicely complement that study, indicating that reduced im-
mune activation outside of the BM may cause MM persistence. This suggests that
differential local immunosuppression may be responsible for fatal tumor outgrowth.
Moreover, extramedullary MM is correlated with high-risk disease and poor out-
come.3,15 Therefore, gaining more understanding of the organ-dependent immuno-
logic responses involved is critical for better treatment of extramedullary MM.
Although the expression of inflammatory factors and the infiltration of the MM
microenvironment by CD8+, CD4+ TH or TREG and NK cells are involved, the
causative relation between all these factors have not been elucidated yet. We hy-
pothesize that in the extramedullary sites MM cells can induce TREG, which can
dampen accumulation of NK cells and their IFN-γ production. Lower levels of IFN-
γ result in reduced chemokine production and all these factors contribute to a reduced
anti-MM immune response. In MM and the pre-malignant state monoclonal gam-
mopathy of undetermined significance (MGUS) patients, an increase in the number
of TREG was observed in the peripheral blood,
16 although previously the reverse ef-
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fects was noted.17 In our study, a stronger induction of TREG was found in the spleen
than in the BM. However, we have not investigated the presence of these cells in the
peripheral blood, and therefore cannot directly relate our findings with these human
studies. In addition, the number of TREG present in the BM and extramedullary
sites of MM patients would be greatly informative. Furthermore, the level of FoxP3
was elevated in TREG residing in the spleen compared to the BM. Previously the
role of this transcription factor was thought to be binary: if CD4+ T cells expressed
FoxP3, they were considered TREG. Currently, a more dose-dependent model is
postulated,14 and in addition the methylation state of the foxp3 gene is a better
indication of CD4+ T cell function than mRNA expression.18 It is known that tran-
sient expression is possible in CD4+ effector cells, and importantly, it is hypothesized
that FoxP3 levels correlate to the suppressive capacity of the TREG. Therefore, in
addition to the increase of TREG in the spleen compared to the BM, these cells are
also possibly more suppressive, contributing to stronger immunosuppression in this
extramedullary tissue.
We observed an increase in the ratio of TREG vs NK cells in the spleen in MM-
bearing mice. Whether or not a direct interaction between NK cells and TREG exists
is not known, but a similar effect as found in our study has been described in thyroid
cancer; TREG tissue infiltration was increased in advanced disease, whereas NK cell
infiltration was decreased in this patient group.19 Alternatively, a direct influence of
TREG on NKT cells has been reported, namely that TREG induced IL-4 production
by NKT cells, resulting in tolerance.20 Therefore, in addition to NK cells, the role
of NKT cells needs to be evaluated in this MM model. On the other hand, as we
observed an increase of CD4+ TH cells in the BM, they seem to have a prominent role
in the difference between the immune reactions in the BM and the spleen. Therefore,
a deeper investigation into the cytokine profile of these TH is warranted. Previously,
IL-17-producing T cells have been implicated in MM,21 but we did not observe
differences in IL-17+ T cells between the BM and the spleen (data not shown).
In addition, co-inhibitory receptors may play a role in the site-specific immune ef-
fects observed. Interestingly, location-dependent expression profiles have been shown
for the co-inhibitory receptor programmed death-1 (PD-1) in chronic viral infection,
and in that case the BM displayed a less immunosuppressive environment.22 Several
clinical trials have been performed in which the PD-1 pathway is blocked by anti-
bodies,23,24 and if in MM these interactions also play a role, it is an attractive target
for therapy. Although we did not observe differences of PD-1 levels on effector T
cells and NK cells in this study (data not shown), PD-1 is essential for TREG func-
tion, as blockade of PD-1 interactions decreased TREG while enhancing the number
of TEFF.
25,26 In addition, a range of other co-inhibitory receptors may play a role
in the immunosuppressive extramedullary sites, and interfering with these pathways
might improve anti-MM immunity.27
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Altogether, we observed differential immune reactions in the BM and the spleen in
MM-bearing mice. Extramedullary MM in humans is correlated with poor prognosis,
which may be due to impaired anti-MM immune responses. Therefore, insight into
these location-specific immunosuppressive mechanisms will likely be beneficial for the
treatment of MM.
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In the last decennia progress towards a cure for hematological malignancies like
acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin lym-
phoma (NHL) has been made. However, although chemotherapy, autologous stem
cell transplantation (SCT) and the application of new drugs may result in clinical re-
sponses, minimal residual disease often remains and most patients eventually relapse.
To date, the most effective curative treatment is allogeneic SCT (alloSCT) followed
by donor lymphocyte infusions (DLI). The therapeutic effectiveness is attributed
to the graft-versus-tumor (GVT) response. During this response donor-derived T
cells become activated by recipient minor histocompatibility antigens (MiHA) that
are presented as ’foreign’ polymorphic peptides on antigen-presenting cells. These
MiHA are also expressed by the tumor cells, and consequently expanded alloreactive
T cells have the capability to target MiHA+ tumor cells. After initial responses,
MiHA-specific memory T cells are formed, which reside in the patient to counter-
act possible relapses and therefore convey potential lifelong protection against tumor
cell recurrence. However, we observed that despite the presence of MiHA-specific
memory T cells, relapses do occur frequently in transplanted patients, indicating the
failure of this potentially powerful GVT reactivity. Upon relapse, therapeutic DLI
can be applied, however too often this is not effective. Furthermore, a significant risk
of alloSCT and DLI is the development of graft-versus-host-disease (GVHD), caused
by donor T cells recognizing MiHA on healthy tissues. This condition greatly deteri-
orates the quality of life and constitutes a major risk for transplant-related morbidity
and mortality. Therefore, there is a strong need to further reduce complications and
the relapse risk after alloSCT.
The studies described in this thesis were performed to gain insight in the dynam-
ics, functional properties and immune inhibition mechanisms that influence MiHA-
specific T cell responses. First, we investigated the susceptibility of myeloid leukemic
progenitor cells for cytotoxic T lymphocytes (CTL) that recognize the hemato-
restricted MiHA LRH-1. In addition, we investigated tumor cell-intrinsic factors
that influence this, such as HLA expression and expression of apoptosis genes. Next,
we studied the role of co-inhibitory receptors in dampening of MiHA-specific immune
responses, and in addition, we explored the role of regulatory T cells (TREG) and
inflammatory mediators in anti-tumor immunity. Finally, we elaborated on future
perspectives in alloSCT that may lead to releasing the full potential of this therapy
against hematological malignancies.
Therapeutically applicable MiHA
Our laboratory has previously identified several MiHA that have a restricted expres-
sion in hematopoietic cells as well as their malignant counterpart: i.e. leukemia, mul-
tiple myeloma and lymphomas.1,2 One of these MiHA is LRH-1, which is presented
by HLA-B7 and derived from the P2X5 protein. Interestingly, LRH-1 is expressed
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by CD34+ progenitor leukemia cells, therefore an alloreactive T cell response against
this antigen has the potential of targeting leukemia stem cells, which is important
to achieve cure of the malignant disease. In Chapter 2, we showed that CD34+
AML and chronic myeloid leukemia (CML) progenitor cells can be efficiently lysed
by LRH-1-specific CTL. In contrast, matured CML cells were not recognized due
to downregulation of the P2X5 gene. This provides a therapeutic option to specif-
ically target remaining leukemia-initiating cells, after the bulk has been destroyed
by chemo- or radiotherapy. At the moment, first line treatment for CML are ty-
rosine kinase inhibitors like Imatinib and Dasatinib.3 These compounds elegantly
target the very cause of CML, namely the BCR-Abl fusion protein, caused by the
CML-specific (9;22)(q34;q11) chromosomal translocation. However, a lifelong depen-
dency on these drugs occurs, and worse, mutations in BCR-Abl lead to resistance
and loss of therapy response.4 Furthermore, CML stem cells are less susceptible to
these drugs, and it has been shown that even years after commencing therapy and in
patients in clinical remission, leukemia initiating cells are still present.5 Therefore, an
immunotherapy which specifically targets these cells would be a solution. In AML,
alloSCT is still the treatment of choice, and it is also used in patients with CML in
blast crisis. Also in these patients, LRH-1-based vaccinations may ameliorate dis-
ease outcome. In addition, we found elevated X-linked inhibitor of apoptosis protein
(XIAP) levels in CD34+ cells after relapse, which were partly resistant against CTL-
induced lysis. Interestly, an antisense oligonucleotide targeting XIAP, AEG35156,
has been introduced into the clinic. Promising results for this compound in combina-
tion with chemotherapy against AML have been achieved,6,7 and studies combining
immunotherapies with XIAP inhibition are an attractive treatment option.
Co-inhibitory pathways involved in T cell inhibition
Even if initially a MiHA-specific anti-tumor T cell response has been induced, re-
lapses still occur, despite the presence of MiHA-specific memory T cells. In chap-
ter 3 and 4 we investigated why these memory T cells are functionally impaired
and unable to control tumor cell recurrence. It is well known that T cells express
multiple co-signaling molecules that modulate their activation upon T cell receptor
triggering. Interestingly, a subgroup of these cell-surface molecules, the co-inhibitory
molecules, negatively regulates T cell activation, thereby putting the brake on im-
mune effects. First, in Chapter 3, we demonstrated that one of these co-inhibitory
receptors, Programmed Death-1 (PD-1), displayed increased expression on MiHA-
specific CD8+ T cells after alloSCT. Furthermore, one of the ligands for PD-1, i.e.
PD-L1, can be highly expressed on leukemia and myeloma cells, indicating that these
malignant cells could evade the immune system by inhibiting T cell function via the
PD-1/PD-L1 pathway. In addition, patients with relapsed leukemia after an initial
MiHA-specific T cell response displayed high PD-L1 expression on leukemia progen-
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itor cells. Most importantly, we revealed that blocking PD-1/PD-L1 interactions
in vitro augments proliferation of MiHA-specific CD8+ memory T cells that were
relatively unresponsive. Interestingly, this augmentation was significantly stronger
in patients who developed relapse compared to patients who remained in remission.
This suggested that PD-1 signaling can contribute to immune evasion and subse-
quent relapse. Collectively, these data indicated that the PD-1/PD-L pathway not
only plays a prominent role in modulating T cell priming, but can be hijacked as an
immune evasion mechanism for cancer after alloSCT.
In addition to PD-1, an ever increasing set of co-inhibitory receptors is shown to
play a role in T cell dysfunction.8 In Chapter 4, we investigated the role of BTLA,
another co-inhibitory receptor, in MiHA-specific T cell dysfunction, and observed a
similar effect. BTLA was expressed by MiHA-specific cells and its ligand HVEM
is present on hematological malignancies. Importantly, upon blockade of BTLA
by antibodies, MiHA-specific T cell proliferation was significantly augmented and
expanded T cells were shown to be functional, i.e. degranulation and secretion of
IFN-γ and TNF-α upon antigen recognition. Although overall the effect was less
prominent than for PD-1, in three out of eleven patients blockade of BTLA enhanced
T cell proliferation stronger than the blockade of PD-1. This indicates that immune
modulation strategies may be patient- and context-dependent, and combining several
blocking antibodies could prevent redundancy of co-inhibitory receptors in impairing
T cell function.
Involvement of multiple factors in immune evasion
In addition to co-inhibitory receptors, regulatory T cells (TREG) are important play-
ers in immune evasion. In Chapter 5 we examined which immunosuppressive mech-
anisms are deployed by MM in intra- and extramedullary sites. Although MM pri-
marily grows in the bone marrow (BM), also extramedullary sites are home of MM
foci. These sites include lymph nodes and the spleen. Interestingly, in a mouse model
we observed that immunosuppression by MM was more potent in the spleen com-
pared to the BM. While in the BM increased levels of inflammatory chemokines and
IFN-γ were present, this was not the case in the spleen. This suggested that only
in the BM an anti-tumor inflammation occurred, although MM cells were present
in both the BM and the spleen. In concordance with a possible immunosuppressive
milieu, the TREG/Natural killer (NK) cell ratio increased in the spleen. In addition,
a lower percentage of NK cells in the spleen secreted IFN-γ. Moreover, the TREG
in the spleen expressed higher level of FoxP3 than their counterparts in the BM,
suggesting a stronger suppressive potential. These data indicate that a combination
of immune evasion strategies are exploited by tumor cells, and therefore it may be
necessary to prevent T cell inhibition on multiple levels. One possibility is to combine
TREG depletion with blocking antibodies against co-inhibitory molecules,
9 however
141
Chapter 6: Summary and future prospects
alleviating immune control at two important points may lead to more adverse au-
toimmune effects. In addition, the depletion of TREG is not possible yet in humans.
Furthermore, TREG also express PD-1 and CTLA-4 and partly execute their effects
via these receptors, and blocking of either receptor already will affect TREG function-
ality. The relative influence of co-inhibitory molecules on TEFF, TREG, tumor cells
and DC needs to be determined, but it has an important role in all these cell-cell
interactions. In addition, the differences observed between anti-tumor immunity in
the BM and the spleen, may enhance the knowledge about extramedullary MM. This
is necessary, since MM tumor growth outside of the BM conveys a poor prognosis,
and optimization of current therapies are necessary.10,11
Future prospects
MiHA-based therapies
Although MiHA identification can still be laborious, in the last decade the focus in
the field shifted from identifying one MiHA to simultaneous discovery of a number of
MiHA in high-throughput fashion.12 Methods like whole genome association13 and
genome-wide zygosity-genotype correlation analysis14 have greatly facilitated new
MiHA discovery. The next leap forward will be the application of this knowledge into
the clinic, especially since our group has proven in an extensive analysis that MiHA
disparity between recipient and donor results in increased relapse-free survival in
sibling transplants, especially in patients suffering from MM.15 Several options exist
for incorporating MiHA-based immunotherapy in SCT treatment scheme. First,
recipient and donor candidates can be screened for disparity of hemato-restricted
MiHA before transplantation, and the donor with most or immune dominant MiHA
mismatches can be selected. Unfortunately, the feasibility of this approach is limited
by the number of available HLA-matched donors. The second approach is to screen
donor and patient, and specifically boost mismatched MiHA after alloSCT by means
of DC vaccination of the patient. A third and novel approach is vaccinating the
donor against MiHA before DLI to induce a MiHA-specific response and achieve a
pool of MiHA-specific cells in the donor.16 This way, an activated high number of
alloreactive T cells can be transferred to the patient, instead of the low number of
na¨ıve MiHA-specific T cells which are normally administered. However, this approach
has considerable ethical issues, since it deals with vaccination of healthy individuals.
Moreover, a major implication may exist for women whom will become pregnant
after vaccination. If the unborn child is MiHA-positive, a recall response against the
MiHA could take place. Therefore, the selection of donors that will be vaccinated
should be stringent. In the end, these clinical strategies would optimize the potential
of MiHA-specific immune responses after alloSCT.
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Figure 6.1: Model for restoring functionality of exhausted MiHA-specific T cells,
by interfering with signaling using small molecule inhibitors. T cell exhaustion is a
dysfunctional state due to signalling through co-inhibitory receptors such as PD-1, BTLA, LAG3,
TIM-3, among others. Alloreactive T cells recognizing MiHA on hematological tumor cells are
known to be functionally impaired. Importantly, tumor cells express ligands for these receptors,
and thereby achieve immune evasion. By interfering with intracellular co-signaling pathways this
exhaustion may be prevented or reversed. Small molecular inhibitors targeting key molecules in these
pathways can be used to perform this specific function. Finally, the exhausted MiHA-specific T cell
will have a restored phenotype, resulting in production of cytokines, expansion, and cytotoxicity
against tumor cells.
Signaling pathways in T cell dysfunction
It has been well demonstrated that PD-1 plays a crucial role in T cell regulation
in various immune responses and is involved in peripheral tolerance, autoimmunity,
infection and anti-tumor immunity.17 Elevated PD-1 expression on viral antigen-
specific CD8+ T cells in chronic viral infections has been recognized as a feature
of T cell dysfunction resulting in diminished cytokine production, proliferation and
cytolytic activity upon antigen re-stimulation.18
Increased PD-1 expression does not only inhibit tumor-reactive T cell responses,
but also plays a pivotal role in exhaustion of virus-specific T cells. Previously, Quigley
et al. have examined gene expression differences between functional and exhausted
HIV-specific T cells, and thereby have found differentially expressed genes specific
for T cell exhaustion, called the ’PD-1 signature’.19 Although PD-1 expression is an
important marker for exhausted cells, it is not a clear cut marker, since non-exhausted
activated T cells also express PD-1. Therefore, not the expression of PD-1 as such,
but the continuous ligation of PD-1 and downstream signaling results in activation of
signaling cascades, finally resulting in altered gene expression. Moreover, concurrent
expression of multiple co-inhibitory receptors on exhausted T cells will have impact
on the overall effect of all these co-inhibitory signals determining the impaired state
of the T cell. Therefore, it is crucial to understand the downstream additive effects
of all these co-inhibitory signals on T cell exhaustion. We hypothesize that non-
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responsive MiHA-specific T cells in alloSCT patients are dysfunctional because of
signaling through multiple co-inhibitory receptors, including PD-1 and BTLA. This
signaling results in altered gene expression, ultimately leading to exhaustion of T
cells. We believe that, similar to exhausted HIV-specific T cells, these cells display
a specific gene signature. By unravelling this ’exhaustion’ signature, it should be
possible to identify key players in MiHA-specific T cell impairment. Subsequently, by
in silico and in vitro selection of a chemical compound library, it might be feasible to
develop small molecule compounds which inhibit these signaling components, thereby
restoring T cell functionality. By administration of this small molecule inhibitor
in vivo, the GVT effect may be reinvigorated (Figure 1). An advantage of this
approach is that it focuses on exhausted T cells, and therefore it may not interfere
with physiological co-inhibitory functions. Ideally, this approach will restore anti-
tumor responses without autoimmune effects.
Novel therapies involving co-inhibitory molecules
Several therapeutic strategies to interfere with the function of co-inhibitory molecules
are being explored in order to enhance anti-tumor T cell immunity. The challenge of
interference with immune checkpoints is to boost anti-tumor reactivity while avoiding
systemic toxicity. This could potentially be achieved by 1) combining the alleviation
of co-inhibition with other therapeutic options, 2) blocking co-inhibitory molecules
that are intrinsically skewed towards anti-tumor responses rather than GVHD or
autoimmune effects and 3) optimal dosage, route of delivery and timing of antibody
administration. Appealing combinations are the simultaneous targeting of multiple
co-inhibitory receptors, or combining with existing cellular therapies. For example,
DC vaccination may be applied together with blocking antibodies or siRNA knock-
down of co-inhibitory molecules to boost anti-tumor immunity, or administration of
agonistic antibodies against co-inhibitory molecules implicated in GVHD may reduce
adverse effects (Figure 2).
Although anti-CTLA-4 and anti-PD-1 monotherapy have shown promising re-
sults, combination therapy with other treatment modalities such as immunomod-
ulatory anti-cancer agents, vaccines or TREG depletion is potentially necessary to
cure hematological cancers. At the moment, several clinical trials are underway that
target co-inhibitory receptors in hematological cancers. The effectiveness of CTLA-
4 blockade by Ipilimumab is investigated in lymphoma patients (NCT00047164),
while the anti-PD-1 monoclonal antibody CT-011 is combined with three different
therapies: in lymphoma patients, CT-011 is administered following autologous SCT
(NCT00532259) and combined with Rituximab (NCT00904722). Furthermore, the
combination of CT-011 with a DC/AML fusion vaccine is being investigated as a
therapy for AML patients (NCT01096602). Recently, we explored another treatment
option in which an antigen-specific stimulation is combined with interference of co-
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inhibition. This strategy was first explored ex vivo by utilizing siRNAs to silence
PD-L1 and/or PD-L2 on MiHA-loaded DC. Upon co-culture with PBMC containing
low numbers of MiHA-specific TEM cells, we were able to greatly enhance prolifer-
ation and functionality of these tumor-reactive T cells.20 Following these promising
results, we will start a clinical trial shortly combining DLI with vaccination of PD-
L1/L2 silenced donor DC loaded with hematopoietic-restricted MiHA (CCMO-trial
no. NL37318). We believe that these clinical studies provide a platform for incorpo-
rating blockade of co-inhibitory molecules in adjuvant therapy of hematological ma-
lignancies, with numerous options for combination therapies. Importantly, the risk
of breaking tolerance systemically by blockade of one co-inhibitory molecule could be
prevented by using lower levels of multiple blocking antibodies targeting different in-
hibitory molecules simultaneously, since together these may boost immune responses
in a non-redundant manner. This is stressed by the fact that exhausted T cells are
known to display multiple different co-inhibitory receptors.8 By analyzing the down-
stream pathways of different co-inhibitory receptors one could limit these options
and exclude combinations of receptors that have redundant effects, and focus on
synergistic combinations. Notably, a clinical trial in solid tumors has started which
combines blocking antibodies against PD-1 and CTLA-4 (NCT01024231), harnessing
the power of these two non-redundant immune checkpoints.
The crux in alloSCT is the separation of GVT and GVHD reactivity. Although
CTLA-4 and PD-1 clearly contribute to T cell exhaustion, their activation might
have too broad consequences early after alloSCT, and interfering with their sig-
naling might deteriorate GVHD. Interestingly, anti-BTLA was recently reported to
impair GVHD while allowing GVT reactions.21,22 Whether or not this important
distinction in alloreactive responses also exists in humans needs to be evaluated, but
it renders BTLA an important candidate for post-transplantation immunotherapy.
Furthermore, the timing of co-receptor blockade seems to be essential to boost GVT
without causing GVHD.23,24 Early after alloSCT, the patient is in a highly activated
immunological state, due to chemotherapy-induced tissue damage and subsequent
inflammation, especially in GVHD-target tissues such as skin and gut. To release
immune checkpoints at this time would be dangerous, since T cells would home to
these inflamed alloantigen-expressing GVHD sites and destroy healthy cells. How-
ever, a delayed treatment window following alloSCT is possible, when there is no
systemic ’inflammatory’ state. However, at the tumor site where the inflammation
is sustained anti-tumor MiHA-specific T cells may be specifically boosted, resulting
in renewed GVT effects.
Altogether, co-inhibitory molecules play a pivotal role in natural and immuno-
therapy-induced T cell-mediated immunity against hematological cancers. With in-
creasing knowledge of a growing number of co-inhibitory molecules, novel mono- and
combinatorial treatment options become available. In the end, this could lead to op-
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Figure 6.2: Therapeutic strategies for interfering with co-inhibitory molecules.
First, blocking antibodies can be used to abrogate binding between co-inhibitory molecules with the
tumor-reactive T cell and tumor cells, thereby enhancing T cell responses. In addition, DC therapy
can be combined with antagonistic antibodies to boost the tumor-specific effect of DC vaccination.
Another method to circumvent co-inhibitory signalling during DC vaccination is silencing of co-
inhibitory molecules. Delivery of siRNA can be achieved either by electroporation or via lipid
nanoparticles. Finally, co-inhibitory molecules which are differentially more involved in GVHD can
be stimulated by agonistic antibodies. This will attenuate GVHD-specific T cell responses, thereby
preventing attack of GVHD-prone tissues.
timized immunotherapy against hematological cancers, with limited risk of adverse
events like the induction of autoimmune diseases and GVHD.
Concluding remarks
AlloSCT is a powerful cellular immunotherapy for hematological malignancies, al-
though the need for improvements remains. Now after decades of research of MiHA-
responses mainly from bedside to bench, it is time to fully incorporate the knowledge
of MiHA-specific CD8+ T cell dynamics in alloSCT treatment strategies, thereby
returning from bench to bedside. Hemato-restricted MiHA like LRH-1 hold the key
for tipping the balance to a selective GVT effect, while GVHD may be prevented.
In addition, co-inhibitory pathways are important immune evasion mechanisms that
limit the effectiveness of alloSCT. Interfering with for example PD-1 or BTLA may
improve or restore GVT immunity. This could be performed by blocking antibodies
or using modified DC in MiHA-based vaccination or adoptive cell transfer strategies.
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Finally, interfering with exhaustion induced by co-inhibitory molecules at the level of
intracellular signal transduction may lead to novel therapeutic options. Altogether,
these novel insights contribute to therapies which ameliorate the quality of life and
enhance the curative rate for patients with hematological malignancies.
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Kankers van het bloedvormend systeem, oftewel hematologische maligniteiten, ne-
men ongeveer 7% van alle nieuwe kankergevallen in Europa voor hun rekening. Tot
deze groep behoren acute en chronische leukemie, lymfomen (lymfeklierkanker) en
de ziekte van Kahler (multipel myeloom). De incidentie en prognose varie¨ren sterk
tussen deze vormen van kanker. Ook de leeftijd en gezondheid van de patie¨nt zijn
belangrijke factoren in de prognose van de ziekte, en kunnen de keuze van de the-
rapie be¨ınvloeden. De standaard behandeling bestaat meestal uit radiotherapie en
chemotherapie. Dit resulteert gewoonlijk in een afname van het aantal tumorcellen
en daardoor het verdwijnen van de symptomen, ook wel klinische remissie genoemd.
Aangezien deze ingrijpende behandelingen ook gezonde bloedvormende cellen ver-
nietigen, worden radio- en chemotherapie soms gevolgd door een autologe stamcel-
transplantatie (SCT). Hierbij worden vo´o´r de radio- en chemotherapie behandeling
gezonde hematopoietische stamcellen van de patie¨nt afgenomen. Na de behandeling
worden deze weer teruggegeven aan de patie¨nt, zodat het bloedvormend systeem zich
snel kan herstellen. Deze therapie kan resulteren in volledige opruiming van de tumor,
maar vaak komt de kanker terug. In de afgelopen jaren zijn er nieuwe therapeutica
ontwikkeld die zich meer specifiek op de tumorcellen richten. Hoewel met deze nieuwe
generatie geneesmiddelen veel vooruitgang is geboekt, hebben ook deze behandelin-
gen nog steeds hun beperkingen. Naast het risico op resistentie en terugkeer van
de ziekte, hebben patie¨nten vaak last van ernstige bijwerkingen. Belangrijk is dat
de meeste behandelingen niet genezend zijn en leiden tot een levenslange afhanke-
lijkheid van medicatie. Daarom is er grote behoefte aan alternatieve en aanvullende
therapeutische strategiee¨n met een sterker genezend effect.
Een van deze aanvullende therapiee¨n is immunotherapie. Hierbij wordt de kracht
van het immuunsysteem ingezet tegen kankercellen. Omdat kankercellen net wat an-
ders zijn dan de gewone cellen van het lichaam, kunnen ze herkend en gedood worden
door afweercellen. Dit gebeurt meestal door zogenaamde T-cellen, die kankercellen
kunnen opsporen en vernietigen. Het doel van deze behandelingen is het stimuleren
en versterken van de immuuncellen van de patie¨nt, of zelfs van immuuncellen van
een gezonde donor. Hierdoor kan er een anti-tumor immuunreactie optreden, waar-
door de kankercellen vernietigd worden en de patie¨nt mogelijk geneest. Vanwege de
potentie¨le kracht en specificiteit is immunotherapie een aantrekkelijke optie voor het
behandelen van hematologische maligniteiten. Met name cellulaire immunotherapie
in de vorm van allogene SCT heeft aangetoond dat het immuunsysteem in staat is
hematologische kankers te genezen. In 1957 vond de eerste allogene SCT plaats door
E. Donnall Thomas, waarvoor hij in 1990 de Nobelprijs voor Geneeskunde ontving.
Bij allogene SCT worden hematopoietische stamcellen van een donor gegeven. Deze
stamcellen zorgen voor een nieuw bloedvormend systeem, en dus ook een nieuw im-
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muunsysteem, in de patie¨nt. Daardoor maakt deze therapie een intensieve chemo- en
radiotherapie voorafgaand aan de transplantatie mogelijk. In de loop van de jaren is
deze procedure een effectieve vorm van immunotherapie geworden, die verschillende
hematologische kankers maar ook erfelijke aandoeningen van het hematopoietische
systeem kan genezen. Het vervangen van het bloedvormend systeem, dat ook de
immuuncellen bevat, met dat van een donor kan echter ook problemen opleveren.
Verschillen tussen de cellen van patie¨nt en donor spelen een cruciale rol bij allo-
gene SCT, en vooral de menselijke leukocyten-antigenen (HLA) zijn erg belangrijk.
Verschillen in HLA-type tussen donor en patie¨nt resulteren meestal in ernstige graft-
versus-host ziekte (GVHZ), ook wel bekend als omgekeerde afstoting. Dit is een
levensbedreigende aandoening waarbij gezonde weefsels zoals de huid, lever en darm
van de ontvangende patie¨nt worden beschadigd. Deze organen worden aangevallen
door zogenaamde alloreactieve T-cellen van de donor. Gelukkig zorgt een volledige
HLA-match tussen patie¨nt en donor voor een sterk verminderd risico. Echter, zelfs
wanneer het HLA-type is afgestemd, zijn er verschillen in DNA samenstelling tussen
de donor en ontvanger als gevolg van de normale genetische variatie tussen indivi-
duen. Deze genetische variatie zorgt voor kleine verschillen tussen de eiwitten van
donor en patie¨nt. De stukjes eiwitten die verschillen tussen donor en patie¨nt worden
minor histocompatibility antigenen (MiHA) genoemd. Aangezien de MiHA’s van
de patie¨nt niet bestaan in de donor, worden ze door het donor immuunsysteem be-
schouwd als ”vreemd”. Deze stukjes eiwit worden gepresenteerd aan T-cellen, en de
T-cellen van de donor wekken hiertegen een immuunreactie op. Daarom zijn MiHA’s
de belangrijkste immunologische doelwitten van alloreactieve T-cel reacties na HLA-
gematchte allogene SCT. Aangezien MiHA’s ook door hematologische kankercellen
gepresenteerd worden, kunnen deze immunogene eiwitbrokstukjes een anti-tumor re-
actie veroorzaken, aangeduid als het graft-versus-tumor effect (GVT). Deze GVT
reactie is een krachtige T-cel-afhankelijke afweerrespons die kan leiden tot uitroeiing
van alle tumorcellen, waardoor de patie¨nt volledig geneest. Helaas worden sommige
MiHA’s niet alleen door kankercellen gepresenteerd, maar ook door gezonde weefsels
van de patie¨nt. Wanneer deze weefsels worden aangevallen door alloreactieve T-cellen
ontstaat de eerder genoemde GVHZ.
Vanwege het genezende effect van GVT en het schadelijke effect van GVHZ, is de
heilige graal in de allogene SCT het scheiden van de herkenning van de kwaadaardige
hematologische cellen aan de ene kant, en van de aanval op gezonde weefsels aan de
andere kant. De sleutel hiervoor zijn MiHA’s die uitsluitend in het hematopoietische
systeem van de patie¨nt, inclusief de kwaadaardige cellen, voorkomen. Aangezien de
hematopoietische cellen van de patie¨nt worden vervangen door donor cellen is de af-
braak van deze cellen niet schadelijk. Daarom hebben onze onderzoeksgroep en ook
andere onderzoekers zich gericht op de identificatie en de toepassing van deze hemato-
specifieke MiHA’s. Ons laboratorium heeft verscheidene MiHA’s met een specifieke
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expressie in hematopoietische maligniteiten onderzocht. In 2005 identificeerden wij
de MiHA LRH-1, onderdeel van het P2X5 purinerge receptor eiwit, wat alleen in he-
matopoietische cellen voorkomt. In een chronische myelo¨ıde leukemie (CML) patie¨nt
vonden we donor T-cellen die LRH-1 herkenden, en bij deze patie¨nt toonden we aan
dat er tijdens een LRH-1-specifieke immuunrespons een groot deel van de leukemie-
cellen verdween. Dit gaf aan dat de LRH-1-specifieke T-cellen hoogstwaarschijnlijk
de kankercellen vernietigden. Bovendien bleek dat LRH-1 niet voorkomt in de GVHZ
doelwitorganen huid, lever en darm. Daarom kan LRH-1 een belangrijke rol spelen
bij het induceren van GVT-specifieke immuniteit tegen myelo¨ıde leukemie. Vervol-
gens wilden we weten of de stamcellen van de leukemie ook vatbaar zijn voor de
LRH-1-specifieke cytotoxische T lymfocyten (CTL’s). In Hoofstuk 2 hebben we
aangetoond dat acute myelo¨ıde leukemie (AML) en CML voorlopercellen efficiie¨nt
worden vernietigd door LRH-1-specifieke CTL’s. Daarentegen werden rijpe CML
cellen niet herkend, omdat ze LRH-1 niet meer tot expressie brengen. Hierdoor kun-
nen LRH-1-specifieke CTL’s zich specifiek richten op resterende leukemie-initie¨rende
cellen, nadat het grootste deel van de tumor is vernietigd door chemo- of radio-
therapie. Momenteel bestaat de eerstelijnsbehandeling bij CML uit toediening van
tyrosine kinase remmers zoals Imatinib en Dasatinib. Deze moleculen richten zich op
de oorzaak van CML, namelijk het BCR-Abl fusie-eiwit. Dit eiwit wordt gemaakt
ten gevolge van het DNA defect dat ten grondslag ligt aan CML, namelijk een (9;22)
chromosomale translocatie. Een nadeel is dat een levenslange afhankelijkheid van
deze medicijnen optreedt, en erger, dat de CML resistent wordt. Bovendien zijn de
stamcellen van CML minder gevoelig voor deze middelen, en is aangetoond dat zelfs
jaren na aanvang van de therapie en zelfs bij patie¨nten in klinische remissie, toch nog
deze leukemie-initie¨rende cellen aanwezig zijn. Daarom zou een immunotherapie die
specifiek gericht is op de vernietiging van deze cellen een oplossing zijn. Afhankelijk
van de leeftijd van de patie¨nt, kan allogene SCT de voorkeursbehandeling zijn voor
AML, en CML in blastencrisis. Ook bij deze patie¨nten zou een therapie gebaseerd op
LRH-1 het therapeutische effect van de allogene SCT kunnen versterken. In een van
onze patie¨nten vonden we dat haar CML voorlopercellen toch gedeeltelijk resistent
waren tegen de LRH-1-specifieke CTL’s. Deze cellen bleken een verhoogde aanwe-
zigheid te hebben van het X-linked inhibitor of apoptosis eiwit (XIAP). Dit eiwit is
betrokken bij de celdood van de tumorcel, en door het verhoogde niveau van XIAP
is de cel gedeeltelijk ongevoelig voor inductie tot celdood. De inductie van celdood is
een manier waarop een CTL een tumorcel vernietigt, en door verhoogde XIAP is het
moeilijker de tumorcel te vernietigen. Het interessante is nu dat er is een medicijn
bestaat dat gericht is tegen XIAP. Een combinatiebehandeling van dit medicijn met
chemotherapie gaf veelbelovende resultaten in AML patie¨nten, en door onze onder-
zoeksresultaten lijkt het combineren van immunotherapie met XIAP-remming ook
een aantrekkelijke behandelingsoptie.
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Na het onderzoeken van deze LRH-1-specifieke afweerreacties, hebben we ons
meer algemeen verdiept in de dynamiek van MiHA-specifieke T-cel responsen na
allogene SCT. Het GVT effect na allogene SCT is verdeeld in verschillende sta-
dia. Na infusie worden na¨ıeve T-cellen gestimuleerd door patie¨nt-specifieke MiHA’s
die worden gepresenteerd op dendritische cellen (DC’s). Deze DC’s zijn gespeci-
aliseerd in het instrueren van andere immuuncellen, en ze activeren de T-cellen,
waardoor deze veranderen in effector T-cellen. Deze vermenigvuldigen zich en mi-
greren naar de doelweefsels, waar ze de tumorcellen doden. Na het hoogtepunt van
de T-cel afweerrespons zijn de meeste of alle tumorcellen vernietigd, en begint de
zogenaamde contractiefase. Hierin ondergaan de meeste MiHA-specifieke T-cellen
geprogrammeerde celdood. Een klein aantal T-cellen blijft toch leven, en die worden
langlevende geheugencellen. Deze geheugencellen kunnen bij eventuele terugkomst
van de tumorcellen een snelle afweerreactie starten. We hebben echter vastgesteld
dat in patie¨nten na allogene SCT, ondanks de jarenlange aanwezigheid van MiHA-
specifieke geheugen T-cellen, tumorcellen toch weer terugkeren. Ook is het zo dat
zelfs wanneer er MiHA-verschillen aanwezig zijn op DNA niveau er niet altijd een
initie¨le T-cel respons waargenomen wordt. Dit geeft aan dat hoewel de GVT reactie
na allogene SCT een krachtig afweermechanisme is, tumorcellen toch vaak kunnen
ontsnappen aan het immuunsysteem. Verschillende van deze ontsnappingsmechanis-
men zijn bekend, waaronder verstoorde antigeenpresentatie, verlaagde expressie van
HLA moleculen, uitscheiding van immunosuppressieve stoffen, het aantrekken van
immunosuppressieve regulatoire T-cellen (TREG) en de eerder genoemde resistentie
tegen CTL-ge¨ınduceerde celdood. Naast deze manieren om het immuunsysteem te
ontduiken, is de laatste tien jaar een ander krachtig mechanisme in de schijnwerpers
gekomen: de co-inhibitoire moleculen.
De activatie van T-cellen is afhankelijk van twee signalen; ten eerste moet de T-cel
een antigen herkennen dat wordt gepresenteerd door HLA; dit is signaal 1. Maar of
de T-cel wel of niet geactiveerd wordt, hangt af van signaal 2: de balans tussen de
activiteit van co-stimulatoire en co-inhibitoire receptoren. Deze receptoren kunnen
worden be¨ınvloed door de cellen waarmee de T-cel contact heeft, dus bijvoorbeeld
DC’s of tumorcellen, en binding aan een co-stimulatoire receptor geeft een activerend
signaal aan de T-cel, terwijl een co-inhibitoire receptor een remmend signaal oplevert.
De netto balans van co-stimulatoire receptoren en co-inhibitoire receptoren bepaalt
of de T-cel wordt gestimuleerd. Door dit mechanisme kan de activatie van T-cellen
worden gereguleerd, zodat er bijvoorbeeld geen T-cellen worden geactiveerd die ei-
gen weefsels aanvallen, wat zou resulteren in auto-immuunziekten. Dit mechanisme
wordt echter ook ”misbruik” door tumorcellen, die de moleculen die binden aan de
co-inhibitoire receptoren tot expressie brengen. Zo kunnen ze de immuunreactie dem-
pen, en als het ware op de rem van het anti-tumor effect drukken. In Hoofstuk 1
hebben we een overzicht gegeven van de rol van co-inhibitoire moleculen in verschil-
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lende hematologische maligniteiten. Vervolgens hebben we onderzocht of de geheugen
T-cellen in de patie¨nten die geen goede anti-tumor respons meer hebben, functioneel
zijn aangetast via de co-inhibitoire receptoren. In Hoofstuk 3 van dit proefschrift
hebben we de rol van de co-inhibitoire receptor Programmed-Death-1 (PD-1) bestu-
deerd. We vonden een hoge PD-1 expressie op alloreactieve geheugen T-cellen, die
hemato-specifieke MiHA’s herkennen in myelo¨ıde leukemie patie¨nten. Ook zagen we
dat onrijpe leukemie voorlopercellen een lage expressie van de co-stimulatoire molecu-
len CD80 en CD86 hadden, terwijl het ligand voor PD-1, PD-L1, sterk tot expressie
kwam, vooral onder inflammatoire condities. Dit geeft aan dat deze kankercellen het
immuunsysteem kunnen omzeilen door het remmen van de T-celfunctie via de PD-
1/PD-L1 interacties. Deze waarnemingen werden gedaan in allogene SCT patie¨nten
waarbij de ziekte terugkeerde, terwijl ze eerder een krachtige MiHA-specifieke T-cel
respons hadden. Daarom veronderstelden wij dat PD-1 expressie betrokken is bij de
”uitputting” van deze T-cellen. Door ex vivo stimulatie met DC’s die waren beladen
met de MiHA, probeerden we deze PD-1-positieve MiHA-specifieke geheugen T-cellen
te laten vermenigvuldigen, oftewel prolifereren. Maar de proliferatie van de T-cellen
bleek niet optimaal, wat wijst op een verminderde functionele staat van deze cellen.
Echter, door het verhinderen van binding van PD-1 aan PD-L1 door blokkerende
antilichamen tegen PD-1 of PD-L1 konden we de expansie van de MiHA-specifieke
geheugen T-cellen versterken. Interessant is dat deze toename significant hoger was
bij patie¨nten die een terugkeer van de ziekte ontwikkelden dan bij patie¨nten die in
remissie bleven. Dit suggereert dat PD-1-signalering kan bijdragen aan het ontduiken
van het immuunsysteem en zo leidt tot terugkeer van de kanker. Daarom is PD-1
een belangrijk doelwit in het verbeteren van de therapie na allogene SCT, aangezien
het de terugkomst van de kanker zou kunnen voorkomen of behandelen.
Naast PD-1 is er een toenemend aantal co-inhibitoire receptoren bekend dat be-
trokken is bij het remmen van T-cellen. In Hoofstuk 4 werd de invloed van B and
T lymphocyte attenuator (BTLA) op de functie van MiHA-specifieke T-cellen onder-
zocht. Ook deze co-inhibitoire receptor bleek aanwezig te zijn op MiHA-specifieke
T-cellen en het ligand voor BTLA, HVEM, ook op verschillende hematologische ma-
ligniteiten. Na blokkade van BTLA door een anti-BTLA antilichaam werd de proli-
feratie van MiHA T-cellen aanzienlijk verbeterd. Naast een goed vermogen tot pro-
liferatie, bleken de T-cellen ook pro-inflammatoire cytokines zoals IFN-γ en TNF-α
te produceren. Hoewel het totale effect van het blokkeren van BTLA minder pro-
minent was dan bij PD-1, zagen we in zeven van de elf onderzochte patie¨nten dat
BTLA-blokkade resulteerde in een betere expansie van de MiHA-specifieke T-cellen.
Ook bleek het effect van BTLA blokkade bij drie patie¨nten sterker dan dat van PD-
1, wat aangeeft dat BTLA een niet-overlappende functie met PD-1 heeft, en ook in
de kliniek een doelwit zou kunnen zijn om de MiHA-specifieke T-cellen te stimule-
ren. Hoofstukken 3 en 4 tonen het effect van co-inhibitoire moleculen op T-cel
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responsen na allogene SCT. Het be¨ınvloeden van deze moleculen heeft de potentie
om de GVT afweerreactie te versterken, en zo de rem van de anti-tumor immuniteit
af te halen. Momenteel worden er klinische studies uitgevoerd waarbij blokkerende
antilichamen tegen PD-1 en PD-L1 aan kankerpatie¨nten worden gegeven. In het
vooraanstaande tijdschrift New England Journal of Medicine zijn in 2012 reeds veel-
belovende resultaten gepubliceerd (Topalian et al. en Brahmer et al. NEJM 2012).
Afhankelijk van het soort tumor, werd in 6-28% van de gevallen een klinische res-
pons waargenomen tegen solide tumoren, waaronder long-, nier- en huidkanker, en
het therapeutische effect was in veel gevallen ook langdurig. Deze overtuigende re-
sultaten bereiden de weg voor therapiee¨n op basis van co-inhibitoire moleculen tegen
hematologische maligniteiten.
De mechanismes die worden gebruikt bij het ontduiken van het immuunsysteem
kunnen ook per locatie in het lichaam verschillen. In Hoofstuk 5 hebben we on-
derzocht welke immunosuppressieve mechanismen worden ingezet door multiple mye-
loom (MM; ook wel ziekte van Kahler genoemd) op twee verschillende plekken in het
lichaam. Hoewel MM voornamelijk groeit in het beenmerg (BM), kan het ook elders
voorkomen. Dit zijn de zogenaamde extramedullaire locaties, zoals bijvoorbeeld de
milt en de lymfeklieren. In een muismodel hebben we waargenomen dat de immu-
nosuppressie in muizen met MM sterker was in de milt dan in het BM. Terwijl in
het BM verhoogde concentraties van inflammatoire chemokines en IFN-γ aanwezig
waren, was dit niet het geval in de milt. Dit suggereerde dat alleen in het BM een
significante anti-tumor reactie optrad. Ook zagen we in de milt dat de balans tussen
de immuunosuppressieve TREG en de Natural Killer (NK)-cellen steeg, en dit past
bij een mogelijk immunosuppressief milieu in de milt. Bovendien vonden we dat een
lager percentage van de NK-cellen in de milt IFN-γ uitscheidde, wat aanduidt dat
ze minder actief waren. Daarnaast hadden de TREG in de milt een hogere expres-
sie van het eiwit Foxp3 dan hun tegenhangers in het BM. De verhoogde expressie
van dit eiwit betekende dat ze mogelijk een sterker afweeronderdrukkend vermogen
hadden. Deze gegevens tonen aan dat verschillende immuuncellen betrokken zijn
bij de immuun-ontwijkingsmechanismes die worden gebruikt door tumorcellen, en
daarom zal het noodzakelijk zijn de remming van anti-tumor immuniteit op meer-
dere niveaus aan te pakken. Ook de verschillen tussen BM en milt zijn opvallend.
Het is bekend dat extramedullaire tumorgroei gecorreleerd is met een slechtere prog-
nose voor patie¨nten met de ziekte van Kahler. Verder onderzoek naar de verschillen
in immunosupressie tussen BM en extramedullaire lokaties kan hiervoor een verkla-
ring geven en uiteindelijk bijdragen aan de verbetering van de huidige beschikbare
therapiee¨n.
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Conclusie
Allogene SCT is een krachtige cellulaire immunotherapie tegen kwaadaardige hema-
tologische aandoeningen, maar er is duidelijk een noodzaak voor verdere verbeterin-
gen. Hemato-specifieke MiHA’s zijn de sleutel voor het omslaan van de balans naar
een selectiever GVT effect, terwijl GVHZ wordt voorkomen. Na tientallen jaren van
onderzoek van MiHA-reacties vooral in het laboratorium, is het nodig om de kennis
over de dynamiek van MiHA-specifieke T-cellen in allogene SCT in nieuwe klinische
behandelingsstrategiee¨n toe te passen. Het specifiek stimuleren van immuunrespon-
sen tegen MiHA’s zoals LRH-1 zou kunnen leiden tot het vernietigen van leukemie-
initie¨rende cellen, waardoor de tumor nooit meer terug komt. Daarnaast kan het
ingrijpen op co-inhibitoire moleculen, zoals PD-1 of BTLA, de GVT immuniteit ver-
beteren of herstellen. Dit kan worden bereikt door gebruik te maken van blokkerende
antilichamen of gemodificeerde DC’s in de context van MiHA-gebaseerde vaccinatie-
strategiee¨n. Deze laatste strategie zullen we in de nabije toekomst in het Radboud
Universitair Medisch Centrum Nijmegen toepassen, door aan patie¨nten DC’s te ge-
ven die beladen zijn met MiHA’s. Deze DC’s zijn tevens dusdanig gemanipuleerd dat
ze de liganden voor PD-1 niet tot expressie brengen. Hierdoor kunnen ze de PD-1-
positieve MiHA-specifieke T-cellen toch goed activeren. De resultaten gepresenteerd
in dit proefschrift laten zowel de potentie als de valkuilen van allogene SCT zien, ter-
wijl nieuwe doelwitten om deze therapie te verbeteren worden gegeven. Uiteindelijk
kan dit leiden tot een optimaal gebruik van de kracht van immunotherapie, waardoor
voor patie¨nten met hematologische maligniteiten de kwaliteit van het leven toe kan
nemen en er een grotere kans op genezing is.
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Mijn dankwoord. Het is heerlijk om eindelijk eens ongebreideld zinnen te kunnen
schrijven, met heel veel komma’s, zonder dat er iemand commentaar op mag hebben,
of een limiet voor het aantal woorden, zoals de artikelen in dit boekje. Toch kan ik de
lezer aanbevelen om de zes hoofdstukken hiervoor te lezen, of desnoods de plaatjes
te kijken, om een idee te krijgen van het werk van de afgelopen jaren. Uiteindelijk
heb ik een goede tijd gehad tijdens die jaren, en dat heb ik te danken aan de mensen
hieronder.
Ten eerste wil ik Harry bedanken. Al vanaf mijn stage heeft jouw enthousiasme me
gestimuleerd, ook al zag ik het even niet zitten, en ik waardeer het dat je mijn mentor
bent. Het enthousiasme en de schouderklop na mooie data, of juist na minder mooie
data, is een belangrijke factor geweest om te zorgen dat uiteindelijk dit mooie boekje
er is. Het altijd objectief bekijken van data, ook al paste het niet in ons straatje, is
een eigenschap die elke wetenschapper moet hebben, en ik ben blij dat we daar het-
zelfde in staan. Ik heb je groep in zes jaar zien groeien van e´e´n aio naar het huidige
aantal, en dat vind ik een grote prestatie. De last-minute mailwisselingen over pre-
sentaties en dergelijke ’s avonds en in het weekend zorgden ervoor dat meestal alles
toch op z’n pootjes terecht kwam. Ik wens je veel succes in het verder uitbouwen van
de groep en hoop dat we nog lang samen werken.
Robbert, als mijn tweede co-promotor wil ik je ook bedanken. Niet alleen voor je
begeleiding bij het muizenwerk, maar ook voor je kritische commentaar op onze re-
sultaten en papers. Het is niet zeker te zeggen, maar misschien hadden we zonder je
opmerking over de opbouw van onze review helemaal geen review in Blood gepubli-
ceerd.
Mijn promotores, Theo en Fred. Theo, je was altijd optimistisch over mijn onderzoek,
en wist ook te benadrukken dat de kliniek het uiteindelijke doel van translationeel
onderzoek is. Fred, bedankt voor je nauwkeurige inzet om dit boekje zo goed moge-
lijk te maken.
Frans en Hans, ik ben blij dat jullie mijn paranimfen zijn. Frans, vanaf 2007 hebben
we samen gewerkt en dan is het mooi meegenomen dat we goed met elkaar kunnen
opschieten. Ook was je bij ons lab met veel vrouwen vaak de enige met wie ik tijdens
de lunch op maandag over voetbal kon praten, en dan ben je ook nog voor de juiste
club. Ik ken niemand die zoveel energie heeft, wat resulteert in rennen, fietsen, maar
ook lekker eten en lange nachten in de plaatselijke kroegen in Glasgow en Berlijn.
Niet te vergeten weet je wat hard werken is, en veel van de data in dit boekje komt
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van jouw nauwkeurige hand. Het was niet altijd makkelijk tijdens het promotieon-
derzoek, de maanden met dat rot-antibody van eBioscience, oude papers af moeten
maken terwijl nieuw interessanter werk wacht, maar uiteindelijk is het boekje af ge-
komen. Ik heb er goede hoop op dat we in het nieuwe project ook mooie resultaten
krijgen en ben blij dat we hierop ook samen werken, en hoop dat je op alle vlakken
een goede tijd te wachten staat.
Samen met Hanny ben je de ruggengraat van het CTI lab. Ik denk dat de goede sfeer
en het werkklimaat op ons lab door de jaren heen vooral door jullie twee bepaald
wordt, en dit voor de onderzoekers een grote hulp is. Hanny, je bent nooit te beroerd
om even mee te denken of te helpen, en het is geen toeval dat je co-auteur bent op
twee van mijn papers. Verder zorg je met je interesse en humor op het lab dat men-
sen zich snel thuis voelen. En niet te vergeten was er zonder de 63 cellen van jouw
n=1 project misschien helemaal geen aioproject voor mij geweest. Marij, je bent een
gezellige toevoeging aan onze groep en een vraagbaak op flow gebied. Anniek, met
jou is er een hoop energie in de groep gekomen. Nu begint al je inzet ook resultaat
op te leveren en ik wens je een goed laatste aiojaar.
Willemijn, jij bent een grote boost voor de PD-1 groep geweest en door jouw werk
zijn de lab resultaten een stap dichter bij de kliniek. Samen hebben we mooie papers
kunnen publiceren, en ik denk dat jouw to-the-point teksten een goede balans geeft
met mijn wat lyrische schrijfstijl. En uiteindelijk zal ik hier toch toegeven dat een
lijstje op zijn tijd ook nuttig kan zijn, maar met mate.
Rob en in de eerste jaren Jeroen, jullie hebben me veel geholpen met het sorteren
van cellen. Kluiten, populaties van 0,001%; ik kwam met uitdagingen die jullie altijd
aangingen. Rob, ook al zit je nu niet meer zo centraal op het lab, je hebt een mooie
faciliteit en hebt gelukkig een upgrade gekregen naar deze eeuw met de Aria, en een
mede-Achterhoeker op het lab is machtig mooi.
Kelly en Sandra, wij begonnen rond dezelfde tijd en hebben, naast een werkkamer,
veel pieken en dalen gedeeld. Kelly, je eerste jaren was de zoektocht naar nieuwe
MiHAs niet vruchtbaar, maar uiteindelijk heb je jouw juweeltje gevonden, en heb je
in recordtijd je proefschrift eruit geknald. Ook moet ik je eigenschappen als scout -
always be prepared - loven, vooral omdat ik die minder heb. Dit is zeker nuttig op
een soms zonnig en soms regenachtig Sardinie¨. Ik wens je veel plezier en succes met
de komende uitbreiding voor jou en Wouter in het diepe zuiden. Sandra, je bent ook
al even weg, maar soms duik je opeens op je vrije dag bij ons op. Ik vond het fijn dat
je m’n collega was en je staat garant voor gezelligheid. Je volhardendheid tijdens je
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promotietijd en nu erna zal je jouw doctorstitel opleveren, terwijl je stiekem allang
dokter bent.
Soley, Jeannette, Karishma, Mieke, Niken, Annelies, Marian en Vivie`nne. Present
and past colleagues of CTI, you all are or were a valuable part of the group, and
contributed to good conditions to perform the studies in this thesis. Basav, het is
een voorrecht om samen een rustige, koele kamer te delen, en ik wens je veel succes
in jouw onderzoek.
Mijn studenten Rene´e en Marije ben ik dankbaar voor hun toewijding aan het onder-
zoek tijdens hun tijd bij mij. Voor een begeleider is het mooi om te zien dat iemand
er vol voor gaat. Omdat jullie onderwerpen hadden die ook relatief nieuw waren
voor mij, hebben jullie veel zelfstandig uitgezocht, en daar heb ik respect voor. Ik
wens jullie beiden veel succes, als arts en onderzoeker. In het algemeen wil ik de
studenten noemen die bij onze unit stage liepen, een deel van het frisse gevoel op een
onderzoekslab komt door jullie aanwezigheid.
All the past and present PhD students from CHL/LH, Laurens, Sylvie, Leilei, Saskia,
Mark, Leonie, Pedro, Niccolo, Gorica, Anne, Larissa. I’m happy that we actually
share the lab now with the molecular unit and it’s always nice to talk. I think only
a fellow PhD student can truly understand what it feels like and I wish Mariam,
Maaike, Myriam, Jimmy and Davide a lot of success with finishing up their thesis.
Also, drinks at the Aesculaaf are always a good idea, and some of you even share my
love for Murakami and South Park. Also, walking around on the lab in the evening
or weekend and seeing you’re not the only one is a plus. Ruth, Thessa en Saskia,
bedankt voor de rol als vraagbaak op moleculair gebied en de gezelligheid.
Alex, Claudia, Nynke en Iris, jullie hebben me als groentje op het CDL veel gehol-
pen. Claudia en Alex, bedankt voor al het geregel en de hulp met de IF injecties, en
ook de goede sfeer. Thomas, we hebben niet lang samengewerkt, maar de lol die we
hadden bij bijvoorbeeld het zoeken naar lymfeklieren had ik van tevoren niet kunnen
verwachten.
Annemieke, je was mijn allereerste vraagbaak op het lab tijdens mijn stage. Je hebt
me, met vallen en opstaan, de nauwkeurige CFSE assays bijgebracht, en we hadden
veel plezier samen. Als ik nog een keer een liedje voor je aan moet vragen, moet je
het maar zeggen.
Ingrid, het lijkt al een eeuwigheid geleden, ik nog als beginnend aio, jij al (gedeelte-
lijk) weg, maar we hebben toch mooi dat paper in Blood gepubliceerd! Marleen, we
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lopen ongeveer even lang rond bij de CTI, en je hebt naast al je kweek-uren nog tijd
voor het bakken. Ik hoop dat we nog veel mogen voorproeven en wens La Rochelle
veel succes. Jan, jouw project heb ik zien uitgroeien van het uitproberen van medium
naar een patie¨ntenstudie met je UCB NK cellen, en das ist doch super toll om te zien.
Hoe kan ik ze vergeten, de dames van het Restofant. Ze zijn voor een goed deel
verantwoordelijk geweest voor mijn eten de laatste jaren, en soms een extra schepje
met een knipoog is een mooie bonus.
De mensen van de BMT wil ik bedanken voor de hulp met de patie¨ntensamples, en
alle andere mensen van de IFT, thrombo-hemostase of morfologie die me ooit ge-
holpen hebben, of al was het alleen maar voor leuke koffiepauzes. Joop, Bert, en
anderen, bedankt voor de interesse en goede vragen over mijn onderzoek. Nelleke, je
staat altijd voor ons klaar en hebt me zelfs een keer van mijn kamer gered.
De mensen van de afdeling Hematologie ben ik dankbaar voor het voor mijn onder-
zoek broodnodige patie¨ntengegevens en -materiaal. Ook zijn jullie een onmisbare spil
in het terug naar de kliniek brengen van onze bevindingen. Ook de medewerking van
de patie¨nten en donoren is hier natuurlijk onmisbaar.
Al de mensen in en buiten Nijmegen die me hebben geholpen met onderzoek wil ik
ook graag bedanken. De LMI, al is het maar voor het lenen van een potje of het
schuiven van wat FACS tijd. Het TIL, ons onderzoek overlapt veel, en resulteert in
interesse en goede vragen tijdens de MACHT meetings. Konnie, bedankt voor het
helpen opzetten van de IHC kleuringen. Marieke, Michel, Fred en Inge uit Leiden
bedank ik voor het aanleveren van patie¨ntensamples en tetrameren, en dit geldt ook
voor het materiaal van Tuna en Rimke uit Utrecht.
I would like to thank my international collaborators. Mike, your findings have sparked
the new direction of my research. Dr. Korman and professor Olive, your antibodies
are essential for our studies and are greatly appreciated. Jim, thanks for welcoming
me to your group, and I’m looking forward to doing research in Philadelphia.
Ik wil ook graag de mensen van mijn stage bij de Autoimmune Biochemie bedanken,
en in het bijzonder Danie¨lle. Jij hebt me echt laten zien wat het betekent om onder-
zoeker te zijn, en toen heb ik besloten dat ik wilde promoveren. Dit was ook een heel
gezellige tijd, en de andere stagiairen van toen zie ik nu nog steeds. Chantal, Sonja,
Floor, Lianne en Ties, al gaan we op professioneel vlak allemaal een andere kant op,
als we elkaar zien is het altijd weer gezellig.
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Ook wil ik de mensen van de Alpe d’HuZes bedanken. Niet alleen voor het toekennen
van de beurs waardoor ik mijn onderzoek voort kan zetten, maar ook voor het mogen
beleven van het evenement. Het zien van de beklimming en het enthousiasme van de
hele organisatie is een inspiratie. Ook is een presentatie bovenop de berg voor een
zaal vol met fietsers een onbeschrijflijke ervaring, daarna lijkt elke presentatie op een
congres een eitje.
Hans, ik ken je al vanaf de basisschool in Vorden maar uiteindelijk ben je in Nijmegen
zelfs mijn overbuurman geworden. Nu ben je bij mijn promotie mijn achterbuurman.
Je hebt me, soms bijna letterlijk, op sleeptouw genomen met mountainbiken en wiel-
rennen. Waarschijnlijk zal ik nooit je Strava records verbreken, maar ik hoop dat we
nog vaak kunnen gaan fietsen, ook al zal je met Anke waarschijnlijk wat verder weg
gaan wonen. En niet te vergeten de niet-sportieve uitjes zoals Lowlands.
Rick, alle ontspanning tijdens de hiphopconcerten en zeker onze reis naar Zuid-
Amerika is voor ons beiden een goede onderbreking van het drukke werk geweest,
dat moeten we vaker doen.
Niels, Erwin, Wendy, Jeffrey, Leonie, Jeroen, ook al wonen jullie wat verder weg,
altijd als we elkaar zien is het meteen weer ouderwets gezellig en we hebben veel
mooie herinneringen samen.
Wout, Jolien, Annet, Bart, Eveline, Paul, de eetavondjes zijn erg gezellig. Wout, als
klaverjasmaat zijn we allebei chagrijnig als we verliezen, misschien dat het daarom
ook niet zo vaak gebeurt, want dan zijn de rapen gaar en de poppen aan het dansen.
Erik, dat dit nawoord, maar vooral de rest van het proefschrift, zo’n strakke layout
heeft, is jouw verdienste. Hartelijk dank daarvoor, het was veel meer werk dan ik,
en jij vast ook, gedacht had. Je hebt maar een jaar Biologie gedaan, maar dat je
uiteindelijk weer in de wetenschap terecht zou komen, stond voor mij wel vast. Je
bent al goed onderweg met jouw boekje en ik kan niet wachten om die layout te zien.
Ook waren de vakanties een goede onderbreking van het onderzoek.
Jurriaan, Thomas en Martijn. De introductie van Biologie is al weer ruim elf jaar
geleden, en ik heb zelfs met twee van jullie jaren in huize Waalzicht gewoond. Dit
waren mooie tijden, en ik ben blij dat we elkaar nog vaak zien. Jurriaan, vorig jaar
mocht ik alvast oefenen als paranimf bij jouw promotie, en ik was vereerd dat je me
gevraagd had. Ik wens je nog veel succes in je verdere leven met Claudia, en waar
ter wereld dat ook mag zijn, ik kom graag langs. Thomas, er zijn weinig mensen
waar ik zo dezelfde humor mee deel als met jou. Ook zijn we allebei even fanatiek
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met squash, en het is altijd een uitdaging om de winst te pakken. Het is mooi dat
je vorig jaar je studie hebt afgemaakt en ik hoop dat je binnenkort een mooie baan
vindt. Martijn, een avond met goed eten, een goede film en een goed gesprek zit bij
jou wel snor. Nu zijn we nog collega’s in het Radboud maar ik hoop dat we in de
nabije toekomst wat verder moeten reizen om samen te lunchen. Natuurlijk zijn wij
vieren ook de Oostblokveteranen, met onze sjoeffel als bewijs. Onze roadtrip door
de Baltische Staten was legendarisch, met jazz clubs, zwervers, rare disco’s, katers,
onverwachte festivals en heel veel ooievaars. Ik hoop dat we nog een reu¨nie reis kun-
nen plannen.
De familie aan de Norde-kant en de Eekman-kant wil ik ook bedanken. De meesten
hebben maar een vaag idee van wat ik precies doe, maar er is altijd welgemeende
interesse. Natuurlijk wil ik mijn grote broer en schoonzus noemen. Geert, ook al
doen we heel andere dingen, ik vind het altijd leuk om langs te komen in Deventer.
Dat heeft natuurlijk ook te maken met Rosalie, en de laatste jaren ook met Evi en
Zoe¨, en binnenkort... Het is altijd een warme ontvangst bij jullie, en ik vind het knap
hoe jullie alles, ook als het tegen zit, regelen. Papa en mama, tenslotte jullie. Ik
kom altijd helemaal tot rust als ik een dagje terug in Vorden op de Wenneker ben, en
dat komt grotendeels door jullie. Het promoveren is moeilijk uit te leggen, en soms
deed ik daar misschien ook geen moeite voor, maar desondanks waren jullie altijd
ge¨ınteresseerd en meelevend. Het is ook door jullie steun de afgelopen dertig jaar dat
ik dit proefschrift heb kunnen schrijven, en daar ben ik jullie dankbaar voor.
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Wieger Norde is op 2 november 1982 geboren te Doetinchem en getogen op “de
Wenneker” te Vorden. Hij doorliep het gymnasium aan het Baudartius College te
Zutphen, en rondde dit in 2001 cum laude af. Datzelfde jaar startte hij de oplei-
ding Medische Biologie aan de Radboud Universiteit (RU) te Nijmegen. Tijdens de
opleiding werden drie onderzoeksstages gedaan; de eerste bij de afdeling Celbiologie
van de Faculteit der Natuurwetenschappen, Wiskunde en Informatica (FNWI) aan
de RU bij dr. Alexander Theuvenet, waar hij onderzoek deed naar de transformatie
van kankercellen. Vervolgens deed hij, wederom bij de FNWI, onderzoek naar de
modificaties van auto-antigenen bij de afdeling Biomoleculaire Chemie onder bege-
leiding van dr. Danie¨lle Hof en prof. dr. Ger Pruijn. Tenslotte onderzocht hij de
vatbaarheid van leukemische stamcellen voor minor histocompatibility-specifieke T
cellen, onder begeleiding van dr. Harry Dolstra. Dit vond plaats bij het Labora-
torium Hematologie, onderdeel van de afdeling Laboratoriumgeneeskunde aan het
Radboud Universitair Medisch Centrum te Nijmegen. Na het begeleiden van stu-
denten als student-assistent tijdens diverse vakken op de FNWI behaalde hij in juni
2007 zijn doctoraal.
Aansluitend begon hij een promotieonderzoek naar de rol van co-inhibitoire recepto-
ren op T cellen na stamceltransplantatie in de groep van dr. Harry Dolstra. Onder
begeleiding van dr. Harry Dolstra en dr. Robbert van der Voort voerde hij het on-
derzoek uit zoals beschreven in dit proefschrift. In 2011 ontving hij de Bas Mulder
Award van de Stichting Alpe d’HuZes. Deze beurs voor jonge onderzoekers stelt hem
in staat onderzoek te doen naar de intracellulaire processen die betrokken zijn bij
het effect van co-inhibitoire receptoren. Dit onderzoek vindt plaats in de groep van
dr. Dolstra, en zal in 2013 onderbroken worden voor een werkbezoek van een jaar
aan de University of Pennsylvania te Philadelphia, onder begeleiding van dr. James
L. Riley op de afdeling van prof. dr. Carl June.
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